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ABSTRACT
The Anelloviruses Torque Teno virus (TTV) and TTV-like minivirus (TLMV) are small,
circular DNA viruses which infect humans and non-human primates. They are highly
prevalent in the general population, however infection is without any apparent pathology.
Both viruses are extremely heterogeneous, especially for DNA viruses, and the role of the
immune system in controlling the infection has yet to be established.
Initial experiments involved establishing prevalence figures for TTV and TLMV as well as
SENV D and H, subtypes of TTV implicated in potential transfusion transmitted non A-E
hepatitis, in Scottish blood donors. TTV and TLMV were co-amplified by PCR using
degenerate primers and the PCR products differentiated by melting curve analysis, a
method developed in the course of this work. 88% of serum samples were PCR positive
for either TTV, TLMV or a heterogeneous mixture of both viruses. The presence of SENV
D and H was determined by Southern blot and revealed 0.5% of samples tested were
infected with SENV D, 10.9% with SENV H and 1% with both SENV D and SENV H.
The immunosuppression associated with HIV infection and AIDS leads to an increase in
TTV/TLMV titres is serum however, there is no data on the effect of immunosuppression
on TTV/TLMV titres in tissues. We compared the titre of both TTV and TLMV in the
bone marrow and spleen from 3 groups: HIV negative individuals, HIV positive
individuals and HIV positive individuals who had progressed to AIDS, leading to
immunosuppression. Limiting dilution PCR using primers situated in the UTR region of
the genome were used to semi-quantitate the virus, and TTV and TLMV were
differentiated. The AIDS group had higher titres, which were statistically significant
compared with both the HIV positive and negative groups for both bone marrow and
spleen. Analysis of TTV/TLMV titre with CD4 T lymphocyte count showed a significant
inverse correlation. On the other hand, neither HCV co-infection nor type of Anellovirus
infection (single TTV or TLMV, or mixed TTV/TLMV) showed any significant
correlation with virus titre.
TTV/TLMV titres in HIV positive and transplant patients were compared to individuals
infected with viruses not known to cause immunosuppression (HCV and HBV) and
healthy blood donors. Both of the immunosuppressed groups of individuals had titres of
TTV/TLMV in serum higher than the other three groups.
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The suggestion that farm animals were infected with TTV similar to human TTV led to an
investigation of TTV/TLMV homologues infecting non-human primates and farm animals.
Although a high proportion of the non-human primates were infected with TTV/TLMV-
like viruses, none of the farm animals were shown to be PCR positive. Sequence analysis
of the primate samples determined they were infected with viruses which were genetically
distinct from human TTV and TLMV.
In summary, this investigation has 1) shown a high prevalence of TTV/TLMV in Scottish
blood donors and determined SENV D and H prevalence in the same population: 2)
established for the first time that the immunosuppression associated with AIDS results in
an increased TTV/TLMV titre in bone marrow and spleen: 3) determined Anellovirus titre
is higher in the sera of immunosuppressed HIV positive individuals and transplant
recipients than in the HCV or HBV positive sera or in healthy individuals and 4) confirmed
that non-human primates are infected with species specific TTV/TLMV-like viruses,
phylogenetically distinct from human viruses.
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New human viruses are periodically described and examined for potential causal links with
conditions of unknown etiology. In the course of these investigations, the original aims
may not be fully satisfied however, unique virological properties may be discovered which
advance the field ofvirology.
Torque teno virus (TTV) and TTV-like minivirus (TLMV) are small circular DNA viruses
that infect humans, non-human primates and some domesticated animals. Humans can be
simultaneously infected with multiple genotypes of TTV and TLMV and remain viraemic
for extended periods of time. They display an unusual degree of heterogeneity for DNA
viruses, which has made investigation of any genotype specific disease association
problematic.
1.1 Discovery and characterisation
1.1.1 TT Virus
TTV was first isolated from the serum of a Japanese patient (initials T. T.) who developed
non A-G hepatitis following a blood transfusion administered during cardiac surgery.
Representational difference analysis was used to compare a serum sample taken two weeks
post transfusion when the patient had normal alanine aminotransferase (ALT) levels with a
sample taken between seven and nine weeks later when the patient's ALT levels had
become elevated. This resulted in the discovery of a 500bp clone (N22 clone) that
contained one putative open reading frame (ORF) encoding 166 amino acids (aa), which
showed no significant homology to any published sequence. The sequence was used to
generate primers for polymerase chain reaction (PCR) and these were used to confirm the
novel sequence was not genomic in origin.
Ultracentrifugation in a sucrose density gradient showed the N22 sequence corresponded
to nucleic acids which appeared in fractions with a peak at 1.26 g/cm3, indicating that it
was associated with a viral particle. The density of the particle was unchanged following
treatment with Tween demonstrating the virus (TTV) was not enveloped [Nishizawa et al.,
1997]. In order to determine if the TTV genome was composed ofRNA or DNA, nucleic
acids were extracted from TTV positive plasma and digested with a variety of nucleases.
TTV was sensitive to DNase I and resistant to RNase A suggesting that TTV was a DNA
virus. This was further substantiated by the sensitivity of TTV to mung bean nuclease,
1
which has an affinity for single stranded DNA [Okamoto, 1998]. The polarity of the
genome was confirmed as negative sense using a hybridisation/nuclease protection assay
and the viral particle diameter estimated to be between 30 and 50nm as determined by PCR
amplification of infected serum after it was passed through polycarbonate filters with
decreasing pore sizes [Mushahwar et al., 1999]. Virus-like particles with a diameter of
between 30 and 32nm have also been visualised from TTV infected serum using electron
microscopy [Itoh et al., 2000]. Cloning and sequencing of the DNA initially suggested the
virus was linear with a genome of 3739 bases but further investigation found an additional
113 nucleotide GC rich region which acts as a bridge to join either end of the genome
forming a covalently closed circular structure [Miyata et al., 1999]. This is the first single
stranded, circular DNA virus known to infect humans.
1.1.2 TTV-likeminivirus
TTV-like minivirus was discovered by serendipity in 1999, two years after TTV was first
identified, when PCR primers designed to amplify TTV annealed to, and amplified, a
homologous region of TLMV. The plasma tested was co-infected with both viruses and it
was only due to a discrepancy with the PCR conditions that TLMV was preferentially
amplified over TTV. TLMV can be amplified without reverse transcription and was
sensitive to mung bean nuclease suggesting that this too was a single stranded DNA virus.
Analysis of the serum on a caesium chloride density gradient showed the viruses could be
found in separate fractions, indicating that TLMV genome was not incorporated into the
TTV virion. TLMV is non-enveloped and the genome is circular and of negative polarity
but, at less than 30nm, it is smaller in diameter than TTV. When sequenced, the full-length
genome was 2860 nucleotides in length, approximately one kb smaller than TTV
[Takahashi et al., 2000b],
1.1.3 SEN virus
SEN virus, like TTV, was originally identified as a potential viral cause for hepatitis of
unknown etiology and was found during a mass screen of some 600 stored blood samples.
It was first detected in, and named after, an Italian intra-venous drug user (IVDU) who was
infected with Human immunodeficiency virus-1 (HIV). Preliminary data showed a
significantly increased proportion of individuals with non A-E hepatitis harbouring the
virus compared with the group of healthy blood donors tested simultaneously, but
subsequent studies showed that like TTV and TLMV, SEN-V can be found at relatively
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high frequencies in healthy individuals. Although initially thought to be a member of a
novel group of viruses, closer investigation showed SENV to be a small, unenveloped,
single stranded DNA virus and genomic analysis revealed it was a subtype of TTV
[Tanaka et al., 2001],
1.2 Classification
It has been problematic to classify TTV and TLMV into a suitable virus family.
Traditionally single stranded DNA viruses with no lipid envelopes that infect vertebrates
were classified as either Parvoviridae, a group of linear DNA viruses, which include the
human virus parvovirus B19, or Circoviridae, which are circular DNA viruses. Upon
further investigation, the similarities of TTV to CAV (family Circoviridae, genus
Gyrovirus) became more apparent, as shown in Table 1.2.1 [Hijikata et al., 1999]. The
subsequent discovery of a 113bp GC rich segment, which forms a linker to make the TTV
and TLMV genome circular, excluded them from the Parvovirus family.












































Table 1.2.1 - Comparison of TTV and TLMV with representative members of Parvoviridae
(B19) and Circoviridae (CAV).
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The family Circoviridae contains a number of small, single stranded, circular DNA viruses
which infect domesticated animal and bird species. This family includes Porcine
circovirus (PCV) and Beak and feather disease virus (BFDV) both of which have a
diameter of 15 to 20nm and genomes of 2kb. Chicken anemia virus (CAV), which has a
slightly larger capsid of 23 to 25nm and genome of 2.3kb, is also a member of this family
and it is this virus in particular which shares characteristics with TTV and TLMV. TTV,
TLMV and CAV show similarities in the genome organisation, particularly in the spatial
arrangements of the open reading frames ORF1 and ORF2 which are partially overlapping
in all three viruses.
In 2002 the International Committee for the Taxonomy of Viruses proposed that TTV and
TLMV should form the founder members of a new genus Anellovirus, derived from
'anello' meaning 'ring' relating to the circular nature of the genome. Although the
similarity to CAV was acknowledged, it was decided that TTV and TLMV were not
significantly similar to members of Circoviridae other than CAV to warrant the inclusion
of these viruses in that family.
They also proposed a new name for TTV: Torque teno virus from 'torques', the necklace,
and 'tenuis', thin, which relates to the single stranded, circular nature of the genome. Also
suggested was the change from TTV-like mini virus to Torque teno mini virus (TTMV).
For the purpose of this thesis TTV-like mini virus (TLMV) will continue to be used.
1.3 Genome organisation and mRNAs
1.3.1 TTV/SENV
On the discovery ofTTV, the lack of any single stranded circular viruses infecting humans
resulted in the comparison of TTV with members of Circoviridae. The Circovirus CAV
has a larger capsid and genome than other members of this family, and appears to share a
similar genomic organisation with both TTV and TLMV (Figure 1.3.1) including a
partially overlapping ORF1 and ORF2. TTV has a negative sense single stranded DNA
genome of approximately 3750 - 3900 nucleotides which may contain up to 5 open
reading frames and a ~1.2kb untranslated region. The non-coding region of the genome
contains a 113 nucleotide GC rich stretch of DNA which includes transcriptional
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This portion of the genome also contains the only nucleotide sequence which has a high
degree of homology with CAV, a 36 nucleotide region which shares 80.6% homology
[Takahashi, 1998].
Until recently, the lack of an appropriate culture system for TTV [Desai, 2005] has
hampered the analysis of the transcription profile, however transfection of a COS cell line
with a plasmid containing permuted whole genome constructs of TTV produced three
species of mRNAs. Northern blotting detected mRNAs of 2.8, 1.2 and 1.0 kb 48 hours
post transfection. All three mRNAs share common 3' and 5' termini (Figure 1.3.2) and
are thought to be transcribed from the same internal promoter, TATA box and cap site
[Kamahora et al., 2000; Okamoto et al., 2000c], Investigation of the TYM9 strain
(accession number AB050448) found a common splicing pattern, which joined nucleotides
181 to 283, occurred in all three mRNA species. Transcription initiation for the major
protein coding sequence in frame 1, ORF1, is thought to occur at the first ATG at position
559 therefore is not affected by this common splice site. This produces a 748 amino acid
product. ORF2, on the other hand, is likely to start at the third ATG in that frame, codon
338, as the first two initiation codons are located in the spliced region spanning nucleotides
181 to 283. ORF2, which is in reading frame two, encodes a 115 amino acid protein. The
1.2 and 1.0 kb mRNAs contained a second splice site which joins nucleotide 681 to
nucleotides 2341 and 2579 respectively. This results in the in-frame joining of ORF2 and
ORF4, producing a product of 260 amino acids. The linking ofORF2 and ORF5 results in
a frame shift and a 249 amino acid product [Kamahora et al., 2000],
This pattern of splicing seen in vitro was corroborated by a study which used reverse
transcription to detect all three species of mRNA in vivo from bone marrow cells infected
with TTV [Okamoto et al., 2000c]. The genotype of TTV found in the bone marrow cells
was considerably different to the prototype TTV strain, sharing only 67% nucleotide
homology, however the shared transcription profile suggests that despite the heterogeneity
of the virus the splice sites remain common to all genotypes.
More recently, transfection of a full length TTV clone has shown that the TTV genome can
generate at least six proteins by translating each of the three species ofmRNA from both
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By comparison, to VP1 of the CAV genome, it is thought that the protein expressed from
ORF1 may code for the nucleocapsid of the virus with the arginine rich N-terminus
involved with binding and encapsidation of the viral genome.
Several motifs are common to products generated by all known TTV isolates, including a
putative Rep (replication associated) protein sequence thought to be involved with rolling
circle replication, a C-terminus serine rich tract in ORF3, a conserved motif (EX8RX2RX4-
6PX5-11PX1-8VX1FX1L) in the C-terminus of ORF4 and a glutamine/glutamic acid rich
domain in ORF1. TTV ORF2 also contains an amino acid motif (\Vx7Hx3Cx1Cx5H) seen
in the Circovirus CAV [Hijikata et al., 1999] as well as in TLMV, which again points
toward a possible common ancestor for all three viruses.
Nucleotide sequence divergence resulting in amino acid substitutions is most notable in the
central portion ofORF1. Three regions ofmarked amino acid conversion, of 22, 47 and 31
amino acids in length, in TTV genotype 1 have been designated HVR1 (hypervariable
region 1), HVR2 and HVR3 [Nishizawa et al., 1999]. Divergence in this area results in the
generation of quasispecies which have been observed in patients with non A-E hepatitis
[Kurihara et al., 2001]
1.3.2 TLMV
The genomes of TLMV isolates range from 2850 - 2950 nucleotides in length and around
25% (-720 nucleotide) of this is untranslated, 5% less than the TTV genome. TLMV
shares similar genomic organisation with TTV, but although four putative open reading
frames have been predicted for some isolates (e.g. isolate CBD-231 used in Figure 1.3.1),
many appear to have only ORF1 and ORF2 suggesting that ORF3 and ORF4 may not be
functional. An initiation codon for the homologue to ORF3 in TTV has yet to be reported
in any TLMV isolate [Biagini et al., 2001]. As with TTV, TLMV has a partially
overlapping ORF1 and ORF2 and a conserved sequence located in the UTR. Although
genomic sequences of TTV, TLMV and CAV contained very little similarity, there are
conserved regions in the UTR which have facilitated phylogenetic comparison of the three
viruses. This analysis confirms that TLMV is more closely related to TTV than to CAV
however the authors propose that TLMV may be an intermediately related to TTV and
CAV [Takahashi et al., 2000b]
The untranslated region of TLMV contains three direct repeats (DR1, DR2 and DR3) of a
27 nucleotide sequence. A 15 nucleotide portion of one of these direct repeats is also
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found in isolation in the UTR of the prototype TTV sequence (TA278) [Takahashi et al.,
2000b]. It has also been proposed that several highly conserved sequences in this non-
coding region could become recombination breakpoints [Biagini et al., 2001] contributing
to the genetic variability of this virus. The largest ORF is ORF1 which codes for 660
amino acids and, like the homologous protein in TTV, is thought to produce the viral
glycoprotein because of the presence of an N-glycosylation site [Takahashi et al., 2000b].
The amino terminus of this protein is not only rich in arginine residues, but also tryptophan
(W), in common with TTV but not CAV, and phenylalanine (F), in common with CAV but
not seen in the ORFs of TTV. TLMV isolates also contain three of the conserved Rep
associated motifs (FTL/FTxL, HxH and YxxK) related to rolling circle replication in
ORF1 [Biagini et al., 2001]. TLMV ORF2 protein is predicted to be 90 amino acids in
length and, as mentioned previously, contains the motifWX7HX3CX1CX5H.
1.4 Replication
It is still not known exactly how TTV and TLMV replicate however, the discovery of a
Rep protein sequence suggests these viruses could replicate using rolling circle replication.
Up to four amino acid motifs can form part of the Rep protein sequence which is conserved
in many plant and animal viruses from the family Circoviridae [Niagro, 1998], The TTV
proteins appear to contain only two of the four motifs: the FTL and YXXK motifs have
both been found in ORF 1 however TTV, like CAV, appears to lack the P-loop motif which
is thought to facilitate ATP/GTP binding. In CAV, the lack of this motif is thought to
indicate the need for host topoisomerase or helicase activity to unwind the DNA strands for
replication [Mushahwar et al., 1999; Niagro, 1998].
Investigation into the kinetics of chronic TTV viraemia in Hepatitis C virus (HCV)
infected patients receiving interferon therapy estimated that 90% of TTV virions are
cleared and renewed on a daily basis. A mathematical model predicted that at least 3.8 x
1010 virions must be produced daily in order to maintain an active infection [Maggi et al.,
2001c],
TTV DNA has been detected in the nucleus of hepatocytes using in-situ hybridisation [Hu
et al., 2002] and titres of the virus have been found at levels 10-100 times higher in bile
than in peripheral blood [Ukita et al., 1999]. This lead to the conclusion that the main site
of TTV replication was the liver, which would lend weight to the suggestion that the virus
is cause of hepatitis and liver disease. Although double stranded replicative intermediates
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of TTV have indeed been found in the liver, this is by no means the only site of viral
replication. Double stranded forms of the virus have also been found in lymph node,
muscle, thyroid gland, lung, spleen, pancreas and kidney [Bando et al., 2001; Okamoto et
al., 2001a] and in liver, spleen, small intestine, lymphoid cells and bone marrow of
experimentally infected rhesus monkeys [He et al., 2001; Xiao et al., 2002].
In 2000, Okamoto reported the detection of replicative forms ofTTV in bone marrow cells
but not in peripheral blood mononuclear cells (PBMCs) [Okamoto et al., 2000d], A more
recent study reported TTV DNA was present in PBMCs however replicative intermediates
and mRNAs were only found in PBMCs stimulated with phytohemagglutinin,
lipopolysaccharide and interleukin-2. TTV has also been shown to replicate in the human
cell lines Chang liver and Raji, a B-lymphoblast cell line as demonstrated by infectious
particles in the cell culture supernatant [Desai, 2005], It is likely that TTV relies on the
host cells replicative machinery to replicate and, like Parvoviruses, may require the host
cell to be actively undergoing mitosis for viral replication to occur.
Although there is currently no data regarding the replication of TLMV, because of the
presence of three of the four Rep associated amino acid motifs it is also thought to utilise
rolling circle replication.
1.5 Transmission
The modes of transmission of TTV and TLMV are poorly understood, with different
detection methods resulting in conflicting results. TTV was originally isolated following a
blood transfusion, and the name Transfusion Transmitted virus was used in some
publications. TTV has been detected in blood, blood products and PBMCs [Okamoto et al.,
1999a; Pisani et al., 1999] and is found at a higher prevalence in populations subject to
repeated blood transfusions or solid organ transplant [Gallian et al., 1999] as well as in
groups at risk of parenterally transmitted viruses such as those with haemophilia [Chen et
al., 1999], thalassemia [Prati et al., 1999] and on haemodialysis [Ali et al., 2004]. The
infectious properties of TTV in blood derivatives was shown by successfully infecting
chimpanzees using TTV-infected human serum [Tawara et al., 2000].
TTV can be found in over 90% of the general population which points towards routes of
transmission other than parenteral. TTV has been detected in bile juices and faeces of
viraemic individuals [Itoh et al., 2001] and viral particles isolated from faeces have been
visualised by electron microscopy [Itoh et al., 2000] suggesting that the faecal-oral route of
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transmission might be significant. TTV of faecal origin has been shown to be infectious
both in tissue culture [Maggi et al., 2001b] and by experimental inoculation of rhesus
monkeys using faecal filtrate [Luo et al., 2000]. A direct correlation between TTV
infection and antibodies to enterically transmitted Hepatitis A virus, primarily transmitted
by the fecal-oral route, has also been established [Saback et al., 1999]. Viral shedding of
TTV in faeces is also likely to be the source of TTV which has been found in molluscs
from the Norwegian coast [Myrmel, 2004] as well as in 97% of influent samples from
wastewater treatment plants in Japan [Haramoto, 2005b] and in 5% of surface water
samples collected from the Tamagawa River in Japan [Haramoto, 2005a], Although it has
yet to be established if TTV from these sources is infectious, this environmental
contamination may account for a proportion of infections.
Initially TTV was thought to be acquired postpartum because virus was not detected in
neonates born to infected mothers or in cord blood [Prati, 1999] however subsequent
studies have found TTV and TLMV DNA both in cord blood, amniotic fluid and breast
milk [Goto et al., 2000; Matsubara et al., 2001] implying that infection might also occur by
vertical transmission from mother to infant either during or immediately after birth.
Analysis of paired blood samples from Italian mothers and cord blood samples showed that
they had similar titres of TTV thus making it unlikely the cord blood samples were
contaminated by maternal blood [Morrica, 2000]. Sequence analysis of paired mother and
infant blood samples demonstrated a varying proportion of shared homology between
samples [Bagaglio et al., 2002; Lin et al., 2002]. This suggests that although intrauterine
transmission of TTV is possible it does not appear to play a significant role. Even infants
born to TTV negative mothers can acquire infection within the first couple of months of
life and risk of infection increases with age [Ohto et al., 2002] so exposure to
environmental factors seems to be more significant in the acquisition ofTTV in childhood.
The role of sexual transmission of TTV has yet to be validated, although a study of
individuals at high risk of sexually transmitted infection in Turkey failed to find an
increased prevalence in these groups compared with the control group [Yazici et al., 2002].
TTV has been detected in saliva at higher levels than in corresponding serum samples
leading to speculation it might be able to replicate in the salivary glands [Deng et al., 2000]
and be transmitted via kissing. Both TTV and TLMV have been found in cervical swabs
[Fornai et al., 2001] and TTV isolated from semen samples [Matsubara et al., 2000]
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however, given the exposure to TTV in the environment and peri- and postnatally, it is
unlikely that individuals reach sexual maturity without previous TTV infection.
1.6 Genetic heterogeneity
TTV has a remarkable range of sequence divergence for a DNA virus leading to
speculation the replication machinery has little or no proofreading activity. This
heterogeneity is unevenly distributed in the genome. The untranslated region is relatively
well conserved with even divergent genotypes only differing by only 30% at the nucleotide
level and some areas, which are presumed to be involved in translation or replication,
displaying 95% nucleotide conservation. The coding regions, on the other hand, have
regions that displayed up to 40% nucleotide sequence divergence [Erker et al., 1999]
although the most sequence divergence appears to be located in three hypervariable regions
situated in ORF1. Substitutions in this area result in the generation of circulating TTV
quasispecies, similar to those seen in HIV and HCV [Nishizawa et al., 1999].
This diversity has inevitably led to problems with PCR based detection of TTV. The
original N22 clone, which was used to generate PCR primers utilised in the initial
prevalence studies, was a portion of the highly divergent ORF1. N22 primers
preferentially amplify genotypes 1 and 2, so these data invariably underestimated the
spread of the virus and do not give an accurate representation of the genotypes present in
vivo. The generation of primers which amplify a region of the more conserved UTR
greatly enhanced the detection capabilities of PCR based assays, however caution needs to
be exercised when selecting primers and interpreting results as different pairs of primers,
even when amplifying the same region, may not produce comparable results.
At least 39 genotypes of TTV have been described to date which differ from each other by
>30% at the nucleotide level of the N22 region (ORF1) [Biagini et al., 1999]. These have
been further classified into five major genetic groups that differ by at least 50% from one
another: group 1 contains the prototype TTV (TA278) representing genotype 1 as well as
genotypes 2-6. Genotypes 7, 8, 17 22 and 23 are representative of group 2. Group 3
comprises genotypes 9-16 and 18-20 as well as the eight SENV genotypes and group 4
contains genotypes 21 as well as nine novel genotypes isolated from infants in China and
Japan. Group 5 contains a further four unidentified novel genotypes, again isolated from
Chinese and Japanese infants [Peng et al., 2002],
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Although TLMV was discovered two years after TTV, there are only 12 complete genome
sequences submitted to GenBank. Analysis of these full length nucleotide sequences have
shown that they can be classified into three genetic groups which differ from each other by
>40% [Biagini et al., 2001], In fact, 53 TLMV sequences cloned from a single French
haemodialysis patient showed very high heterogeneity, with a genetic distance of 40.5%
[Gallian et al., 2002]. These preliminary studies suggest that the TLMV genome is equally
or even more divergent than the TTV genome.
Two studies have suggested that homologous recombination may occur frequently in both
TTV and TLMV [Biagini et al., 2001; Worobey, 2000]. Evidence for recombination both
between genotypes and among the same genotypes has been described with a large
proportion of the recombination breakpoints for both viruses found in the relatively




TTV was initially isolated from an individual with post transfusion hepatitis in Japan,
however the virus was quickly isolated from a number of different populations including
blood donors [Charlton et al., 1998]. Epidemiological studies carried out since then have
confirmed the global distribution of the virus [Prescott, 1998].
Early studies utilised the N22 PCR amplifying a sequence in ORF1. As described earlier,
this limits the detection to genotypes 1 and 2 so data from these publications does not give
a true representation of the global prevalence of these viruses. The development of the
UTR PCR invariably increased the detection of TTV in geographical regions from less
than 30% to over 70%, as shown in Table 1.7.1, however these primers may also bias the
genotypes amplified.
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Country N22 primers UTR primers Reference(s)
UK 1.9% 77% [Simmonds et al., 1998; Simmonds
etal., 1999]
Holland 6% 72% [Prescott et al., 1999; Simmonds et
al., 1999]
Italy 10% 87% [Zehender et al., 2001]
France 5% 75% [Biagini et al., 1998; Biagini et al.,
2000]
Finland 17% 73% [Kakkola et al., 2004; Simmonds et
al., 1999]
Egypt 29% 85% [Abe et al., 1999; Gad et al., 2000]
Saudi Arabia 19% 100% [Prescott et al., 1999; Simmonds et
al., 1999]
Japan 23% 92% [Takahashia, 1998]
Table 1.7.1 - Prevalence of TT virus in the general population of different countries as
determined by PCR analysis using primers situated in ORF1 (N22 primers) and the non-
coding region (UTR primers).
The continuation of research into the genetic variability of this virus will undoubtedly lead
to the documentation of further genotypes, and may result in the discovery of near
universal global infection.
1.7.2 SENV
Although there are eight SENV genotypes, designated A to H, the possible association
between strains D and H and non A to E hepatitis have led to investigation of these strains
dominating the research. Certainly, the incidence of SENV D and H infection is
significantly higher in transfusion recipients who developed non A-E hepatitis than in
those who had received a blood transfusion but did not subsequently develop hepatitis
[Umemura et al., 2001b]
14
The distribution of these strains in blood donors varies geographically (Table 1.8.1) with
6.75% and 5% of blood donors infected with SEN D and SENV H respectively in China
[Mu et al., 2004], This is compared with 3% and 5% in Germany, 7% and 3% in Japan
and 0.9% for both SENV D and SENV H in the USA [Shibata et al., 2001; Umemura et al.,
2003],
Although there are relatively few studies investigating the prevalence of these viruses in
Europe, it appears that the ratio of SENV D and SENV H in Europeans is different than in
the Asian populations studied. The general population of China, Japan and Taiwan (as
represented by blood donors and healthy controls) all have a higher proportion of SENV D
than SENV H however in both Germany and Turkey the opposite is true (Table 1.8.1).
This theory is investigated in chapter three.
1.7.3 TLMV
Very little is known about the epidemiology of TLMV. Prevalence studies have shown
that 48% of sera from Norwegian blood donors and 72% of Brazilian blood donors are
TLMV DNA positive [Moen et al., 2002a; Niel and Lampe, 2001]. As previously
mentioned, TLMV may be more heterogeneous than TTV and the most sensitive PCR
based systems rely on primers situated in the UTR of the genome. TTV and TLMV share
a partially conserved UTR and care needs to be exercised to ensure that only the genome of
interest is amplified.
1.8 Pathogenicity
TTV was originally isolated from a patients with post transfusion non A-G hepatitis
[Nishizawa et al., 1997] at titres which correlated with ALT levels. This led researchers to
hypothesise that TTV was responsible for cases of unexplained chronic and acute hepatitis
however further studies produced data which cast doubt on this. Of most note was the
finding that TTV was highly prevalent in the general population, with one study reporting
that TTV was detected in 92% of individuals in Japan [Takahashia, 1998]. Comparison of
the prevalence of TTV in healthy controls and in those with cryptogenic hepatitis showed
there were no significant differences [Fukuda et al., 1999; He et al., 1999] and there was
also no association between ALT levels and TTV positive and negative individuals
[Fukuda et al., 1999; Takahashia, 1998].
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It was also shown that acquiring TTV following blood transfusion was not associated with
the development of liver disease or an increase in ALT levels [Gimenez-Barcons et al.,
1999; Matsumoto et al., 1999]. This evidence suggests that TTV is unlikely to be
pathogenic per se, however the heterogeneous nature of TTV means that some of the
genotypes may be involved in a disease process. The prevalence of TTV in the general
population frequently leads to viral co-infections and transmission of TTV during blood
transfusion may lead to the introduction of TTV or novel genotypes of TTV in individuals
with underlying conditions. Zein and co-workers studied a cohort of HCV positive
patients with well characterised disease and found TTV to be significantly more prevalent
in those with advanced liver disease (decompensated cirrhosis and hepatocellular
carcinoma) compared to those with stable liver disease (chronic hepatitis and compensated
cirrhosis). Univariate analysis showed that TTV was important for predicting the stage of
liver disease in HCV positive individuals [Zein et al., 1999]. Another study investigating a
group of patients with fulminant hepatic failure discovered 100% of those with TTV died
compared with only 47% of those who were negative for TTV DNA [Tanaka et al., 1999].
Other investigator's findings failed to support this and reported that TTV infection has no
impact on disease progression in HCV positive patients [Kao et al., 2000; Tangkijvanich et
al., 1999],
Histopathological analysis of liver tissue taken via percutaneous needle biopsy from TTV
positive and negative non-B, non-C and non-G chronic hepatitis patients showed mild
fibrosis and periportal/piecemeal necrosis which were not seen in the TTV negative control
group [Suzuki et al., 2001]. Hu also found mild pathogenicity when TTV DNA positive
liver biopsy samples from patients suffering from non A-G hepatitis were studied [Hu et
al., 2002],
During experimental inoculation of hepatocyte cell lines with TTV genotype 1 to generate
an in vitro replication system, infection of a Chang liver cell line (derived from a non
malignant liver tissue) produced morphological changes in the cells. The initial cytopathic
effect (CPE) occurred 2-3 days post inoculation and was characterized by focal cell
rounding and granulation. By day six the entire cell layer had degenerated. This suggests
that TTV genotype 1 may be able to cause cell damage in the liver of infected individuals
when unrestricted replication of the virus occurs [Desai, 2005]. Interestingly, although a
phytohemagglutinin stimulated TTV negative PBMC cultures and a B lymphoblast cell
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line were also shown to support active TTV replication in the same study, no
morphological changes were observed in these cells.
The possible pathogenicity of TTV was also investigated in research which compared the
apoptotic potential of a protein encoded by ORF3 of TTV with Apoptotin, a protein
produced by CAV which has been documented to cause apoptosis solely in cancer cell
lines. The 105 amino acid protein from TTV genotype 1, putatively named TTV-derived
apoptosis-inducing protein (TAIP), was shown to cause apoptosis in a hepatocellular
carcinoma (HCC) derived cell line at a significantly higher level than in a non-HCC cell
line [Kooistra et al., 2004], Unfortunately, the effect of the TAIP construct on normal liver
cells was not determined but these data do appear to suggest a pathological role for TTV,
at least in relation to HCC.
The pathogenicity ofTTV in mice was examined in vivo by creating transgenic mice using
a gene expression cassette which contained ORFs 1, 2-4, 2-5, 3 and 6 from TTV genotype
1. Of the 84 mice born, eight were transgenic and contained a mixture of the ORFs in the
constructs. One of the mice produced offspring, which contained only ORF1 and had a
phenotype of reduced growth, retardation and premature death from ascites. These mice
had high levels of gene expression in the kidneys and had pathological changes in this
tissue which resembled nephrotic syndrome in humans. There were no abnormalities seen
in the liver of any of the transgenic mice [Yokoyama et al., 2002],
Transmission studies have also been used to try to assess the pathogenicity of TTV.
Mushahwar used human serum from patients with chronic non A-E hepatitis and TTV
infection to inoculate chimpanzees however no histological of biochemical evidence of
hepatitis or liver disease was seen [Mushahwar et al., 1999]. In a separate experiment,
two chimpanzees were infected with human TTV extracted either from feces or from
serum. One chimpanzee had detectable TTV DNA in its serum from week five to week 15
post inoculation (p.i.). An increase in ALT levels, which corresponded to mild
biochemical and histological changes in the liver, was seen just before the virus was
cleared at week 15. The second chimpanzee became viraemic at week seven p.i. but had
failed to clear the infection at week 30 when observation ceased. A peak in ALT levels
was seen in week 16 which again corresponded with mild ballooning and degeneration of
hepatocytes [Tawara et al., 2000]. Both these experiments suggest that TTV, or at least
TTV genotype 1, may be pathogenic.
21
The finding that TTV was not solely a hepatotropic virus led to an increase of
investigations into the role of TTV in extrahepatic diseases or complications of liver
diseases which are not directly related to liver function. Using the N22 PCR which detects
TTV genotype 1, platelet count in patients with chronic hepatitis C infection and chronic
hepatitis with no markers of HCV or HBV was found to be lower in those who were TTV
DNA positive compared with the TTV negative group [Tokita et al., 2001]. A further
study compared platelet counts in chronic hepatitis C patients before and after treatment
with interferon and found that individuals who had concomitant TTV infection with
genotypes 1-4 had significantly increased thrombocytopenia both before and after
interferon treatment [Tokita et al., 2002]. TTV has also been implicated in aplastic anemia
following post transfusion hepatitis [Kikuchi et al., 2000] however other investigators
[Poovorawan et al., 2001; Udomsakdi-Auewarakul et al., 2000] have refuted this.
TTV has also been implicated in the exacerbation of autoimmune disorders such as
multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Investigation of in vivo
clonally expanded T-cells isolated from the cerebrospinal fluid of an MS patient during
relapse showed that peptides from the arginine rich N-terminus of TTV ORF1 could
stimulate autoreactive T cell clones which may lead to disease exacerbation [Sospedra,
2005], In patients with SLE, not only was TTV found to be significantly more prevalent
than in blood donors, but TTV was thought to generate antibodies cross reactive to a
human endogenous retrovirus nuclear protein, an autoantigen associated with SLE
[Gergely, 2005].
SENV, like TTV, has been extensively investigated to establish conclusively a link
between the virus and cryptogenic hepatitis. SENV D and SENV H in particular have
been found in a significantly higher percentage of patients with liver disease as well in
those with a history of frequent blood transfusion and intravenous drug users than in
healthy, low risk populations (Table 1.8.1). There seems to be little doubt that SENV D
and H are more prevalent in high risk groups but no evidence that they are involved in
causing hepatitis directly or in increasing the severity of hepatitis caused by HCV or HBV
[Kao et al., 2002; Umemura et al., 2003].
TLMV is still very much an unknown quantity with, at the time of writing, only 17 papers




The most characteristic feature of TTV and TLMV is their ability to produce chronic
infection, although little is known about the mechanisms of persistence. The ubiquity of
the virus and the prevalence in the general population has led some researchers to
hypothesize that TTV may have a commensal relationship with humans [Simmonds,
2002], It is also possible that infection either in utero or peripartum leads to a degree of
immune tolerance as seen with hepatitis B virus (HBV).
Sequence analysis of TTV genotype 1 isolated from patients with chronic and acute TTV
infections showed that those with chronic infection had a high percentage of substitutions
in the hypervariable region ofORF1. This resulted in the generation of quasispecies which
may help the virus escape immune surveillance. These quasispecies were not seen in
acutely infected individuals who also had a higher proportion of free TTV compared with
IgG complexed TTV as determined by immunoprecipitation with goat anti-human IgG
followed by PCR of both the precipitate and supernatant. On the other hand, immune
complexes tended to be frequent in chronically infected patients, by far outweighing any
free virus present [Nishizawa et al., 1999]. Immune complexes of virus with IgG are
discussed in chapter five of this thesis.
Ott and colleagues carried out a western blot using a recombinant C-terminus protein from
ORF1 and serum from French blood donors, healthy children and patients with cryptogenic
hepatitis. A positive serological response (anti TTV IgG + IgA + IgM) was determined in
98.7%, higher than the 76.1% who were PCR positive. Further analysis demonstrated that
none of the sera tested were positive for anti-TTV IgM, therefore none of the viraemia was
the result of novel infections [Ott et al., 2000], The authors suggested that the C terminus
ofORF1 was an immunodominant epitope, likely to be highly antigenic in vivo.
IgM class antibodies have been detected in two patients with post transfusion non A-G
hepatitis and in an individual with acute TTV infection. The time from TTV DNA
detection in the serum of these individuals and IgM production was between 2-7 weeks. In
one patient, anti-TTV IgG was detected after IgM had disappeared from circulation but in
the other 2 individuals, both IgM and IgG were present simultaneously [Tsuda et al.,
2001], In a second study, IgM class antibodies against a recombinant protein generated
from ORF2a and ORF2b of TTV genotype 6 were detected in 9% of healthy individuals.
Interestingly, anti-TTV IgM against the product of ORF2b were detected over a number of
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years during follow up, with and without the presence of TTV DNA in serum. It is as yet
unknown why the IgM phase of immune response persisted in these individuals. Only
10% were IgG antibody positive to the same antigens, with all of these individuals also
being TTV DNA positive [Kakkola et al., 2004].
Approximately 80-95% of TTV isolated from the sera of HIV positive individuals with
high TTV DNA titre is complexed with IgG, however TTV in faeces is usually in the form
of uncomplexed free virus. Electron microscopy of TTV infected sera visualised
aggregates of TTV with IgG. An aggregate of TTV particles could be visualised in fecal
supernatant only on the addition of y-globulin which contained TTV-specific antibodies
[Itoh et al., 2000].
These data conclusively prove that some individuals are capable of eliciting both an IgM
and an IgG immune response to some of the proteins encoded by the TTV genome. It is
unknown if these antibodies are cross protective, however the presence of TTV DNA
simultaneously with antibodies suggests they might not be [Kakkola et al., 2002]. From
these limited data, it is difficult to ascertain if the paradigm of IgM antibody in early
infection followed by IgG can be applied to these viruses.
There is evidence that TTV and TLMV titres in the serum of immunosuppressed
individuals are raised. Soldiers undergoing an intensive week long training program
known to cause physical and mental exhaustion and shown to impair their immune systems
(30% decrease in circulating lymphocytes and decreased immunoglobulins) had an
increase in TTV and TLMV titre however the change was not statistically significant.
Patients subject to immunosuppressive treatment following kidney transplant experienced
a significant increase in TTV and TLMV viral loads [Moen et al., 2003], This is
corroborated by increased TTV titres in liver transplant recipients who were also taking an
immunosuppressive drug regime [Shang et al., 2000]. The change in TTV and TLMV titre
in relation to the immunosuppression associated with HIV infection and AIDS is discussed
in chapter four.
The role of the immune system in the control of TTV viraemia is further supported by
reports that stimulation of the immune system with interferon for the treatment of HCV
reduced the TTV titre or completely cleared the virus in the majority of cases [Maggi et al.,
2001c; Nishizawa et al., 2000]. In many cases, however, this decrease in circulating TTV
was not maintained [Maggi et al., 1999; Maggi et al., 2001c]. Touinssi also discovered the
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apparent increased prevalence of TTV in haemodialysis patients and diabetics actually
reflected an increase in elevated viraemia in these populations, resulting in an increase in
patients whose viraemia was above the detection limit of the assay. Haemodialysis
patients and diabetics can display a degree of immunosuppression, which could act as an
explanation for this phenomenon [Touinssi et al., 2001],
1.10 HIV/AIDS and Anelloviruses
Acquired Immunodeficiency Syndrome (AIDS) was first described in 1981 following an
outbreak of immunodeficiency related opportunistic infections among homosexual men in
the Los Angeles area of the United States [CDC, 1981]. In 1982, similar symptoms were
observed in further populations including haemophiliacs, blood transfusion recipients and
the babies of high-risk mothers, which led scientists to believe they were looking for a
pathogenic agent transmitted via blood and body fluids. By 1984, scientists had isolated a
candidate Retrovirus which was later named Human immunodeficiency virus (HIV)
[Barre-Sinoussi et al., 1983].
1.10.1 HIV virion
HIV is a member of the genus Lentivirus, from the Retroviridae family of non-oncogenic
viruses infecting humans, non-human primates and some domesticated mammalian species
[Ratner et al., 1985], It is an icosahedral virus (Figure 1.10.1), 80-1 lOnm in size, with a
lipid envelope that is largely derived from the host cell plasma membrane. This lipid
bilayer is spiked with the two main viral envelope proteins: glycoprotein (gp) 120
protrudes from the virus and is essential for the attachment of the virus to the CD4 receptor
on host cells, and the transmembrane protein gp41 which spans the lipid bilayer and
facilitates the fusion of the viral and cell membranes.
The capsid encapsulates two copies of single stranded RNA as well as reverse transcriptase
and other enzymes needed for viral replication. The nine kb of viral genome contains nine
genes (Table 1.10.1): structural genes gag, pol and env, transactivation genes rev and tat,
and accessory genes nef, vpu and vif [Hirsch et al., 1996; Varmus et al., 1998],
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Figure 1.10.1 - Diagram of HIV virion.
1.10.2 HIV life cycle
The HIV life cycle begins with the viral glycoprotein gpl20 binding with high affinity to
the CD4 receptor on the surface of the host cell T-lymphocyte or macrophage. Co-receptor
binding is also needed for viral entry into the cell, for X4 strains of HIV the chemokine
receptor CXCR4 is used, and R5 strains ofHIV use the receptor CCR5. Once receptor and
co-receptor binding has occurred glycoprotein gp41 facilitates the fusion of the viral
envelope and the cell membrane allowing viral RNA, gag proteins and pol enzymes to
enter the cell cytoplasm [Chan et al., 1998; Dimitrov et al., 1997].
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rev (regulator of viral
expression)
encodes virus core proteins:
p24 - capsid protein
pi7 - matrix protein
p9 - binds to viral RNA
p7 - binds to viral RNA
encodes enzymes:
reverse transcriptase - converts RNA to DNA
integrase - integrates virus into host cell DNA
protease - cleaves non-functional core precursor
proteins
encodes virus envelope proteins:
gpl20 - mediates binding of virus to CD4 receptor on
host cell
gp41 - fuses virus with cellular membrane
encodes Tat protein - upregulates viral transcription
encodes Rev protein - regulates viral RNA transport
and splicing
vif (viral infectivity factor) encodes Vif protein - facilitates virion maturation
vpu (viral protein U)
nef (negative-regulation
factor)
encodes Vpu protein - promotes virus budding
encodes Nefprotein - interacts with host cells inducing
longevity in infected cells and apoptosis in non infected
cells
vpr (viral protein R) encodes viral protein R - regulates gene expression and
induces cell cycle arrest
Table 1.10.1 - Function of HIV genes.
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The viral reverse transcriptase then catalyses the production of double stranded DNA from
the single stranded RNA and this migrates to the nucleus of the cell where it integrates
with the host DNA to form a provirus. Once the provirus has been inserted into the
genome the only way the virus can be eliminated is by destroying the cell itself [Hirsch et
al., 1996],
Once integrated, the provirus can either remain latent or use the host cell's RNA
polymerase II to produce RNA transcripts, which are spliced into mRNAs that are
transported into the cytoplasm to be translated into regulatory or precursor proteins. The
precursor core proteins are cleaved by the viral protease and components for a new virion
assemble and move towards the cell's surface, pinching off from the cell to form an
infectious virus. Virus can also be released from an infected cell when the cell lyses
[Hirsch et al., 1996].
1.10.3 Pathogenesis of HIV infection
Primary infection with HIV is usually characterised by 'flu like symptoms,
lymphadenopathy, rash and weight loss, which is the result of the virus replicating
unchecked by the immune system and disseminating throughout the body. The virus also
forms reservoirs of infection in the lymph nodes and gut associated lymphoid tissue
[Brenchley et al., 2004], The high viral load stimulates the production of HIV specific
CD4+ T lymphocytes to control the infection however viral protein gpl20 has a high
affinity for the CD4 receptor and these cells are quickly infected and destroyed. As the
production of cytotoxic CD8 T lymphocytes, which kill the infected cells, and the trapping
of the virus in follicular dendritic network of the lymph nodes decreases the amount of
virus in the bloodstream and as the viral load decreases, the CD4 count rises towards the
pre infection level (Figure 1.10.2)[Fauci et al., 1993],
After primary infection and seroconversion, a state of dynamic equilibrium occurs between
the numbers of cells becoming infected, the number of CD4+ T lymphocytes being
produced and dying, and the level of viral replication. This chronic stage ofHIV infection
lasts on average ten years and during this time there is usually a slow progressive increase
in viral load and decrease in CD4 count as the immune response becomes less and less
effective against the virus. The rate of disease progression appears to be dependent on the





Figure 1.10.2 - HIV titre, CD4+ and CD8+ T lymphocyte numbers during stages of HIV
infection.
Initially the R5 strain of the virus, a non-syncytial forming strain which uses the
chemokine receptor CCR5 as the coreceptor, predominates but a shift towards strains that
use the coreceptor CXCR4 and have the ability to form syncytia tends to occur over time.
This change of the predominant virus population allows the virus to kill CD4+ T
lymphocytes which are not directly infected and is responsible for a more rapid decline of
CD4+ cells and a faster progression towards AIDS [Connor et al., 1993].
AIDS is confirmed when the CD4 count falls to less than 200 cells per pi or by the
presence of one of 25 conditions which indicate severe immunodeficiency such as
Pneumocystis carinii pneumonia and toxoplasmosis.
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1.10.4 Effect ofHIV on the immune system
The predominant cells infected and destroyed by HIV are CD4+ T lymphocytes but the
impact that the virus has on the immune system is not restricted to these cells. CD4+ T
cells also play a pivotal role in the induction CD8 T and B cells which are crucial for an
effective immune response. A summary of effects the reduction ofCD4+ lymphocytes has
on the immune system is outlined in Figure 1.10.3. The type of immune deficiency
associated with the depletion of CD4+ T lymphocytes and the direct and indirect effects
this has on the immune system leaves the patient vulnerable to infections by fungi,
protozoa, bacteria and viruses. It is this central role in immune control that makes the CD4
count the most accurate way of assessing disease progression and therefore the level of






















Figure 1.10.3 - Effect of CD4+ T lymphocyte depletion on immune system.
CD8 T lymphocytes are also critical to the immune system and the sudden depletion of
these cells often precedes the decline into AIDS. Unlike CD4+ cells, CD8 cells are not the
primary targets for the virus although some CD4+CD8+ cells have been documented
which would be susceptible to infection [Imlach et al., 2001]. CD8 lymphocytes express
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the coreceptor CXCR4 and it appears that the syncytia forming strain which dominates the
latter stages of infection can bind to this ligand and induce apoptosis in these cells leading
to a sharp decline in cell numbers [Herbein et al., 1998; Livingstone et al., 1996],
1.10.5 HIVand concomitant viral Infections
The immunodeficiency associated with HIV infection and AIDS results in opportunistic
infections (OIs) by pathogens that would usually cause a mild or asymptomatic infection in
immunocompetent individuals. These usually occur after the CD4 count has fallen below
500 cells per pi and signify the progression towards full-blown AIDS.
Similar routes of transmission often result in HIV positive individuals harbouring
concomitant viral infections, for example up to 80% of intravenous drug users and 98% of
haemophiliacs are also infected with HCV [Mohsen et al., 2002], These co-infections can
have both positive and negative effects on the disease outcome for both HIV and the
second virus.
Although still not conclusively proven, there are some studies indicating that HCV
infection has an adverse effect on HIV pathogenesis and can speed the progression towards
AIDS [Greub et al., 2000]. HIV also results in an increased HCV viral load and a more
rapid onset of liver disease, possibly due to the depletion ofCD4+ T lymphocytes [Valdez
et al., 2000].
Conversely, GBV-C has been reported to have a beneficial effect on disease progression
[Cainelli et al., 2001], It was first described in 1995 and shares routes of transmission with
HIV making co-infections common. The beneficial effect on HIV prognosis only occurs
before seroconversion, during which viral clearance occurs. The presence of IgG antibody
to GBV-C (usually with the absence of any detectable GBV-C RNA) is accompanied by a
negative effect on HIV disease progression and a worse prognosis than seen with GBV-C
uninfected individuals [Williams et al., 2004].
1.10.6 TTV/TLMV and HIV
No pathological role for TTV/TLMV infection has been established, however the high
prevalence of virus in the general population leads to a high level of co-infections with
other viruses. The immunodeficiency associated with HIV can result in opportunistic
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infections and the reactivation of latent viruses so the natural history of TTV/TLMV in
HIV positive individuals is of particular interest.
The role of TTV/TLMV in HIV infection and the progression towards AIDS is still
uncertain with many studies publishing conflicting results on the significance of co-
infection. A Danish HIV cohort had significantly higher prevalence and titre of TTV
compared with blood donors (76% vs. 7%) [Christensen et al., 2000] however the number
of blood donors testing positive for TTV appears to be particularly low. This is probably
due to the use of PCR primers sited in ORF2 of the TTV genome which would restrict the
genotypes of virus amplified. HIV positive patients tend to be infected with a higher
number of mixed infections than blood donors [Devalle and Niel, 2004; Sherman et al.,
2001] so PCR amplification of the most prevalent genotype is more likely in those with
HIV. Further analysis of the HIV positive cohorts showed a significant inverse correlation
between TTV titre and CD4+ T cells [Christensen et al., 2000; Shibayama et al., 2001] and
high serum TTV and SENV H concentrations were also cited as an independent factor
associated with decreased survival [Christensen et al., 2000; Sagir et al., 2005],
These studies appear to indicate a role for the immune system in the control of
TTV/TLMV replication however a study following changes in TTV and TLMV viral load
in individual samples failed to find a significant increase in titre following progression to
AIDS or in conjunction with changes in CD4+ and CD8+ T lymphocytes counts [Moen et
al., 2002b],
The high number of co-infections of HIV and HCV and the high prevalence of TTV in
HIV positive populations invariably also results in HIV, HCV and TTV co-infections.
Although it is now thought to be unlikely that TTV is the cause of non A-E hepatitis, there
is evidence that infection with TTV combined with dual HIV and HCV infection increases
the ALT levels in patients indicating more severe hepatitis than in patients infected only
with HIV and HCV [Shieh et al., 2003] and with TTV and HIV [Sherman et al., 2001].
1.11 TTV-like viruses in non-human primates
Soon after TTV was discovered in humans, research to investigate TTV homologues in a
number of non-human primate and animal species began. Romeo and colleagues used
UTR PCR to amplify TTV from the serum and faeces of naive chimpanzees {Pan
troglodytes) bred in captivity in the USA. They found a high proportion of sera (65%)
were PCR positive with sequences which were significantly different from published
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human sequences, appearing to rule out transmission from human contact [Romeo et al.,
2000], TTV sequences from chimpanzees kept in captivity in The Netherlands and in a
separate US facility showed 85-91% nucleotide homology and 93-96% homology at the
amino acid level to the sequence published by Romeo, suggesting a chimpanzee specific
TTV [Verschoor et al., 1999]. This was refuted by a study which found sequences isolated
from chimpanzees, owl monkeys (Aotus trivirgatus) and tamarins (Sanguinus labiatus) as
well as from farm animals were not genetically dissimilar from human sequences [Leary et
al., 1999]. The primers utilized in this study annealed to the relatively non-conserved N22
coding region of the genome, known in humans to be an unreliable detection system
because of the heterogeneity in this region.
TTV-like sequences have also been isolated from chimpanzees, Japanese macaques
(Macacca fuscata), red-bellied tamarins (Saguinus labiatus), cotton top tamarins (Saguinus
oedipus) and owl monkeys (Aotus trivirgatus) using UTR primers (Table 1.11.1).
Sequences analysis showed that the UTR sequences, usually highly conserved (85-100%
similar) within all human genotypes, did not show a high degree of conservation when
compared with non-human primate sequences. Comparison of the prototype human TTV
sequence (TA278) with nucleotide sequences from chimpanzees, macaques, tamarins and
owl monkeys showed similarities of 66-90% similarity (chimpanzee), 62-72% similarity
(macaque) and up to 57% similarity for both tamarin and owl monkey. Only TTV from
chimpanzees was detectable using the N22 primers, suggesting that none of the TTV-like
viruses infecting the Old World monkeys were sufficiently similar to the human strains in
the ORF1 coding region to be amplified using this primer set [Okamoto et al., 2000a].
As with human TTV, the virus amplified from chimpanzee is extremely heterogeneous. At
the present time, at least four genetic groups have been identified, differing by at least 30%
at the nucleotide level in the N22 region. Phylogenetic analysis has revealed that
chimpanzee sequences are not clustered in a separate group from the human sequences,
rather chimpanzee and human sequences are interspersed [Okamoto et al., 2000a]. The
possibility of human TTV infecting chimpanzees has been shown by transmission
experiments however there has yet to be any incidence of chimpanzee TTV detected in
humans [Mushahwar et al., 1999; Okamoto et al., 2000a].
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Species TTV positive Reference
serum (%)
Chimpanzee (Pan troglodytes) 98% [Abe et al., 2000]
Japanese macaque (Macaca fuscata) 90%
Red bellied tamarin (Saguinus labiatus) 100%
Cotton-top tamarin (Saguinus oedipus) 83%
Owl monkey/Douroucouli (Aotus 100%
trivirgatus)
Crab eating monkey (Macaca fascicularis) 14%
Tupaia (Tupaia belangeri chinesis) 26%
Dog (Canis familiaris) 38%
Cat (Felis catus) 43%


















Table 1.11.1 - Detection of TTV-like viruses in non-human primates and domesticated
animals by PCR.
A TTV-like virus has also been detected in tupaias (tree shrews), which have
characteristics of both primates and insectivores. Although the genomic organisation and
transcription profile of the isolated viruses are analogous to the previously characterised
TTV and TLMV, the genome differs from these by more than 50% [Okamoto et al.,
2001b],
34
The tupaia virus has a small genome, more comparable in size to the animal viruses CAV
and BFDV than to human TTV or TLMV (Table 1.11.2) however phylogenetic analysis
showed the tupaia virus was closer to TLMV isolated from humans than from the TTV-
like viruses infecting tamarins and owl monkeys [Okamoto et al., 2001b],
Species Virus Genome size
(nucleotides)
Reference
Human (Homo sapiens) TTV 3852 [Kamahora et al.,
2000]
Human (Homo sapiens) TLMV 2915 [Takahashi et al.,
2000a]
Chimpanzee (Pan troglodytes) TTV-
like
3690 [Okamoto et al.,
2000b]
Japanese macaque (Macaca TTV-
fuscata) like
3798 [Okamoto et al.,
2000a]
Cotton-top tamarin (Saguinus TTV-
oedipus) like
3371 [Okamoto et al.,
2000a]
Owl monkey/Douroucouli (Aotus TTV-
trivirgatus) like
3718 [Okamoto et al.,
2000a]
Dog (Canis familiaris) TTV-
like
2797 [Okamoto et al.,
2001b]
Cat (Felis catus) TTV-
like
2064 [Okamoto et al.,
2001b]
Pig (Sus domesticus) TTV-
like
2878 [Okamoto et al.,
2001b]
Chicken (Gallus domesticus) CAV 2319 [Noteborn, 1991]
Table 1.11.2 - Comparison of genome sizes of Anelloviruses infecting humans, non-human
primates and domesticated animals.
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As well as primates, species-specific TTV-like viruses infect domesticated cats, dogs and
pigs. Like tupaia TTV, virus genomes from cats, dogs and pigs are smaller than human
TTV (Table 1.11.2) and phylogenetic analysis showed these three novel viruses have less
than 45% homology with previously reported TTV and TLMV genomes as well as
differing from each other by 54% at the nucleotide level. However, even in these
genetically distant viruses, regions of homology with human and non-human primate TTV
and TLMV were found, most notably two conserved 15 nucleotide sequences located in
the UTR [Okamoto et al., 2002]. Further investigation of pigs from a herd in Brazil
discovered a single swine infected with two strains of TTV which displayed only 45%
homology, suggesting that swine TTV is as heterogeneous as its human counterpart [Niel
et al., 2005].
Aims
The project had the following aims:
• to evaluate the prevalence ofAnelloviruses in the Scottish blood donor population
• to investigate Anelloviruses in non-human primates
• to establish if domesticated farm animals are infected with Anelloviruses




2 MATERIALS AND METHODS
2.1 Suppliers
Unless otherwise stated, all the chemicals used were supplied by Sigma-Aldrich.
Oligonucleotide primers and digoxigenin labelled probes were synthesised by Operon.
Company Address
Amersham Amersham Place, Little Chalfont,
Buckinghamshire, HP7 9NA
Anachem Anachem House, Charles Street, Luton,
Bedfordshire, LU2 OEB
BDH McQuilkin & Co., 21 Polmadie Avenue,
Glasgow, G5 Obb
bioMerieux UK Ltd. Grafton Way, Basingstoke, Hampshire, RG22
6HY
Camblab Camlab House, Norman Way Industrial Estate,
Over, Cambridge, CB4 5WE
Dynal Biotech Invitrogen Ltd., 3 Fountain Drive, Inchinnan
Business Park, Paisley, PA4 9RF
Eppendorf-Netheler-Hinz GmbH D22331 Hamburg, Germany
Kodak Anachem, D'Arcy Way, LLandarcy, Neath, SA10
6EZ
National Diagnostics Fisher Scientific Ltd. Biship Meadow Road,
Loughborough, LEI 1 5RG
Operon Biotechnologies GmbH Nattermannallee 1, D50829, Cologne, Germany
PerkinElmer Chalfont Road, Seer Green, Beaconsfield, Bucks,
HP9 2FX
Promega UK Ltd. Delta House, Chilworth Science Park,
Southampton, SO 16 7NS





Bell Lane, Lewes, East Sussex, BN7 1LG
The Old Brickyard, New Road, Gillingham,
Dorset, SP8 4XT
Table 2.1.1 - Contact information for suppliers used to source reagents for this thesis.
2.2 Reagents
Reagent Constituents
2% agarose gel 1 g agarose
50 ml 0.5X TBE
0.5 M EDTA 186.12 gEDTA
adjusted to 1 L with df^O
LB medium 10 g Bacto-Tryptone
5 g Bacto-yeast
lOgNaCl
adjusted to 1 L with dhLO




adjusted to 1 L with dtLO
Lysis buffer 0.11 M NaCl2
55 mM Tris pH 8.0
1.1mM EDTA pH 8.0,
38
0.55% sodium dodecyl sulphate [SDS]
1 mg/ml Proteinase K
40 pg/ml poly A
adjusted to 1 L with dH20




adjusted to 1 L with dH20
Sanger TBE
3 M sodium acetate (NaAc)
324 g Tris base
85 g boric acid
19 g EDTA
adjusted to 2 L with dH20
40.8 g NaAc
adjusted to 100 ml with dH20
0.9% sodium chloride (NaCl) 0.9 g NaCl
adjusted to 100 ml with dH2Q
10% SDS lOOg SDS
adjusted to 1 L with dH20
10X SSC 175.32 g sodium chloride
88.23 g sodium citrate
adjusted to 1 L with dH2Q
SOC medium 5 g Tryptone Peptone
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10 ml 20% glucose
adjusted to 1 L with d H20
0.5X TBE 54 g Tris base
27.5 g boric acid
20ml 0.5 M EDTA
adjusted to 1 L with dH20
Table 2.2.1 - Table detailing the components of solutions used in this thesis.
2.3 Samples
Minipool plasma samples were acquired from the Scottish National Blood Transfusion
service which assures the safety of all blood donated in Scotland and Northern Ireland by
testing for HCV and HIV by PCR. The sensitivity of this assay allows for this testing to be
carried out on 95 individual donations amalgamated into a single 'minipooT sample. The
minipools used in this study were all HIV, HCV and HBV PCR negative. Fifteen
Taiwanese minipools were also used to confirm the sensitivity of the SENV assay
developed for this project.
One hundred and ninety two human plasma samples were obtained from the Scottish
National Blood Transfusion Service. These had been sent to the PCR Reference
Laboratory for confirmatory testing following indeterminate serology results. All of the
samples had been HIV, HCV and HBV negative by PCR testing.
Six post mortem, HIV positive, bone marrow samples and nineteen post mortem, HIV
positive, paired, bone marrow and spleen samples were supplied by the Medical Research
Council Brain and Tissue Bank of Edinburgh (Western General Hospital, Edinburgh).
Bone marrow, spleen, left cerebellum, lymph node, thoracic spinal cord and liver from the
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same HIV positive individual were also provided by the same source. Seven post mortem,
HIV negative, paired, bone marrow and spleen samples were supplied from Medical
Research Council Sudden Death Brain & Tissue Bank and the same number of bone
marrow aspirate samples were collected from patients investigated for haematological
abnormalities at the Royal Infirmary, Edinburgh. The use of tissue samples was approved
for research by the Lothian Ethics of Research committee.
Ten serum samples from blood donors with either HIV, HCV or HBV and 10 samples
from HIV/HCV/HBV negative donors were supplied by the Scottish National Blood
Transfusion Service.
Twenty serum samples from patients undertaking an immunosuppressive drug regime
following heart, lung or both heart and lung transplant surgery were collected previously
for a study investigating Epstein-Barr virus and were used with the permission of Professor
Dorothy Crawford and Dr Paul Hopwood.
Sera from 13 drills, two mandrills, four cherry-capped mangabeys, five chimpanzees, 14
orangutans, 19 gibbons and one gorilla were selected as representative samples from non-
human primates and investigated for the presence of TTV/TLMV. These were collected
by sanctuaries in Nigeria, Cameroon and Taiwan with the exception of the gorilla serum,
which was provided by Edinburgh Zoo. Again with the exception of the gorilla, all of the
primates had been wild caught and each of the species were housed separately from other
primate species.
The Roslin Institute, Edinburgh, made sera from 20 cows, 20 sheep, 20 goats and 29
chickens available. These samples had been collected from animals kept in a variety of
locations in England and Scotland.
2.4 Nucleic Acid extraction
2.4.1 Nuclisens Method
The nuclisens extraction method (bioMerieux) is a guanidine thiocyanate and silica based
semi automated extraction method in which between 200 pi and 1 ml of the samples was
added to a lysis buffer containing 5 mol/1 guanidine thiocyanate, Triton X-100 and
Tris/HCl which had been pre-incubated at 37°C. Fifty pi of hydrochloric acid-activated
silicon dioxide particles was then added to each sample and these were incubated for 30
minutes at 37°C, after which the samples were centrifuged for two minutes at 13000 rpm
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to produce a silica pellet. The pellet was resuspended in a small volume of the lysis buffer
and added to the extractor cartridge (Figure 2.4.1). Air pressure applied into the cartridge
resulted in the sample being forced through the cartridge leaving the silica particles
binding to the filter. Multiple wash cycles are performed with a wash buffer containing
guanidinium thiocyanate as well as with acetone and 70% ethanol. The silica was air dried
at 56°C before the nucleic acid was eluted in elution buffer (Tris/HCl) at 56°C and
transferred to a clean tube at the bottom of the cartridge.
2.4.2 Phenol-Chloroform Method
One hundred pi of serum or plasma was added to 400 pi of lysis buffer which had been
pre-incubated at 37°C to inactivate endogenous RNAses. This was then incubated for a
further 10 minutes at 37°C. A portion of tissue equivalent to 0.5-1.0 cm3 was dissected
from frozen tissue samples and added to 500 pi of pre-incubated lysis buffer. These were
then incubated overnight at 56°C and vortexed frequently to aid the digestion process.
Once the serum, plasma and tissue samples had been lysed, extraction was carried out with
the addition of 450 pi of water-saturated phenol (Sigma) to separate the protein from the
nucleic acid.
After vortexing for 5 minutes, the samples were centrifuged for 10 minutes at 13000 g.
The aqueous phase was then removed and added to an eppendorf containing 450 pi 50:1
chloroform:iso-amyl alcohol (BDH) solution. This was then vortimixed for a further 2
minutes before being centrifuged for 5 minutes at 13000 g. The aqueous phase was
removed and transferred to an eppendorf to which 40 pi 3 M Sodium Acetate pH 5.2 had
already been added. One ml of 100% ethanol (-20°C) was then added and the tubes
inverted to mix the solution, which was then left overnight at -20°C to allow the nucleic
acids to precipitate. The nucleic acids were pelleted by centrifugation at 13000 g for 10
minutes (0°C) and washed with 600 pi 80% (v/v) ethanol. The resultant pellet was left to
air dry at 37°C for 10 minutes to allow any remaining ethanol to evaporate before being
















2.4.3 High Pure PCR Template Preparation kit
Nucleic acids were extracted from serum and tissues using the High Pure PCR Template
preparation kit (Roche) following the manufacturers instructions. Briefly, 25-50 mg tissue
was incubated at 55°C for 1 hour with tissue lysis buffer (4 M urea, 200 mM Tris, 20 mM
NaCl, 200 mM EDTA) and proteinase K. Following the addition of binding buffer (6 M
guanidine HC1, 10 mM urea, 10 mM Tris-HCl, 20% Triton X-100), the sample was
incubated a 70°C for 10 minutes. Serum (200 pi) was added to binding buffer and
proteinase K and also incubated at 70°C for 10 minutes. The remaining extraction method
was the same for both tissue and serum and involved the addition of isopropanol before the
solution was centrifuged through a glass fibre packed filter tube to capture the nucleic
acids. Contaminating cellular components were removed during a series of washing steps
with inhibitor removal buffer (5 M guanidine-HCl, 20 mM Tris-HCl) and wash buffer (20
mM NaCl, 2 mM Tris-HCl). Finally, a low salt buffer (10 mM Tris) was used to elute the
nucleic acids from the glass fibre.
2.4.4 QIAamp MinElute Virus Spin kit
Nucleic acids from serum samples were extracted using QIAamp MinElute Virus Spin kit
(Qiagen) following the manufacturers protocol. If a serum sample volume was less than
200 pi, it was first made up to the appropriate volume using 0.9% sodium chloride solution
then protease and buffer AL added. This was incubated at 56°C for 15 minutes and 100%
ethanol added before being transferred to a column. The sample was centrifuged to
remove the lysate and the nucleic acid bound to the filter washed with buffer AW2 and
100% ethanol. The nucleic acid was eluted from the membrane using buffer AVE.
2.5 Quantitation of Nucleic Acids
2.5.1 Quantitation by spectrophotometry
The extracted nucleic acids were analysed on a spectrophotometer to determine the
concentration of the DNA and the purity of the sample. Spectrophotometric absorbance
reading were taken at 260 nm, the wavelength at which DNA absorbs light, and 280 nm,
which is the absorbance maxima ofproteins.
The concentration ofDNA calculated using the equation:
DNA concentration (pg/ml) = A260 X D X 50
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Where A260 is the optical density of the sample at 260 nm, D is the dilution factor and 50
(pg/ml) is the concentration of double stranded DNA that results in an A260 of 1.
The A280 gave an estimate of the concentration of protein within the samples. The purity
of the sample was ascertained using the ratio of A260/A280 where a value of >1.5 was
deemed to be sufficiently pure.
2.5.2 Quantitation by limiting dilution
The sensitivity of the PCR reaction and its ability to amplify single molecules of target
DNA allows for the quantification of viral genomes by limiting dilution. This involved the
titration of a DNA samples in ten fold serial dilution steps until the endpoint is achieved.
The last PCR positive dilution is considered to contain at least one copy of the molecule of
interest. To quantify the titre ofTTV and TLMV, the samples were subject to 10 fold serial
dilution before being amplified using UTR nested PCR or TTV/TLMV specific PCR
methods (see section 2.6).
The titre ofTTV/TLMV was estimated using the following calculation:
Total DNA in one cell = 6.6 pg ■ 6.6 x 10~6 pg = 10"6 cells containing 6.6 pg DNA
DNA concentration of sample = Y pg/pl
Number of cells per pi (n) = Y/6.6 x 10~6 pg
Number of cells added to 1st dilution of dilution series (N) = n X number of pi neat DNA
added to 1st dilution of dilution series
Number of cells added to primary PCR (Z)= (no. of pi of 1st dilution added to 10 PCR /
total volume of 1st dilution in dilution series) X N
Dilution 1 contains Z cells
Dilution 2 contains Z/10 cells
Dilution 3 contains Z/100 cells etc
Approximate number of viral copies per cell = 1 /number of cells in last positive dilution.
45
2.6 Polymerase Chain Reaction
PCR allows the amplification of a target region of DNA from a sample containing
heterogeneous DNA sequences. Heating of the sample forces the DNA to denature and
allows two small oligonucleotides, which are synthesised to complement the sequence of
regions flanking the target DNA, to hybridise to opposite strands of the now single
stranded DNA. A thermostable DNA polymerase then catalyses the extension of the
primer sequence in a 5' to 3' direction. Multiple cycles of this denaturation, primer
annealing and extension results in the almost exponential amplification of the target DNA
sequence. Nested PCR, in which a second set of primers internal to the first set are used in
a secondary reaction, increases the sensitivity and specificity of the reaction allowing even
single molecules in a heterogeneous DNA sample to be detected.
All PCR reactions used Taq DNA polymerase in storage buffer B: 20 mM Tris-HCl pH 8,
100 mM KC1, 0.1 mM EDTA, 1 mM DTT, 50% glycerol, 0.5% Tween 20 and 0.5%
Nonidet-P40 and Taq 10X buffer: 500 mM KC1, 100 mM Tris-HCl pH 9, 15 mM MgCl2
and 1% Triton XI00 (Promega). Sequences of the primers used in the following reactions
are shown in Table 2.6.1. All PCR reactions contained nucleic acid extracted from
minipool plasma as positive controls and water as negative controls unless otherwise
stated. Frequently a large number of PCR reactions were carried out simultaneously with
control reactions and visualised on either one large agarose gel or several smaller ones.
For this reason, it has not always been possible to include control reactions in the figures


























































The UTR primers are situated in the partially conserved untranslated region of the genome
and ambiguities were introduced into the primer sequences to allow both TTV and TLMV
to be amplified simultaneously (Figure 2.6.1).
In the primary PCR reaction, 5 pi ofDNA was added to a total volume of 50 pi containing
5 pi 10X PCR buffer, 30 pM of dATP, dTTP, dCTP and dGTP, one unit Taq DNA
polymerase and 0.25 pM of primers CVOS and CVOA. A secondary reaction was carried
out by transferring 2 pi of the primary reaction to a final reaction volume of 20 pi in which
the primers CVOS and CVIA were used. Both the primary and secondary PCRs were
amplified using 30 cycles of 94°C for 18 seconds, 55°C for 21 seconds and 72°C for 90
seconds.
2.6.2 N22 primers
The N22 primers are situated in the coding region of the TTV genome and were used in
some of the original epidemiological studies (Okamoto et. al. 1998). The reaction mix and
amplification program were the same as for the UTR PCR but primers NG059 and NG063
were used in the primary reaction and NG059 was substituted for NG061 for the secondary
PCR.
2.6.3 N22/2 primers
The N22/2 primers are a fully nested primer set which amplifies a region of the TTV
coding sequence. The primary PCR used 2 pi of total nucleic acids in a final volume of 10
pi which included 1 pi of 10X PCR buffer, 1 pM of primers F1 and Rl, 2 pM MgC^ and
0.75 units of Taq polymerase. In the nested PCR reaction, 1 pi of the primary product was
transferred to a final volume of 25 pi which contained 2.5 pi 10X PCR buffer, 0.5 pM of
primers F2 and R2, 2mM MgC12 and 0.625 units of Taq polymerase. Amplifications for
both the primary and secondary PCRs were 35 cycles: 20 seconds at 94 °C, 30 seconds at




TTV Human Human Human Chimpanzee
t—-r TCTACGTCCTCA TAAG AG ACTTCCGAATGGCTGAGTTTTCCACGCCCGTCCGCAGCGGTGAAGCCACG AGGGAGATCTCCGC C— ...T.CCGGCC..GATGC.GAGGAGGC CTGCC.CCGA.—
TLMV Human Human Chimpanzee
GACT.CA.ACTTA.CATGC. .-.G..A TGGCAGTTCACT.AT .CAG .TGA ACAAGTGATGC.A.-. ..GAAG .TCA.TTTAGT.ACTGCAGA.TGA G.C.ATCATCTTC..AT C...TA A.-.G..A.AA..TAGTCGCAGACT.AC.TCG.TGT
Macaque Macaque Tamarin Owlmonkey
GAA.A.GG.CACC.AT.C.C.G .A.-G .G C ..C.C.CA CC.GGTGAGTGACC GGACGAAAACTA ..CC.G G.GAA TC.GT-.T. . .AT.C CAGC- .TCGG.AGAGGCGAA.GT..G ATCTGCCGA. C C ACA C-
CAV
CAAG.C..TCTTG.GG -..A.A.CGG.C.GCAGTAGG.ATAA.G G.TC G....G.TGGAAC .CG A CVIACVO
1713'CCCGCCCWCGGCYTCCA T 5'3'TCAGWTCCCCGTTAAGCCCGA5'249
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2.6.4 TTV/TLMV specific primers.
In order to amplify only TTV or TLMV from a sample, primers specific for both viruses
were designed upstream of the UTR primer CVOS. A fully nested PCR was carried out
with the TTV or TLMV specific primer and CVOA utilised in the primary reaction and
CVIA and CVOS in the secondary reaction. The reaction mix and conditions were the
same as for the UTR primers.
2.7 Agarose gel electrophoresis
Gel electrophoresis allows PCR products to be separated because they migrate at different
rates when a current is applied across the gel. Products from the secondary PCR reaction
(20 pi) were run on 2% agarose gels (Sigma) in a flatbed electrophoresis rig. A 0.5X TBE
solution was used both in the making of the gel and as the electrophoresis buffer. The gels
were stained with 0.1 pg/ml ethidium bromide which binds to the DNA and allows it to be
visualised under ultraviolet (UV) light. All gels were run at 150 volts for between 25
minutes and 1 hour with an appropriately sized marker to accurately determine the size of
the products. Unfortunately, due to the number ofPCR products run simultaneously on the
agarose gels, it has not always been possible to include the size marker in all of the figures
included in this thesis
2.8 Lightcycler Real-Time PCR
The Roche Lightcycler enables 'real-time PCR' making it possible to visualise the
accumulation of the PCR products during amplification. This is because unlike other
themalcyclers, which use solid thermal blocks, the Lightcycler uses air as the medium of
heat conduction. The reactions take place in thin walled glass capillaries that have a high
surface to volume ratio, allowing very efficient heat transfer. There are two detection
formats, which can be used with the Lightcycler; hybridisation probes which are based on
FRET (Fluorescence Resonance Energy Transfer) technology, and SYBR green.
Hybridisation probes are sequence specific oligonucleotides labelled with fluorescent dyes
which bind within 1-5 base pairs of each other, internal to the PCR primers, during the
annealing stage of amplification. On excitation by an LED the 'donor' probe emits energy
which in turn excites the acceptor probe. This then fluoresces at a different wavelength
from the original LED and the fluorescence is detected and quantified by the Lightcycler
(Figure 2.8.1). The accumulation of the target PCR product as cycling progresses allows
















Figure 2.8.1 - Real-time PCR using hybridisation probes.
The second format uses SYBR green, a fluorescent dye which binds to the minor groove of
double stranded DNA as is synthesised by the polymerase during the elongation stage of
cycling, and emits light when excited by an LED (Figure 2.8.2). Again, the accumulation
of the target DNA sequence as the reaction proceeds results in an increase in dsDNA
available for the SYBR green and therefore an increase in the fluorescence.
2.8.1 PCR reaction using SYBR green format
Two p,l of the primary PCR reaction using the UTR primers was added to a final reaction
volume of 20 pi containing 2 pi Lightcycler FastStart reaction mix SYBR Green 1
(FastStart Taq DNA polymerase, reaction buffer, dNTP mix, SYBR green 1 dye and 1 mM
MgCH) (Roche), 3 mM MgCh and 1 pM of UTR secondary PCR primers CVOS and
CVIA. The reaction was carried out using the following conditions: 95 °C for 2 seconds,
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light emissions which
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lightcycier
Figure 2.8.2 - Real-time PCR using SYBR green.
For melting curve analysis to take place, following amplification the PCR products were
heated to 95 °C to allow complete denaturation of the products. Cooling to 60°C ensured
the products were double stranded before being heated to 95 °C in 0. l°C/second intervals to
determine the exact temperature each of the products dissociated from the complementary
strand and became single stranded.
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2.9 Hepatitis C Virus PCR
A nested HCV PCR reaction was carried out using primers situated in the 5' non- coding
region (5'NCR) and part of the core region. The first round was carried out using a one
tube, two enzyme Access PCR system (Promega) to allow the generation of cDNA from
the RNA, followed by amplification of the cDNA template. Five pi of nucleic acid was
added to a reaction mixture which contained IX AMV/7/7 reaction buffer, 0.2 pM of dNTP
mix (containing 10 mM of each dNTP), 1 pM of primers Z4130 and Z4133 (Table 2.9.1),
1 mM Mg2S04, 0.1 unit/pl AMV reverse transcriptase, 0.1 unit/pl of Tfl DNA polymerase
and nuclease free water to a final volume of 50 pi. Conditions for this reaction were 48°C
for 45 minutes for reverse transcription of RNA, 2 minutes at 94°C to inactivate the
reverse transcriptase and denature the RNA/cDNA and primers. This was followed by 40
cycles of 94°C for 30 seconds, 55°C for 21 seconds and 72°C for 1.5 minutes.
Two pi of the primary PCR reaction were transferred into a secondary PCR carried out on
the Roche Lightcycler using the hybridisation probe method outlined in Figure 2.8.1. A
final volume of 20 pi containing 4 mM of MgCl2, 0.4 pM of the probes HCV-P and HCV-
F (Table 2.9.2), 0.5 pM of primers Z4131 and Z4132 (Table 2.9.1) and IX DNA Master
Hybridisation Probes (Roche). Amplification is carried out using the following cycling
parameters: 94°C for 2 minutes followed by 25 cycles of 94°C for 2 seconds, 60°C for 10





























PCR products were cloned using pGEM-T Easy Vector System and JM109 competent cells
(Promega). This system incorporates a 3' thymidine overhang into the vector that
increases the efficiency of the ligations and is compatible with the 3' deoxyadenosine
generated by the Taq polymerase used to generate the PCR products. The multiple cloning
site for this vector is situated within the coding region for the enzyme (3-galactosidase,
allowing identification of recombinant clones by blue/white colour screening.
2.10.1 Ligations
The PCR product concentration was determined by comparison to a sample of known
concentration when both were run simultaneously on an agarose gel. The amount of PCR
product required for optimal insert:vector ratios was then calculated using the following
equation.
ng of vector (50 ng) x Size of insert (kb) Insert:
x vector = ng Gf vector
Size of vector (3.0 kb) molarratio
Table 2.10.1 shows the ligation reaction which was set up and left overnight at 4°C to help
produce the maximum number of transformants.
2.10.2 Transformations
The eppendorfs containing the ligation reactions were centrifuged and 2 pi was transferred
to a 1.5 ml microfuge tube which had already been placed on ice. JM109 high efficiency
competent cells (genotype recA 1, endAl, gyrA96, thi, hsdR 17 (rk-, mk+), relA 1, supEAA,
(lac-proAB), [F', traD36,proAB, lacZ M15]) were thawed on ice and mixed gently before
50 pi was added to each of ligation reactions.
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Reagent Volume
2X rapid ligation buffer, T4 DNA ligase
(60 mM Tris-HCl, 20 mM MgCU, 20 mM
DTT, 2 mM ATP, 10% polyethylene
glycol)
pGEM-T easy vector (50 ng) lpl
PCR product Xpl
T4 DNA ligase (3 Weiss units/pl) lpl
Deionised water 10-X pi
Table 2.10.1 - Ligation reaction for pGEM-T easy vector system.
After 20 minutes incubation on ice the cells were 'heat-shocked' by being placed in a 42°C
water bath for 45-50 seconds before being returned to the ice. Nine hundred pi of SOC
medium was added to each tube and the reactions were left for 1.5 hours at 37°C in a
shaking incubator. After transformation, 100 pi of each culture was plated on LB agar
plates supplemented with 100 pg/ml ampicillin, 0.5 mM IPTG and 80 pg/ml X-Gal. The
plates were incubated for between 16 and 24 hours at 37°C.
2.10.3 Screening colonies
In recombinant plasmids the insert disrupts the LacZ coding region, resulting in white
bacterial colonies which can easily be differentiated from cells with the non-recombinant
plasmid, which are coloured blue. Cells from white colonies were screened by using a
toothpick to transfer a small number of cells to a PCR reaction that contained primers
CVIA and CVOS (Table 2.6.1). The PCR products were visualised either on an agarose
gel (section 2.7) or by using the Lightcycler (2.8.1).
2.10.4 Plasmid DNA minipreps
LB media was supplemented with 50 pg/ml of ampicillin and 3 ml was aliquoted into 15
ml sterile tubes. These were seeded with the colonies which had already been PCR
screened to confirm the presence of the insert and were left overnight at 37°C in the
shaking incubator to produce bacterial cultures. 1.5 ml of the resulting culture was
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transferred into a 1.5 ml eppendorf tube and the DNA extracted using QIAprep spin
miniprep kit (Qiagen). Cells were harvested by centrifugation for 5 minutes at 6500 rpm
and the supernatant removed. The cells pellet was resuspended in 250 pi of resuspension
buffer PI and transferred to a microfiige tube before the addition of 250 pi of lysis buffer
P2. This solution was inverted gently until it became viscous and slightly transparent after
which 350 pi of neutralisation buffer N3 was added and the solution mixed by inversion
again. A compact white pellet was formed after centrifugation for 10 minutes and the
supernatant decanted to a QIAprep spin column. The spin column was centrifuged for 1
minute to allow the DNA to bind to a membrane and the flow through discarded. The
bound DNA was washed with first with 0.5 ml of buffer PB then with 0.75 ml buffer PE,
both of these buffers were removed in turn by centrifugation for 1 minute. Finally, 50 pi
of water was added onto the centre of the spin column and allowed to stand for 1 minute
before being centrifuged for 1 minute to elute the DNA.
2.10.5 Restriction digests
The multiple cloning site of pGEM-T Easy vector is flanked by restriction enzyme sites
which facilitate the removal of the insert from the vector using a single digestion (Figure
2.10.1).
Figure 2.10.1 - Restriction map of pGEM-T Easy vector.
The restriction enzyme Eco RI (Promega) was used to cut the vector at two sites, and the
digested DNA analysed to ensure the clones contained the desired inserts. The recognition
sequence for Eco RI is shown below (Figure 2.10.2). Two pi of DNA (see section 2.10.3)
was added to a reaction mix containing 1 pi 10X buffer H (90 mM Tris-HCl, 10 mM
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Figure 2.10.2 - Recognition sequence for restriction enzyme Eco RI.
All 10 pi from the overnight reaction was run on a 2% agarose gel (see section 2.7) and
any bands visible on the gel compared with a DNA marker of a known size to confirm it
corresponds to the insert excised from the plasmid.
2.11 Sequencing of cloned DNA fragments
Manual DNA sequencing was performed using a thermosequenase radiolabeled terminator
cycle sequencing kit (Amersham). This is based on the Sanger sequencing method which,
like PCR, involves the amplification of a DNA sequence using sequence specific
oligonucleotides complementary to the DNA strand of interest to 'prime' the start of
replication. DNA polymerase catalyses the reaction and deoxynucleotides are incorporated
as the 'building blocks' for the new strand. The sequence is determined using DNA chain
terminating [a-33P] labelled di-deoxynucleoside triphosphates (ddNTPs)(PerkinElmer),
which are integrated into the DNA, resulting in truncated DNA terminated only at a
position where a particular ddNTP has been incorporated. The fragments can be separated
according to size by electrophoresis on a polyacrylamide gel. Using this method, when
reactions for all four of the radiolabelled bases (ddGTP, ddATP, ddTTP and ddCTP) are




Figure 2.11.1 - Representative film from cycle sequencing reaction.
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Following DNA recovery using QIAprep spin miniprep kit (section 2.10.4), 50-500 ng of
DNA was added to a sequencing reaction which contained 2 pi reaction buffer (260 mM
Tris-HCl (pH 9.5), 65 mM MgC^), 10 pmoles M13 forward or reverse primer, 0.5 pi
thermosequenase enzyme (4 units/pl thermosequenase DNA polymerase enzyme, 50 mM
Tris HC1 (pH 8), 1 mM DTT, 0.1 mM EDTA, 0.5% Tween-20, 0.5% nonidet P-40, 50%
glycerol) and water to a final volume of 20 pi.
Termination mixes were made by adding 2 pi of dGTP termination master mix (7.5 pM
dGTP, 7.5 pM dATP, 7.5 pM dTTP and 7.5 pM dCTP) with 0.5 pi of a-33P labelled
ddNTP, one for each base. Four tubes were labelled (G, A, T and C), and 2.5 pi of
termination mix and 5 pi of the DNA/reaction buffer mix added to each tube. The
reactions were overlayed with mineral oil and subjected to 30 cycles of 94°C for 30
seconds, 55°C for 30 seconds and 72°C for one minute. Following the thermal cycling, 6
pi of each reaction was transferred into the well of a 96 well microtitre plate containing 4
pi of stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05%
xylene cyanol FF).
2.11.1 Polyacrylamide gel electrophoresis
The sequencing products were resolved by electrophoresis through a 6% polyacrylamide
gel. Glass plates were cleaned thoroughly with distilled water, methanol and finally
acetone and placed together, separated by 1 mm spacers. The gel mixture was prepared by
dissolving 21 g urea (BDH), 6 ml Sequagel XR concentrate (National Diagnostics), 5 ml
10X Sanger TBE and 0.05 g ammonium persulphate (APS)(Sigma) in distilled water to a
final volume of 50 ml. After polymerisation of the gel was initiated by the addition of 20
pi TEMED (N,N,N',N,-tetramethyethyediamine)(Sigma), the gel immediately poured
slowly between the plates to avoid the incorporation of bubbles and left to set for 1 hour.
Denatured samples were loaded into the wells of the gel in the order G, A, T and C and the
samples electrophoresed at 75 watts for approximately 2.5 hours or until the bromophenol
blue was visible at the bottom of the gel using IX Sanger TBE as the electrophoresis
buffer. The gel was removed from the glass plates and transferred onto filter paper before
being vacuum dried at 80°C for 1.5 hours and exposed to X-ray film (Kodak) for 1-2 days
depending on the intensity of the signal. Sequencing gels were read and manually aligned
using Simmonic 2000 software package developed by Professor Peter Simmonds.
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2.12 Southern blotting
Southern blotting is a method that allows the detection of sequences, which have been
transferred from an agarose gel to a membrane, by hybridising them with a sequence
specific labelled probe and visualising them using an appropriate detection system.
2.12.1 Amplification andgel electrophoresis
Initially a single round of amplification was carried out with either primer D10S (SENV D)
or C5S (SENV H) with L2AS (Table 2.12.1). Ten pi of nucleic acid was added to 40 pi of
mastermix containing one unit of Taq polymerase, 30 pM of dATP, dTTP, dCTP and
dGTP, and 0.25 pM of each of the primers. Amplification was carried out at 94°C for 10
minutes followed by 45 cycles of 94°C for 25 seconds, 58°C for 60 seconds and 72°C for
30 seconds. The products were electrophoresed on a 1.2% agarose gel at 150 V for 30
minutes.
To increase the sensitivity of the PCR, outer primers (SENV sense and SENV anti-sense
(Table 2.12.1)) were designed to amplify both SENV D and SENV H simultaneously.
These were used as a primary PCR reaction followed by a secondary PCR using the
primers and conditions described above. Amplification for the primary PCR was carried
out using 30 cycles of 94°C for 18 seconds, 55°C for 21 seconds and 72°C for 90 seconds.
Ten pi of the secondary product was mixed with 3 pi 6X loading dye and wet loaded into
alternate wells of a 1.2% agarose gel stained with 25 pg EtBr. Three pi of a digoxigenin
labelled DNA molecular weight marker was also run on the gel to allow comparison of the
fragment sizes. The gel was run at 110 V for 45 minutes in a flat bed gel tank containing
0.5X TBE buffer supplemented with 250 pg EtBr after which the gel was visualised under
UV light and a picture taken for reference purposes. The gel was then washed in 0.25 N
HC1 solution for 10 minutes to allow depurination before the DNA in the gel was
denatured by washing in a 0.5 N NaOH and 1.5 M NaCl solution for 30 minutes. The
denaturation solution was neutralised using a 0.5 M Tris and 1.5 M NaCl solution in which




























2.12.2 Transfer ofDNA to nylon membrane
Two pieces of 3 mm Whatman paper (Camlab), a piece of sponge and a sheet of positively
charged nylon membrane (Roche) were cut to size 1 cm larger than the size of the gel and
soaked in 10X SSC buffer. The Whatman paper, membrane, gel and sponge were placed
on the porous membrane support pad of a Posiblot 30-30 pressure blotter in the order
shown in Figure 2.12.1. To ensure the complete saturation of the sponge with transfer
buffer, 10X SSC was pored onto the sponge until it began to seep out of the bottom edges.
The posiblot unit was closed and sealed and a hose connected to a pressure control station
attached. The pressure was adjusted to 75 mm mercury (Hg) and the system left for 1 hour
to allow the complete transfer of the DNA from the gel to the nylon membrane.




Figure 2.12.1 - Schematic diagram of DNA transfer to a nylon membrane using the Posiblot
30-30 pressure blotter.
After the DNA transfer was complete, the membrane was removed from the apparatus and
washed briefly in 2X SSC before being left on Whatman for 15 minutes to allow the
membrane to air dry. The DNA was cross-linked to the membrane by exposure to UV
light for three minutes and 45 seconds.
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2.12.3 Hybridisation and detection
After DNA cross linking the membrane was rolled up length ways and placed in a clean
glass tube which had been pre-incubated 55°C in the blotter. Twenty-five ml of pre-
hybridisation solution (Table 2.12.2) was added to the cylinder and the membrane
incubated with this solution at 55°C for 1 hour.
Reagent Volume
20X SSC 12.5 ml
10X Blocking reagent (from DIG 5 ml
Wash and Block buffer set)
10% SDS 100 pi
30% sarcosine 167 pi
dHzO 32.23 ml
Table 2.12.2 - Pre-hybridisation solution.
The pre-hybridisation solution was then replaced with 10 ml of the same solution
supplemented with 100 pmol of digoxigenin labelled oligonucleotide specific to either
SENV D or SENV H (Table 2.12.3) and incubated at 55°C for 3 hours. The membrane
was washed twice with 25 ml of 2X SSC with 0.1% SDS and twice with 0.5X SSC with
0.1%SDS, all for 30 minutes at 55°C.
Detection was carried out using the DIG wash and block buffer set (Roche) following the
manufacturers instructions. The membrane was washed for 5 minutes in IX washing
buffer before incubation for 30 minutes in blocking solution. A further 30 minutes
incubation in 50 ml of blocking solution containing 1.875 units of anti-digoxigenin
antibody (Roche) followed by two 15 minutes washes in washing buffer to remove the






SENVD5'digoxigeninATGATGGCTTCCCYTACT[Umemuratal.,2001 ] SENVH5'digoxigeninCCCCTTCCAGGTATTGCATGAAGAGTATTAC[Umemuratal.,2001 ]
Table2.12.3-HybridisationprobesusedforCVsecon aryreal-timeP R.
The membrane was removed from the detection buffer, drained to remove the excess
solution and covered evenly with the chemiluminescent substrate CDP-star (Roche). After
five minutes, the excess solution was removed and the membrane wrapped in cling-film
and placed in a development cartridge with Bio-Max Light film (Kodak) for between 5-25
minutes.
2.13 IgG capture assay
Protein G magnetic beads (Dynal Biotech) were used to capture IgG from a variety of
serum samples. The protein G which coats the beads is derived from Group G
Streptococci bacteria and has a high affinity for the immunoglobulin IgG. In each case, 50
(Ltl of protein G magnetic beads were washed twice with 0.1 M sodium citrate (pH 5)
before the addition of 50 pi of serum. This was incubated at room temperature for 40
minutes with gentle mixing to allow Protein G and IgG to form complexes. The samples
were placed on a magnet and the supernatant removed and reserved. The beads were then
washed three times with 0.1 M sodium citrate (pH 5) to purify the IgG. Elution of the
antibody was performed using 0.1 M sodium citrate buffer with a lower pH (pH 2). This
elution process was carried out twice with 30 pi of buffer. Finally, the magnet was used
again to capture the beads allowing the removal of the supernatant containing the IgG from
the serum sample. The supernatant and eluate from the IgG capture process was extracted
using QIAamp Minelute Virus Spin kit (section 2.4.4) and the titre of virus quantified
using limiting dilution (section 2.5.2).
2.14 Statistical analysis.
Statistical analysis of samples was carried out using SPSS for Macintosh. A variety of
tests were used to analyse these data however, in all cases a P value of less than 0.05 was
considered to be significant.
2.14.1 Spearman's rank correlation coefficient.
Spearman's Rank Order Correlation Coefficient was used as a non-parametric measure of
the strength of relationship between two variables. It gives the correlation coefficient rs, an
indication if the two variables have a positive correlation, a negative correlation or no
correlation, and the P-value associated with the rs. The P-value predicts how likely it is
that the given correlation coefficient would be generated by a random sample. In order to
compare the variables, each value is given a rank to compare it with the other variables
within the group.
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2.14.2 Mann-Whitney U test
The Mann-Whitney U test, also known as the Wilcoxon-Mann-Whitney test is a non-
parametric test which assess whether the differences in medians between two observed
distributions is normal. The null hypothesis that there is no difference between the medians
of two sets of data from unpaired samples.
2.14.3 Wilcoxon signed ranks test
The Wilcoxon Signed Ranks test is the non-parametric equivalent of the paired T-test,
which tests a hypothesis about the median of a population distribution. It can be used to
test the significance of treatment or experimental manipulation on a population.
2.14.4 Kruskai-Wallis test
The Kruskal-Wallis test is a non-parametric test to compare three or more samples. It is
used to test the null hypothesis that all populations have identical distributions and thus the
means are equal.
2.14.5 Linear regression
Linear regression is a statistical tool which attempts to model a relationship between two
variables. In this test, a linear equation is fitted to a set of data points in order to measure
the effect of a single variable.
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Chapter 3
Characterisation of Anelloviruses in the Blood
Donor Population
3 CHARACTERISATION OF ANELLOVIRUSES IN
THE BLOOD DONOR POPULATION
3.1 Introduction
After the discovery of TTV in 1997 efforts were made to assess the prevalence of this virus
within the blood donor population. A preliminary study of the Scottish blood donors
showed just 1.9% of individuals had detectable TTV DNA in their serum [Simmonds et al.,
1998], however this figure was based on a PCR assay using primers from the
heterogeneous N22 region of the genome. It is widely accepted that as primers from this
region only amplify a limited range to TTV genotypes.
There is no standardised PCR protocol for the detection of TTV but the use of primers
from the relatively conserved UTR region of the genome allows for amplification of the all
the known TTV genotypes. The UTR of TLMV is sufficiently conserved with TTV to
allow the simultaneous amplification of both viruses with some of the UTR based primers,
however the viruses are rarely differentiated in literature.
Two SENV genotypes, SENV D and H, are frequently associated with post transfusion non
A-E hepatitis although the clinical significance of these viruses in the disease process has
yet to be ascertained [Umemura et al., 2001b]. There is limited data concerning the
prevalence of these two variants in Europe with most epidemiological data from Eastern
Asia where there appears to be a higher prevalence of SENV D than SENV H in almost all
the populations studied [Kao et al., 2002; Sugiura et al., 2004; Umemura et al., 2003]. In
contrast, data from blood donors in Germany and the USA demonstrate a higher
prevalence of SENV H than SENV D [Umemura et al., 2003].
This chapter describes the characterisation of Anelloviruses in Scottish blood donors. The
prevalence of TTV and TLMV is updated using primers from the UTR and the frequency
of SENV D and H infection is ascertained for the first time.
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3.2 Results
3.2.1 Differentiation ofAnelloviruses on the Roche Lightcycler
3.2.1.1 UTRPCR
Sequence analysis of both TTV and TLMV has shown regions of the genome which
remain partially conserved amongst all the known genotypes. This untranslated region was
chosen as the site for PCR primers to ensure the maximum number of viral genotypes were
amplified.
Ten HCV/HBV/HIV PCR negative minipools, each consisting of 95 individual Scottish
donor plasma samples, were tested using a hemi nested PCR consisting of a first round
using primers CVOS/CVOA and second round with primers CVOS/CVIA. All ten of the
samples contained a visible band of around lOObp when run on an agarose gel (Figure
3.2.1).
k- 100bp
1 2 3 4 5 6 7 6 9 10 11
Figure 3.2.1 - PCR for Anelloviruses carried out using serum from 10 minipool plasma
samples. Lanes 1-10: minipool plasma secondary PCR product; lane 11: negative control
(water).
3.2.1.2 Characterising products of UTR primers on a Roche Lightcycler
Two p.1 of the primary product from each of the 10 minipool samples used in the standard
UTR PCR amplification reaction were added to a secondary reaction carried out on the
Roche Lightcycler using the fluorescent dye SYBR green. Amplification was carried out
for 40 cycles and a product was obtained for all 10 of the samples as shown in Figure
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The melting temperature (Tm) for each sample was calculated by the rate of change in
fluorescence with temperature (-J(Fl/c/T). The amplicons fell into two different
distributions of Tms when characterised, as shown in Figure 3.2.5. It was hypothesised
that these corresponded to the two Anelloviruses (TTV and TLMV).
3.2.1.3 Differentiating Tms of PCR products
Based on the supposition that the two distributions of Tms correspond to the two known
Anelloviruses, primers were designed to amplify sequences specific to TTV or TLMV.
Twenty HIV/HBV/HCV PCR negative plasma samples were amplified with primer CVOA
and either TTV-OS for the TTV specific PCR or TLMV-OS to detect TLMV. The
secondary PCR was carried out with primers CVOS and CVIA.
Of the 20 samples, six were PCR positive using the TTV specific primer (Figure 3.2.3),
two were positive using the TLMV specific primer (Figure 3.2.4) and four were positive
using both primers as shown in Table 3.2.1.
•4- lOObp
Figure 3.2.3 - PCR using TTV specific primers on plasma from 20 Scottish blood donors.
Lanes 1-20: Secondary PCR product from plasma samples; Lanes 20 & 21; Negative control
(water); Lanes 23 & 24: Positive control (minipools).
lOObp
Figure 3.2.4 - PCR using TLMV specific primers on plasma from 20 Scottish blood donors.
Lanes 1-20: Secondary PCR product from plasma samples; Lanes 20 & 21; Negative control
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Table 3.2.1 - Detection of viruses in plasma samples using TTV and TLMV specific primers
analysed on an ethidium bromide gel. Samples gave a different result when analysed on a
Roche Lightcycler are shown in brackets.
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The primary product from each sample amplified with TTV and TLMV specific primers
was subjected to a secondary nested PCR on a Lightcycler using the generic internal
primers CVOS/CVIA.
Of the 20 samples analysed on the Lightcycler, seven were PCR positive using the TTV
specific primer, one with the TLMV specific primer and six were positive with both
primers. The increased incidence of PCR positive samples when using the Lightcycler
could be because this is a more sensitive detection format than agarose gel electrophoresis
and the one-step secondary PCR and analysis method utilised by the Lightcycler cuts down
on operator error.
When the plasma amplified with the TTV specific products was analysed using a melting
curve on the Lightcycler (Figure 3.2.6) they showed Tms with a median value of 91.06°C
(range 89.4-92.02°C). This appears to correspond to the higher distribution of values seen
in 3.2.1.2. The median Tm for the samples that were amplified using a TLMV specific
primer (Figure 3.2.7) was 86.79°C (range 85.47-87.56°C), which corresponds with the
lower distribution of Tms seen with the UTR primers.
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3.2.1.4 Cloning and sequencing products from TTV and TLMV specific PCR
To identify the products amplified with the virus specific primers conclusively, four
plasma samples positive with the TTV specific primer and four samples positive with the
TLMV specific primer were cloned into a vector and sequenced.
Eleven sequences from TTV specific primers and 15 from TLMV specific primers were
compared with prototype TTV and TLMV sequences and other previously published
sequences submitted to GenBank (Figure 3.2.8). In both cases the sequences obtained
from the clones closely matched the known TTV and TLMV sequences.
The clones used in the sequencing reaction were re-amplified on the Lightcycler for a final
time and melting curve analysis performed to determine their Tm (Figure 3.2.9). The
TTV-like sequences correspond to the distribution of amplicons with the higher Tms and
the TLMV-like sequences with the lower melting temperature distribution. Analysis of the
sequences suggested the differences in Tms between the two viruses might be down to two
factors. Firstly, the TTV sequences are generally 2-4 bases longer in the UTR region in
which the PCR primers are sited. The TTV sequences also have a higher guanine +
cytosine (G+C) base content in the region of interest, with a mean G+C value of 65.4%
compared with 58.6% G+C composition in the comparable region of TLMV. Both these
facets will increase the binding strength of the amplicon, contributing to the higher
temperature needed to melt the TTV product.
Two of the clones, TLMV 1/1 and 1/2 showed a lower Tm (83.7°C) than the other
products amplified with the TLMV specific primer (median value 87.14°C, range 85.9-
88.4°C). When the corresponding sequence was analysed, it contained a five nucleotide
deletion not present in the other TLMV sequences. This is further evidence of the
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3.2.2 Prevalence of Anelloviruses in the Scottish blood donor
population
3.2.2.1 Prevalence of TTV and TLMV in Scottish blood donors
Using the method of differentiating TTV and TLMV described in 3.2.1, 100 plasma
samples from HIV/HBV/HCV negative Scottish blood donors, a low risk adult population,
were screened. After PCR with the outer primer set CVOA/CVOS, a hemi nested PCR
was carried out on the Roche Lightcycler. The melting temperature for each sample was
analysed and the presence ofTTV and/or TLMV in the sample determined.
Of the 100 samples tested, 88 were PCR positive. Using the Tms of the products, these 88
could be categorised into those that were TTV positive (34/88, 38.6%), those that were
TLMV positive (18/88, 20.5%) and those that contained a heterogeneous mix of both
viruses (36/88, 40.9%). The distribution of Tms within these PCR positive samples is














Figure 3.2.10 - Distribution of Tm values from 88 TTV/TLMV PCR positive Scottish blood






























3.2.2.1.1 Comparison of UTR and N22 primers
The prevalence of Anellovirus infection varies greatly between published studies. This is
partially explained by the lack of consistency when investigators chose PCR primers. To
compare the frequency of virus infection identified with different primer sets, 100 blood
donor samples were amplified with the UTR primers described earlier as well as with a set
of hemi- nested primers situated in the N22 region [Okamoto, 1998] and visualised on an
ethidium bromide stained agarose gel. Of the 100 samples tested, 88 were positive using
the UTR primers and five with the N22 primers. This confirms that studies using the N22
primers as the basis for their survey are likely to be underestimating the prevalence of
these viruses.
3.2.2.2 Prevalence of SENV D and SENV H in Scottish blood donors
A one round PCR reaction was carried out on 15 Scottish blood donor minipools samples
with SENV D and SENV H specific sense primers (D10S and C5S) and a generic anti-
sense primer (L2AS) [Umemura et al., 2001a]. The resulting product was visualised by gel
electrophoresis on a 1.5% agarose gel stained with ethidium bromide, however no bands of
the correct size were visible.
The process was repeated and, after gel electrophoresis, the DNA transferred onto a
membrane and probed with SENV D and SENV H specific digoxigenin labelled probes.
This yielded positive signals for 0/15 samples for SENV D and 5/15 for SENV H (roughly
equivalent to five positive donors in 1425 samples). This was a significantly lower level of
infection than expected so, in order to increase the sensitivity of the PCR, a set of outer
primers were designed to amplify a portion of SENV D/H that lies outwith the amplicon
produced by the published primers. Fifteen minipools samples were subjected to a nested
PCR using the new outer primers followed by a SENV D and H specific inner PCR and
Southern blotting with genotype specific digoxigenin labelled probe. The results of this
were compared with Southern blots carried out on the DNA from a one round PCR
reaction.
As Figure 3.2.11 shows, no virus was detected in any of the samples after one round of
PCR however the improved sensitivity of the nested reaction revealed 3/15 were SENV D
PCR positive (Figure 3.2.12). Although the one round SENV H Southern blot (Figure
3.2.13) detected virus in 5/15 minipools, the inclusion of the outer primers increased the
sensitivity and in the nested PCR 15/15 samples were positive (Figure 3.2.14).
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Figure 3.2.11 - Southern blot of one round SENV D PCR (primers: D10S and L2AS). Lanes
1-15: Scottish blood donor minipools 1-15; Lane 16: Negative control (water); Ladder:









Figure 3.2.12 - Southern blot of nested SENV D PCR (primers: first round: SENV anti-sense
and SENV sense; second round: D10S and L2AS). Lanes 1-15: Scottish blood donor
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Figure 3.2.13 - Southern blot of one round SENV H PCR (primers: C5S and L2AS). Lanes 1-
15: Scottish blood donor minipools 1-15; Lane 16: Negative control (water); Ladder:








Figure 3.2.14 - Southern blot of nested SENV H PCR (primers: first round: SENV anti-sense
and SENV sense; second round: C5S and L2AS). Lanes 1-15: Scottish blood donor
minipools 1-15; Lane 16: Negative control (water); Ladder: Digoxigenin labelled molecular
weight marker.
The cross reactivity of the probes used for Southern blotting was investigated by probing
SENV D PCR product with SENV H probe and visa versa. No cross reactivity was found
(data not shown).
A total of 192 individual plasma samples from Scottish blood donors were tested for the
presence of SENV D and SENV H DNA by the method described. Of those samples,
1/192 contained SENV D DNA (0.5%), 21/192 samples contained SENV H DNA (10.9%)
and 2/192 contained both SENV D and SENV H (1%).
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The prevalence of SENV D in the Scottish blood donor population was significantly lower
than data collected from other countries. To confirm the discrepancy between the level of
SENV D in Scotland and the higher prevalence seen in Asia was a result of geographical
differences in virus distribution, fifteen minipools from Taiwanese blood donors (each
containing plasma from 95 individual donations) were tested for the presence of SENV D.
All fifteen of the samples were positive for SENV D DNA (data not shown).
3.3 Discussion
The extreme genetic diversity of TTV and TLMV has hampered the development of
accurate methods of determining the prevalence of these viruses. Fortunately, regions of
conservation within the UTR were detected which have been instrumental in the discovery
of the ubiquitous nature ofTTV, even in healthy populations. The primer sites lie in close
proximity to sequences known to associate with transcriptional machinery and the high
degree of conservation within this region is probably the result of functional constraints
[Hijikata et al., 1999],
An alignment of published human TTV and TLMV sequences was used to design primers
which were capable of amplifying TTV and TLMV simultaneously from a heterogeneous
population of viruses within a single sample. This method was used to screen a cohort of
healthy Scottish blood donors for the presence ofTTV and TLMV. It was found that 88%
of blood donors were infected with an Anellovirus, confirming the high prevalence of
infection reported in other countries [Biagini and de Micco, 2006; Huang et al., 2001].
Analysis of the Tms of the PCR products using melting curve analysis allows for fast and
accurate differentiation of TTV and TLMV from a single sample. Sequence analysis
determined this was possible because of both length polymorphisms between TTV and
TLMV and differences in the proportions of guanine and cytosine base pairs. The TTV
sequences were determined to be between two and four bases longer than the TLMV
sequences with a mean G+C content of 65.4% for TTV and 58.6% for TLMV. G+C base
pairing results three hydrogen bonds compared with two bonds when adenine and thymine
(A+T) are paired. This increases the stability of G+C pairs, which in turn increases the
temperature needed to disrupt the bonding and denature the DNA.
By differentiation of the Anelloviruses in Scottish blood donors, it was revealed that 34%
were infected with TTV, 18% with TLMV and 36% with a heterogeneous mixture of both
viruses. This indicates that 70% of the Scottish blood donor population are infected with
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TTV and 54% with TLMV. In 2006 a study investigating the prevalence of Anelloviruses
in French blood donors reported findings similar those described here, with a total
prevalence of 88%, 66% infected with TTV, 62% with TLMV and 44% with mixed TTV
and TLMV infection [Biagini and de Micco, 2006]. Although the presence of TTV and
TLMV in any of the samples cannot be ruled out as low titres of virus might be below the
level of detection of the assay, these data show that TTV and TLMV are equally prevalent
and both viruses can replicate and co-exist in a large proportion of apparently healthy
individuals.
The N22 region derived from ORF1 of TTV has been the target of the majority of PCR
based assays and, although they have been greatly improved, amplification with primers
situated in this region is restricted to TTV genotypes 1-6 [Itoh et al., 1999], To compare
the detection of TTV in plasma with different primer sets, the same 100 blood donor
samples that were used to assess the prevalence ofTTV using the UTR primers were tested
with N22 primers. Only 5% of the samples were PCR positive using this method,
suggesting a low prevalence of genotypes 1-6 within the Scottish blood donor population.
This also reinforces the discrepancy in sensitivity between the two sets of primers,
signifying that studies using the N22 method to assess the incidence of TTV infection are
likely to underestimate the true frequency of the population.
SENV D and H are found in a higher percentage of patients with fulminant hepatitis than
in healthy blood donors, which has led to the hypothesis that these viruses might play a
role in liver diseases [Sugiura et al., 2004; Tangkijvanich et al., 2003]. There is a lack of
prevalence data for these viruses in the Western world and, given the putative pathogenic
character of these viruses, an investigation into the frequency of infection in Scottish blood
donors was appropriate. SENV D was found at low frequencies in the population studied,
with only 0.5% of donors infected. A total of 10.9% of the samples had evidence of SENV
H DNA and 1% were infected with both SENV D and SENV H. These data contribute to
the increasing evidence of the global distribution of these viruses. Interestingly, the high
level of SENV H compared to SENV D in Scottish blood donors is the reverse of what is
observed in healthy adults and blood donors in China, Greece, Japan and Taiwan [Kao et
al., 2002; Mu et al., 2004; Umemura et al., 2003], It is not known why this is the case,
however it could be the route of transmission differs between the subtypes.
As with TTV and TLMV, the presence of SENV D and H in apparently healthy individuals
suggests they are not pathogenic per se. Many studies use blood donors as a control group
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for SENV infection in patients with hepatitis and liver disease, however it has been
suggested that because blood donors are generally younger, from a high socioeconomic
group and without exposure to injection drug use it is inappropriate to use them in this
way. Using patients with non-viral liver diseases such as autoimmune hepatitis and
primary biliary cirrhosis as controls, it was found there was no significant increase in the
prevalence of SENV in individuals with cryptogenic hepatitis [Shibata et al., 2001]. Kao
and colleagues also showed that although SENV D and H infection did appear to be
associated with a slight increase in serum ALT levels, it was not found to be significant.
They also reported that individuals with dual SENV/HCV or SENV/HBV infection did not
have ALT levels significantly higher than those infected solely with HCV and HBV [Kao
et al., 2002], This suggests that SENV D and H infection, even in conjunction with
hepatitis inducing virus, does not increase the extent of the liver damage.
In conclusion, using an assay developed in the course of this project, this survey has
demonstrated a high prevalence of TTV and TLMV infection in Scottish blood donors.
The frequency of infection of SENV D and H has also been established in Scotland for the
first time. A high degree of dual TTV and TLMV infection was observed however, the
frequency of infection with TTV genotypes 1-6 and SENV D and H was relatively low.
These data contribute to the premise of widespread global distribution of Anelloviruses.
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Chapter 4
TTV and TLMV Levels in Tissue Samples
4 TTV AND TLMV LEVELS IN TISSUE SAMPLES
4.1 Introduction
TTV was initially found in the serum of a blood transfusion recipient with non A-E
hepatitis and the putative association with hepatitis and liver disease lead to investigations
into the titre ofTTV in the liver. An early publication reported that TTV DNA was present
in the liver at levels 10-100 fold higher than in the serum of the same patient [Okamoto,
1998], contributing to the liver disease association debate. Further investigations
discovered that TTV was not restricted to the liver, with detection in extrahepatic tissues
including kidney, intestines, spleen and stomach using in situ hybridisation [Fan et al.,
2000],
It was first hypothesised that TTV may be present and replicating in the bone marrow
when a significant decrease in the titre of TTV in serum was observed in the
myelosuppressed period following bone marrow transplantation [Kanda et al., 1999].
Subsequently double stranded replicative intermediates were confirmed in bone marrow
cells [Okamoto et al., 2000d] however this was not accompanied by any pathology.
The TTV titre in the serum ofHIV positive individuals has been the subject of a number of
papers [Martinez et al., 2000; Moen et al., 2002b; Pistello et al., 2001] however there is a
lack of data on the presence of TTV in the tissues of these individuals. There are several
haematological complications of HIV and AIDS, such as thrombocytopenia and
neutropenia, whose underlying cause remains somewhat of a mystery. Given the evidence
of TTV replication in the bone marrow and the increased titre ofTTV in the serum of those
infected with HIV, it is possible that TTV will play a role in the unexplained
haematological abnormalities seen in HIV positive patients.
In this chapter, the findings of an investigation into the titre of TTV and TLMV in tissues
taken from HIV positive and negative individuals are presented and discussed. In the
instances of the HIV positive cases, correlation of the titre of Anellovirus with the CD4




4.2.1 TTV/TLMV titres in HIV positive and HIV negative bone
marrow
4.2.1.1 TTV/TLMV titres in HIV positive bone marrow
Firstly, to determine if bone marrow samples were infected with TTV/TLMV, six post
mortem, bone marrow samples from individuals who were infected with HIV (two female,
four male, mean age 36; range 28-48 years) were provided by Jeanne Bell, Professor of
Neuropathology, Western General Hospital, Edinburgh, EH4 2XU and stored at -40°C
until required. After DNA extraction using the phenol chloroform method, DNA from each
of the samples was added to a PCR that used primers situated in the UTR of TTV and
TLMV. All six samples (12, 292, 87, 23, 11 and 8) produced a band of the correct size
(»100bp) and were considered positive for either TTV or TLMV.
To determine the titre of Anellovirus present in each of the samples, limiting dilution PCR
was carried out. In short, samples were titrated to an endpoint in eight, serial, ten fold
dilution steps before analysis using the UTR PCR method (Figure 4.2.1 & Figure 4.2.2).
The concentration of DNA was analysed using a spectrophotometer and the amount of
DNA contained in each dilution calculated. The final dilution producing a visible signal
was observed and, as it was presumed this contained at least one copy of the target of
interest, the titre of virus in the bone marrow sample estimated. The endpoint dilution was
not achieved in the first eight dilutions for samples 87 and 23, which were further diluted
in order that the last PCR positive dilution could be observed (Figure 4.2.2).
The titre of TTV/TLMV present in each of the six bone marrow samples is summarised in
Table 4.2.1 (mean 107 copies per cell, median 1.33 copies per cell). The CD4+ T cell
counts for each sample were provided by Jeanne Bell and served as an indicator of the
level of immunosuppression of each patient.
The table shows that all six of the HIV positive bone marrow samples were infected with
either TTV or TLMV. The viral titres ranged from one viral copy per 200 cells to over 350
copies per single cell. Spearman's rank order coefficient was used to investigate if any
correlation between viral titre and CD4+ T cell count could be established. This test
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Figure 4.2.1 - Secondary UTR PCR products of DNA extracted from six HIV positive bone
marrow samples. Each sample was serially diluted eight times in water. Lane 1:1 in 10
dilution of bone marrow DNA; Lanes 2-8: Consecutive 1 in 10 dilutions of bone marrow DNA




Figure 4.2.2 -Extended limiting dilution PCR for samples 87 and 23. Lanes 1-4, 6-9, 11-12:
10 fold serial dilutions of DNA extracted from HIV positive bone marrow added to the
primary PCR reaction (Lane 1; 1 in 10 dilution of DNA in water and further dilutions to Lane













12 28 F 0.0371 12
292 43 M 2.63 292
87 48 F 285 87
23 31 M 357 23
11 33 M 0.00471 11
8 34 M 0.0222 8
Table 4.2.1 - Data from post mortem HIV positive bone marrow samples. Viral copies per
cell estimated using limiting dilution PCR. CD4+ T cell count provided by Jeanne Bell. The
'copies per cell' data are shown to three significant figures.
4.2.1.1.1 Differentiation ofAnelloviruses in HIVpositive bone
marrow using melting curve analysis
Although PCR using the UTR primers and visualisation by gel electrophoresis enables the
simultaneous detection of TTV and TLMV, it does not allow differentiation between the
two viruses. Two of the bone marrow samples (87 and 23) had a considerably higher titre
of virus present than the other four samples and it was of interest to determine if these
samples were infected with TTV or TLMV of had mixed TTV/TLMV infection. To
investigate this, these samples were analysed by real time PCR using Roche Lightcycler to
differentiate between the two Anelloviruses, TTV and TLMV.
The primary product from the serial dilutions used to determine the endpoint of these
samples was used as a template for a secondary PCR reaction on the Roche Lightcycler
with the UTR primers CVOS/CVIA and SYBR green fluorescent dye. The melting curve
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The Lightcycler melting curve profiles show that sample 87 was infected only with TTV.
Sample 23 was infected with both TTV and TLMV however the final dilution contained
only TTV indicating that there was a higher titre of TTV than TLMV in that bone marrow
sample.
4.2.1.2 TTV/TLMV titres in HIV negative bone marrow
Given the variable titre of Anelloviruses in the HIV positive bone marrow samples, HIV
negative bone marrow samples were acquired to act as a comparison. Seven bone marrow
aspirate samples from patients (five male, one female, one unknown, mean age 64.8 years,
range 25-81 years) who were being investigated for haematological abnormalities were
obtained from Dr Christopher Ludlum, Clinical Director of Haematology, Royal Infirmary,
51 Little France Crescent, Edinburgh, EH 16 4SA. These aspirates came in the form of
whole blood with bone marrow fragments suspended within it. The bone marrow
fragments were separated from the whole blood sample by centrifugation, collected with a
pastette and washed several times with PBS. Plasma was also collected from each whole
blood sample.
Nucleic acids were isolated from the bone marrow using the phenol chloroform extraction
method and the concentration quantified using a spectrophotometer. DNA from the bone
marrow samples was diluted and 0.1 p.g DNA added to the first dilution of the PCR
followed by a further seven ten fold dilutions to endeavour to quantify the relative titre of
the sample using limiting dilution PCR. A hemi-nested PCR was carried out with the UTR
primers (Figure 4.2.5 and Figure 4.2.6).
Plasma corresponding to each bone marrow aspirate sample was extracted using the
Qiagen QIAamp minelute virus spin kit and the viral titres estimated using limiting
dilution PCR with the UTR primers (Figure 4.2.7). The last positive dilution was used to
estimate the number of viral copies per ml of plasma. Sample BM7P/KG failed to give a
PCR positive signal when the DNA equivalent of four p,l of plasma was added to the
primary PCR. The PCR for this sample was repeated with the DNA equivalent of 40 p.1 of
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Figure 4.2.5 - PCR for TTV/TLMV on sequential dilutions of DNA extracted from bone
marrow aspirates. Sample numbers are shown above each row of the agarose gel. Lanes
1-8: Dilutions of DNA in water added to the primary PCR reaction (Lane 1: 0.1 pg DNA then
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Figure 4.2.6 - PCR for TTV/TLMV on sequential dilutions of DNA extracted from bone
marrow aspirates. Sample numbers are shown above each row of the agarose gel. Lanes
1-8: Dilutions of DNA in water added to the primary PCR reaction (Lane 1: 0.1 ng DNA then
10 fold dilutions to Lane 8: 1x108pg DNA); Lane M: 100bp DNA ladder. Row 4, Lanes 1-3:


















Figure 4.2.7 - PCR for TTV/TLMV on sequential dilutions of DNA extracted from plasma.
Sample numbers are shown above each row of the agarose gel. Lanes 1-5: Dilutions of
DNA in water added to the primary PCR reaction (Lane 1: amount of DNA equivalent to 4 pi
plasma then 10 fold dilutions to Lane 5: amount of DNA equivalent to 4x105 pi plasma);
Lane M: 100bp DNA ladder. Controls, Lanes 1&2: Positive controls (minipools); Lanes 3&4:
Negative controls (water).
The number of viral copies per bone marrow cell (mean 0.028 copies per cell, median
0.001 copies per cell) and per ml of plasma (mean 4075 copies per ml, median 250 copies
per ml) were estimated (Table 4.2.2) based on the last PCR positive dilution visible on the
agarose gels shown in Figure 4.2.5-Figure 4.2.7. As the graph in Figure 4.2.8 shows, there
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does not appear to be any relationship between the titre of virus in bone marrow and the
concentration of virus in one ml of plasma.








BM3/AN N/D N/D 0.0000658 250
BM4/RC N/D M 0.0000658 250
BM5/JW 75 M 0.0658 250
BM6/AB 81 M 0.000658 2500
BM7/KG 25 F 0.658 25
BM8/WH 81 M 0.000658 250
BM9/JM 62 M 0.685 25000
Table 4.2.2 - Estimation of the number of copies of TTV/TLMV per bone marrow cell and
number of copies of TTV/TLMV per ml of plasma from HIV negative bone marrow aspirate
samples. Semi-quantitation carried out by limiting dilution PCR using UTR primers. N/D
indicates no data were available. Virus copies per cell are shown to three significant
figures.
4.2.1.3 Comparison of TTV/TLMV titres in HIV positive and negative bone
marrow samples
Compared with the HIV positive bone marrow, the HIV negative bone marrow samples
appear to contain considerably less TTV/TLMV. All of the HIV negative bone marrow
samples contain less than one copy of virus per cell, ranging from one copy in 1.45 cells to
one copy in 10000 cells.
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To investigate the possibility that HIV status might influence the titre of TTV/TLMV in
bone marrow, the data obtained from the quantification of the viruses in HIV positive
(Table 4.2.1) and HIV negative (Table 4.2.2) bone marrow were compared (Figure 4.2.9).
Statistical analysis was carried out using the Mann-Whitney U test with the null hypothesis
(Ho) that there is no difference between the titre of virus in HIV positive and HIV negative
bone marrow. This test produced a p-value of 0.084 which means that although the null
hypothesis can not be rejected in this instance, and a significantly higher titre of
TTV/TLMV in HIV positive bone marrow than in HIV negative cannot be conclusively
proved, there does seem to be a trend towards this which should be investigated further
using an increased sample size.
4.2.2 TTV/TLMV titres in paired HIV negative and HiV positive
bonemarrow and spleen samples
4.2.2.1 TTV/TLMV titres in paired HIV positive bone marrow and spleen
samples
Previous experiments suggested that bone marrow from HIV positive individuals may have
a higher titre of TTV/TLMV than bone marrow extracted from HIV negative individuals.
In order to investigate further the titre of TTV/TLMV in HIV positive tissues, titres of
Anelloviruses in pairs of tissue samples were investigated. Nineteen post mortem, HIV
positive, paired bone marrow and spleen samples (15 male, four female, mean age 31.5
years, range 20-60 years) were obtained from Professor Jeanne Bell and kept at -40°C until
required. Fourteen of the 19 patients (13 male, one female, median age 32 years) the cause
of death was AIDS related while the cause of death in the remaining five (three male, two
female, median age 30 years) was unrelated to their HIV status. DNA was extracted from
these samples using the Roche High Pure PCR template kit and the DNA concentration
determined using a spectrophotometer. A standardised DNA concentration was utilised as
the starting point for limiting dilution PCR with UTR primers (a representative agarose gel
is shown in Figure 4.2.10). The last PCR positive dilution was assumed to contain at least
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Figure 4.2.10 - PCR for TTV/TLMV on sequential dilutions of DNA extracted from paired HIV
positive bone marrow and spleen samples. Sample numbers are shown above each row of
the agarose gel. Lanes 1-8: Dilutions of DNA in water added to the primary PCR reaction
(Lane 1: 0.1 pg DNA then 10 fold dilutions to Lane 8: 1x10s pg DNA); Lane M: 100bp DNA
ladder.
As Table 4.2.3 shows, all of the bone marrow and spleen samples were positive for
TTV/TLMV (bone marrow: mean 129.89 copies per cell, median 65.79 copies per cell;
spleen: mean 63.13 copies per cell, median 6.58 copies per cell). The Mann-Whitney test
was used to analyse the difference in titre of virus between bone marrow and spleen
samples using the null hypothesis was there was no difference. The p-value was 0.36 so
overall there was no significant difference between the titres of TTV/TLMV in these
tissues.
Of the nineteen pairs of tissue samples: six pairs (31.6%) had the same titre for both tissue
types, four pairs (21.1%) had one log more virus in spleen than in bone marrow, seven
pairs (36.8%) had one log more TTV/TLMV in bone marrow than in spleen and two
(10.5%) pairs had three logs more virus in bone marrow than in spleen.
104
Table 4.2.3 - Estimation of the number of copies of TTV/TLMV per bone marrow and spleen
cell of HIV positive, post mortem tissue using limiting dilution PCR with primers situated in
the UTR region of the genome. Individuals who died of an AIDS related illness are shown in
red and individuals whose cause of death was unrelated to their HIV status are shown in
orange. * indicates samples found to be co-infected with hepatitis C virus. CD4+ T cell
counts provided by Jeanne Bell. N/D indicates that no data were available. The number of





























































































































Using the Wilcoxon signed ranks test the differences between bone marrow and spleen
samples from the same individual were analysed (p=0.22), however again the differences
were not shown to be significant. Differences between the titre of TTV/TLMV in bone
marrow and spleen for individuals within the HIV positive and AIDS groups were also not
found to be significant (AIDS p=0.24, HIV positive p=0.68).
Analysis to compare the titre of TTV/TLMV in bone marrow between the two groups
showed significantly higher titre of virus in the AIDS cohort compared with the and HIV
positive group (p=0.006). Significantly higher titres were also seen in the AIDS cohort
when the TTV/TTMV was quantified in spleen (AIDS vs. HIV positive: p=0.022). This
supports the role of the immune system in regulating TTV/TTMV titre although the exact
mechanism of this remains unclear.
Where available, the CD4+ T cell counts were provided by Jeanne Bell to give an
indication of the level of immunosuppression of the individual so any relationship between
the immune status and virus titre could investigated further. To this end, Spearman rank-
order correlations were used to test for correlations between the titre of TTV/TLMV in
bone marrow and spleen and the CD4+ T cell count for the same individual. This test gave
a p-value of 0.007 for bone marrow and p=0.008 for spleen indicating a inverse correlation
between the number of copies of the virus per cell and CD4+ T cell count. Thus it appears
that as the CD4+ T cell count of an individual drops as they progress towards AIDS, the
titre ofTTV/TLMV in both bone marrow and spleen increases significantly.
4.2.2.1.1 Differentiation of TTVand TLMV in HIVpositive paired
bonemarrow and spleen samples on Roche Lightcycler
Again, it was deemed appropriate to use real-time PCR analysis on the Roche Lightcycler
to characterise the nature of the Anelloviruses present. Primary product from 4.2.2.1 was
used as a template and following amplification, the secondary products were heated to
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As Table 4.2.4 shown, the HIV positive samples show a range of single TTV and TLMV
infection and dual infection with both Anelloviruses. Of the nineteen bone marrow
samples, eight (42.1%) were positive for TTV, five were positive for TLMV (26.3%) and
six (31.6%) were positive for both TTV and TLMV. Six (31.6%) of the nineteen spleen
samples were positive for TTV, four (21.1%) for TLMV and nine (50%) for both viruses.
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Bone marrow Spleen
Sample TLMV TTV TLMV TTV
111 + + + +
153 - + + +
102 + - + +
240 - + - +
180 + + + +
99 - + - +
145 + + + +
209 - + - +
173 + - + +
181 + - + -
184 + - + -
135 + + + +
117 - + + -
155 + - + -
188 + + + 4-
222 ■ - + - +
156 - + - +
194 + + + +
224 - + - 4-
Table 4.2.4 - Frequency of TLMV (shown in green), TTV (shown in blue) and mixed
TTV/TLMV infection (shown in red) in paired HIV positive bone marrow and spleen samples.
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4.2.2.1.2 Hepatitis C infection in HIVpositive bone marrow and
spleen samples
It has been well documented that viral co-infections can change the dynamics of an
infection, for example the Flavivirus GBV-C has a positive impact on disease progression
in HIV infected patients [Northfield, 2005], HIV and HCV share transmission routes and,
as such, up to 30% of those infected with HIV also have a chronic hepatitis C infection, a
figure which increases when applied to HIV positive intravenous drug users [Mohsen,
2002], In cases of co-infection, it appears HIV can increase the disease progression of
hepatitis C and in vitro studies have shown the HCV replication rate can be increased by as
much as eight times in an individual who is also infected with HIV [Northfield, 2005],
The effect of HCV/HIV co-infections on the titre of TTV/TLMV has yet to be ascertained,
therefore it was of interest to investigate the HCV status of the HIV samples used in
4.2.2.1.
Nineteen paired, HIV positive, bone marrow and spleen samples were tested for the
presence of Hepatitis C virus to investigate the effect of HCV/HIV co-infections on the
titre ofTTV/TLMV present in the tissues. Nucleic acid from each sample was subjected to
a nested PCR and visualised on the Roche Lightcycler (Figure 4.2.13). Unlike TTV and
TLMV, the HCV genome is sufficiently conserved to allow the use of sequence specific
probes for detection on the Lightcycler instead of the non-specific SYBR green used for
the detection of Anelloviruses. Of the 38 samples tested, six bone marrow samples (153,
173, 181, 155, 188, and 156) and one spleen sample (156) were positive for the presence of
HCV.
The Mann-Whitney U test was used to investigate any difference in titre between samples
co-infected with HCV and HIV compared with those infected with HIV alone. The null
hypothesis was that there was no difference between the two groups of samples. The p-
value produced using this test was 0.69 for bone marrow and 0.52 for spleen indicating that
co-infections of HCV and HIV did not significantly alter the titre of TTV/TLMV in the
bone marrow and spleen samples.
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4.2.3 TTV/TLMV titres in paired HIV negative bone marrow and
spleen samples
In order to compare the results obtained in 4.2.2.1 with a group who were not
immunocompromised, seven HIV negative paired bone marrow and spleen samples (two
male, two female, three unknown; mean age 78.6 years, range 69 to 84 years) were
obtained from Jeanne Bell and stored at -40°C until required. DNA was extracted from
each of them using the Roche High Pure PCR template kit and the concentration of DNA
was determined using a spectrophotometer. Limiting dilution PCR was used to estimate
the number of virus copies present. A representative agarose gel is shown in Figure 4.2.14.
The last positive dilution from each of the samples was used to calculate an approximate
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Figure 4.2.14 - PCR for TTV/TLMV on sequential dilutions of DNA extracted from paired HIV
negative bone marrow and spleen samples. Sample numbers are shown above each row of
the agarose gel. Lanes 1-5: Dilutions of DNA in water added to the primary PCR reaction
(Lane 1: 0.1 pg DNA then 10 fold dilutions to Lane 5: 1x105 pg DNA); Lane M: 100bp DNA
ladder.
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Table 4.2.5 - Estimation of the number of copies of TTV/TLMV per bone marrow and spleen
cell of HIV negative, post mortem tissue using limiting dilution PCR with primers situated in
the UTR region of the genome. N/D indicates that no data were available. Values for
number of virus copies per cell are shown to three significant figures.
As the table shows, all of the bone marrow and spleen samples were positive for
Anelloviruses (bone marrow: median 0.039 copies per cell, mean 0.066 copies per cell;
spleen: median 0.031 copies per cell, median 0.006 copies per cell). Of the seven pairs of
samples, two pairs had the same titre of TTV/TLMV in both the bone marrow and spleen.
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The other five pairs had differences between the pairs of tissues with a maximum
difference in titre of two logs.
The Mann-Whitney U test, used to compare the number of copies of TTV/TLMV per cell
in bone marrow and spleen, gave a p-value of 0.65. Any significant differences between
the titre of virus in the bone marrow and spleen on the same individual were investigated
using the Wilcoxon signed ranks test, which gave a p-value of 0.59. These statistics show
there is no significant difference in Anellovirus titre between the bone marrow and spleen
samples as a group and on an individual level.
The Mann-Whitney U test was used again, this time to compare the titre of TTV/TTMV in
bone marrow between the AIDS and HIV positive samples from section 4.2.2.1 with bone
marrow from HIV negative patients. This analysis showed significantly higher titres of
virus in the AIDS cohort compared with both the HIV positive group (p=0.006) and the
HIV negative group (p<0.001). Significantly higher titres were also seen in the AIDS
cohort when the TTV/TLMV was quantified in spleen (AIDS vs. HIV positive: p=0.022,
AIDS vs. HIV negative: p<0.001). The increased titre in AIDS patients who are severely
immunocompromised suggests the changes associated with this immunodeficiency in some
way affect the dynamics ofAnellovirus infection.
4.2.3.1 Differentiation of TTV and TLMV in HIV negative paired bone marrow
and spleen samples on Roche Lightcycler
The first dilution of primary product from each of the seven HIV negative paired bone
marrow and spleen samples were run on the Lightcycler to differentiate between TTV and
TLMV in each of the tissue samples. Primers CVOS and CVIA were used in conjunction
with SYBR green fluorescent dye to amplify a product of approximately lOObp that was
then subjected to melting curve analysis to determine the Tm of each of the samples
(Figure 4.2.15).
Table 4.2.6 shows the distribution of TTV and TLMV in each of the samples. Of the
seven bone marrow samples, two (28.6%) were positive for TTV and five (71.4%) for both
TTV and TLMV. Two (28.%) of the spleen samples had a Tm consistent with the
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Bone marrow Spleen
Sample TLMV TTV TLMV TTV
A + + + +
DFN + + + +
B + + + +
C + + + -
F395 - + + +
F396 + + - +
F407 - + - +
Table 4.2.6 - Frequency of TLMV (shown in green), TTV (shown in blue) and mixed
TTV/TLMV infection (shown in red) in paired HIV negative bone marrow and spleen
samples.
4.2.4 TTV/TLMV titres in HIVpositive tissue samples
Okamoto studied the titre of TTV found in the tissues of three HIV negative individuals
and discovered that although titres appeared to be higher in bone marrow, lung, spleen, and
liver than in other tissues (lymph node, muscle, thyroid gland, pancreas and kidney) the
viral load varied between individuals [Okamoto et al., 2001a], Previous experiments within
this study showed similar titres of Anelloviruses in bone marrow and spleen samples. To
investigate the titre of TTV/TLMV in a wider range of tissues from an HIV positive
individual, four further tissue samples were obtained from individual 224 (Table 4.2.3), a
female aged 29 years who died pre-AIDS of a dipipanone over dose.
Nucleic acid was extracted from bone marrow, spleen, left cerebellum, lymph node,
thoracic spinal cord and liver using the Roche High Pure PCR Template kit. The DNA
concentration was analysed before limiting dilution PCR analysis was carried out (Figure
4.2.16 and Figure 4.2.17). The last PCR positive dilution was used to estimate the number
of viral copies per cell.
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Figure 4.2.16 - PCR for TTV/TLMV on sequential dilutions of DNA extracted from bone
marrow, spleen, cerebellum and lymph node samples. Tissue types are shown above each
row of the agarose gel. Lanes 1-5: Dilutions of DNA in water added to the primary PCR
reaction (Lane 1: 0.1 pg DNA then 10 fold dilutions to Lane 5:1x10s fig DNA); Lane M: 100bp
DNA ladder.
224 - thoracic spinal cord
- - -
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Figure 4.2.17 - PCR for TTV/TLMV on sequential dilutions of DNA extracted from thoracic
spinal cord and liver samples. Tissue types are shown above each row of the agarose gel.
Lanes 1-5: Dilutions of DNA in water added to the primary PCR reaction (Lane 1: 0.1 pg DNA
then 10 fold dilutions to Lane 5:1x10s pg DNA); Lane M: 100bp DNA ladder.
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Bone marrow, cerebellum and liver had roughly one viral copy per 1500 cells while
spleen, lymph node and thoracic spinal cord had one viral copy per 150 cells. A graph of
the number of copies of TTV/TLMV per 100 000 cells for all of the tissue types is shown
in Figure 4.2.18.
4.2.4.1 Differentiation of TTV and TLMV from HIV positive tissue samples
To investigate the populations of TTV and TLMV present in the different tissue types, the
second round of the hemi-nested PCR was repeated however, this time the amplification
was carried out on the Roche Lightcycler using SYBR green as a fluorescent dye to label
the amplification reaction. Differentiation of TTV and TLMV was carried out by
analysing the differences in Tm between the two viruses after melting curve analysis had
been carried out (Figure 4.2.19).
Analysis of the melting curves of the samples shows that tissues either contain TLMV
(cerebellum), TTV (bone marrow, thoracic spinal cord, lymph node and liver) or a
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4.3 Discussion
The compromised immune system resulting from HIV infection is well documented, as is
the risk of opportunistic infections as immunosuppression becomes more severe on
progression towards AIDS. Co-infections with other viruses are common in HIV infected
patients and evidence is mounting that these can result in the modification of the HIV
disease processes.
TTV and TLMV are small, circular, DNA viruses which can be transmitted through
parenteral, non-parenteral and faecal oral routes [Puig-Basagoiti et al., 2000; Tawara et al.,
2000], Since they share some of the same transmission routes as HIV, TTV and/or TLMV
co-infections in HIV infected individuals are common. TTV was originally thought to be a
candidate novel hepatitis virus and although its role in liver disease remains controversial,
until its pathogenic potential is fully characterised it will remain relevant to investigate the
implications in those with immune dysfunctions.
This study used a semi-quantitative method to investigate Anellovirus titre in bone marrow
and spleen tissues from three cohorts: HIV positive individuals who died of AIDS related
infections, HIV positive patients who died pre-AIDS and HIV negative individuals. It has
been shown for the first time in this study that significantly increased viral loads are
present in tissues removed from those with an AIDS defining illness compared with both
the HIV positive and negative groups suggesting that the immune system does have a role
of regulating TTV and TLMV viraemia. Although not thought to be significant, it is
noteworthy that the sampling methods were different for the HIV positive and negative
bone marrow. The HIV positive bone marrow was removed during post mortem. The
HIV negative bone marrow, on the other hand, was extracted from living patients during
investigation for haematological abnormalities and came in the form of aspirates.
A significant inverse association between CD4+ T lymphocyte count TTV/TLMV titre was
also established, corroborating studies showing and inverse relationship between TTV viral
load and level of immunosuppression [Shibayama et al., 2001; Touinssi et al., 2001].
There was no correlation between the TTV/TLMV viral load in bone marrow and spleen
and the sex of the infected individual (p>0.05). The role of the immune system in the
natural history of these viruses is further implicated by the evidence that TTV viraemia is
decreased in response to interferon therapy for concomitant HCV infection [Nishizawa et
al., 2000]. However, to conclude that CD4+ T cells are in some way central to the
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clearance of TTV is contrary to studies suggesting that the immune reconstitution
associated with high-activity antiretroviral therapy (HAART) did not lead to a decrease in
TTV viraemia [Takamatsu et al., 2001],
Analogies can be made between TTV/TLMV and Chicken anemia virus, which shares
genomic organisation with TTV. CAV replicates in both the bone marrow and thymus of
infected chickens, causing anemia, thrombocytopenia and depletion of T lymphocytes.
This is aggravated upon co-infection with a second virus. There are several facets ofHIV
infection which are largely unexplained, namely thrombocytopenia, neutropenia and
anemia, which could be attributed to the high titre of TTV/TLMV seen in the bone marrow
of HIV infected individuals. Indeed, TTV has already been implicated in
thrombocytopenia and aplastic anemia [Safadi et al., 2001; Tokita et al., 2001]
Although there was no significant correlation found in this study between the TTV/TLMV
titre and age, it should be noted that the median age of the individuals in both the HIV
positive and the AIDS groups was lower than the HIV negative cohort. This is not thought
to have influenced the increased titre of TTV/TLMV seen in the AIDS cohort. TTV has
been detected in a wide range of age groups, however there is evidence to suggest that
prevalence of TTV infection and virus titre increases with the increasing age of the
population studied [Nagano et al., 1999; Saback et al., 1999], If this was true of the
populations studied here, it would suggest an even greater difference in titre between the
AIDS cohort and negative groups.
Co-infections ofHIV and HCV are very common due to the shared routes of transmission,
so it was important to investigate the HCV status of the tissues analysed in this study.
None of the HIV negative samples were HCV PCR positive however, six of the HIV
positive samples were also infected with HCV. It should be noted that detection of
Hepatitis C virus RNA in extrahepatic tissues is controversial, and although it has been
detected in both bone marrow and spleen of AIDS patients, it is unknown if HCV can
infect or be detected in bone marrow and spleen cells in immunocompetent individuals. It
therefore cannot be confirmed that the lack of a positive PCR signal represents an
individual not harbouring HCV infection. The HCV status of the individuals used in this
study did not appear to alter the titre of TTV/TLMV in their tissues. It is generally
accepted now that TTV infection does not affect HCV titre or reduce the efficacy of
interferon treatment [Maggi et al., 2003; Nishizawa et al., 2000] however there is a body of
evidence to suggest that HCV adversely affects the course of HIV infection and the
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baseline CD4+ cell count is reduced in HIV/HCV co-infected patients [Northfield, 2005].
Although the evidence presented here suggests that a combination of Anelloviruses and
HCV/HIV infections does not serve to increase the titre of TTV/TLMV, it does not draw
any conclusions about the effect on HCV and HIV themselves.
It is hypothesised that TTV may be able to replicate in the haematological compartment
and double stranded replicative intermediates have been found in the bone marrow as well
as in liver in humans [Okamoto et al., 2000d; Okamoto et al., 2000e] and in the liver, bone
marrow and small intestine of experimentally infected rhesus monkeys [Xiao et al., 2002],
Peripheral blood mononuclear cells (PBMCs) were thought to act as a reservoir for TTV
but double stranded intermediates have not been isolated from these cells suggesting that
this is not a site of replication [Okamoto et al., 2000d]. However, TTV replication has been
achieved in vitro by stimulation of PBMCs with phytohemagglutinin, lipopolysaccharide,
and interleukin-2 [Desai, 2005; Mariscal et al., 2002].
The lack of significant differences in titres of TTV/TLMV between the paired bone
marrow and spleen tissues in any of the three groups investigated here suggests the spleen
is also a site of replication for these viruses or the cells which are the main site of
replication are able to infiltrate spleen tissue. There was also no apparent association
between the titre of virus in plasma and bone marrow suggesting that the virus present in
bone marrow is not just a result of circulating virus. This conclusion was also reached by
Pollicino and colleagues [Pollicino et al., 2003] who found consistently lower titre ofTTV
in sera of samples compared with the corresponding paired tissue samples.
The use of PCR primers, which can simultaneously amplify both TTV and TLMV, and the
real time PCR method of differentiating between them provides much needed data on the
relationship between these viruses. These data show that like TTV, TLMV can infect and
possibly replicate in bone marrow and spleen tissue both independently and in the presence
of TTV. Surprisingly, the highest percentage of dual TTV and TLMV infection occurred
in the bone marrow of the HIV negative cohort, which had the lowest virus titre. There
was no significant association between the presence of dual TTV and TLMV infection and
Anellovirus titre in either the bone marrow or spleen tissues.
It has not yet been ascertained if the increased titre of virus in immunosuppressed
individuals observed here and in other publications is the result of an increase in viral
replication or a decrease of immune mediated viral clearance. A high percentage (71%) of
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mixed infections, sometimes with up to five isolates of TTV from different genotypes,
have been noted in HIV infected patients compared with blood donors (21%) and HBV
carriers (29%) [Devalle and Niel, 2004], It is possible that people with compromised
immune systems are unable to mount an immune response on exposure to new genotypes
of TTV. This would support the finding that stimulation of the immune system with
interferon can result in clearance or reduction of TTV viraemia [Akahane et al., 1999;
Hagiwara et al., 1999; Maggi et al., 2001c].
The presence of TTV in extrahepatic tissue is the subject of a number of scientific papers
[Okamoto et al., 2001a; Pollicino et al., 2003; Suzuki et al., 2001] however, since many of
the samples used in this study were from HIV positive individuals it was considered of
importance to further investigate presence of TTV/TLMV in a wider range of tissues.
Given the increased titre of TTV/TLMV seen in the tissues taken from the AIDS cohort, it
was more appropriate to use tissues from an HIV infected individual who had died of a
drug overdose before the progression to AIDS. TTV and/or TLMV were found in all six
of the tissues tested with bone marrow, cerebellum and liver having lower titres than
spleen, thoracic spinal cord and lymph node. Interestingly, both the thoracic spinal cord
and the cerebellum were infected with Anelloviruses: the spinal cord with TTV and the
cerebellum with TLMV. Although it cannot be said with certainty that the virus detected
was not the result of contamination with blood during collection, the presence of two
different viruses within the confines of the central nervous system (CNS) makes this
unlikely. The presence of TTV DNA has been demonstrated in the cerebrospinal fluid
(CSF) [Maggi et al., 2001a] of both an AIDS patient and two patients without HIV,
however a link with any disorder of the CNS has yet to be demonstrated.
In conclusion, this study has demonstrated that both TTV and TLMV may infect bone
marrow and spleen and the titres of these viruses increases in response to the
immunosuppression and decreased CD4+ T cell count associated with the progression to
AIDS, implying the replication of these viruses is regulated by the immune system. The
mechanisms that result in this increased viraemia warrant further investigation however it
seems unlikely that the depletion of lymphocytes alone can account for this phenomenon.
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Chapter 5
Titres of TTV and TLMV and Anti-TTV IgG in Sera
from Immunosuppressed and Immunocompetent
Individuals
5 TITRES OF TTV/TLMV AND ANTI-TTV IGG IN
SERA FROM IMMUNOSUPPRESSED AND
IMMUNOCOMPETENT INDIVIDUALS
5.1 Introduction
The role of the immune system in controlling TTV/TLMV infection is still widely debated.
Although several studies have described increased titres in immunosuppressed individuals,
such as those infected with HIV and AIDS and transplant recipients [Shibayama et al.,
2001; Touinssi et al., 2001], serial samples taken from HIV positive individuals before and
after progression to AIDS failed to find any increased titre on an individual level [Moen et
al., 2002b],
Anti-TTV IgG and IgM have been isolated both from humans and from chimpanzees
infected with human TTV recovered from the faeces of an infected individual [Kakkola et
al., 2002; Tawara et al., 2000; Tsuda et al., 2001]. These limited studies investigating the
antibody status of people infected with TTV/TLMV have given differing accounts
regarding the sequential appearance of circulating IgG and IgM.
This chapter aims to build on the results outlined in chapter four, which investigated
variation in the titre of Anelloviruses in HIV positive and negative tissue samples and
showed there are significant differences between those two groups of patients. The
increased titre of TTV/TLMV in response to a decreased CD4+ T cell count suggested the
immune system plays a role in controlling the replication of the virus leading to a higher
viral load in those whose immune system is compromised. Unlike HIV infection, infection
with HCV and HBV does not lead to immunodeficiency so samples containing there
markers were used in this study to represent virally infected individuals without
compromised immune systems.
5.2 Results
5.2.1 Comparison of TTV/TLMV viral titres in sera from HiV, HCV
or HBVpositive individuals with non co-infected controls
To investigate the titre of TTV/TLMV circulating in the serum of individuals who are
immunocompromised and those who are immunocompetent, ten serum samples from
patients infected with either HIV, HCV or HBV, and ten serum samples from patients with
none of the aforementioned viral markers were provided by Ms. Carol Lycett, Clinical
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Scientist B, NAT Reference Laboratory, Scottish National Blood Transfusion Service,
Royal 'Dick' Vet School, Summerhall, Edinburgh, EH9 1QH. These were anonymised
and no sample data were available.
DNA was extracted from the serum samples using the Roche High Pure Viral Template kit
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Figure 5.2.1 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from HIV
positive serum. Sample numbers are shown above each row of the agarose gel. Lanes 1-5:
Dilutions of DNA in water added to the primary PCR reaction (Lane 1: amount of DNA
equivalent to 4 pi serum then 10 fold dilutions to Lane 5: amount of DNA equivalent to 4x10'
4 pi serum); Lane M: 100bp DNA ladder. Controls, Lane 1: Positive control (minipool); Lane
2: Negative control (water).
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Figure 5.2.2 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from HCV
positive serum. Sample numbers are shown above each row of the agarose gel. Lanes 1-5:
Dilutions of DNA in water added to the primary PCR reaction (Lane 1: amount of DNA
equivalent to 4 pi serum then 10 fold dilutions to Lane 5: amount of DNA equivalent to 4x105
pi serum); Lane M: 100bp DNA ladder. Controls, Lanes 1&2: Positive controls (minipools);
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Figure 5.2.3 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from HBV
positive serum. Sample numbers are shown above each row of the agarose gel. Lanes 1-5:
Dilutions of DNA in water added to the primary PCR reaction (Lane 1: amount of DNA
equivalent to 4 pi serum then 10 fold dilutions to Lane 5: amount of DNA equivalent to 4x10"
4 pi serum); Lane M: 100bp DNA ladder. Controls, Lanes 1&2: Positive controls (minipools);
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Figure 5.2.4 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from HIV,
HCV and HBV negative serum. Sample numbers are shown above each row of the agarose
gel. Lanes 1-5: Dilutions of DNA in water added to the primary PCR reaction (Lane 1:
amount of DNA equivalent to 4 pi serum then 10 fold dilutions to Lane 5: amount of DNA
equivalent to 4x10^ pi serum); Lane M: 100bp DNA ladder. Controls, Lanes 1&2: Positive
controls (minipools); Lanes 3&4: Negative controls (water).
The last positive dilution was used to estimate the number of copies of TTV/TLMV per ml
of serum, as shown in Table 5.2.1. All of the serum samples taken from individuals who
were infected with either HIV, HCV or HBV were PCR positive for TTV/TLMV although
co-infection with HIV was associated with the highest titre of Anelloviruses, as shown in
Figure 5.2.5 (HIV positive sera: mean 382750 copies per ml, median 250000 copies per
ml; HCV positive sera: mean 6100 copies per ml, median 2500 copies per ml; HBV
positive sera: mean 10375 copies per ml, median 1375 copies per ml).
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HIV positive serum sample
Number
Numberof copiesf TTV/TLMV permlof serum
HCV positive serum sample
Numberof copiesf TTV/TLMV permlof serum
HBV positive serum samples
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Of the ten sera collected from patients with no known viral infection, four were PCR
negative for TTV/TLMV. The six that were PCR positive had a mean of 5125 copies per
ml and a median of 1375 copies per ml.
The Kruskal-Wallis test was used to test for differences between the four groups. A p-
value of <0.001 was obtained, indicating significant differences, however the test is unable
to indicate between which groups the significant differences occur. In order to ascertain
this, each pair of samples was subjected to analysis using the Mann-Whitney U-test. The
p-values for each pair of samples is shown in Table 5.2.2.
Comparison of the titre of TTV/TLMV in sera using the Mann-Whitney p-value
U-test
HIV/HCV/HBV negative sera vs. HBV positive sera 0.063
HIV/HCV/HBV negative sera vs. HCV positive sera 0.07
HIV/HCV/HBV negative sera vs. HIV positive sera <0.001
HBV positive sera vs. HCV positive sera 0.871
HBV positive sera vs. HIV positive sera 0.002
HCV positive sera vs. HIV positive sera 0.001
Table 5.2.2 - p-values from Mann-Whitney U-test used to compare titres of TTV/TLMV in
serum. The null hypothesis is there is no significant difference of viral titre between the
two groups. Significant p-values where the null hypothesis can be rejected are shown in
red.
The table shows a notably greater titre of TTV/TLMV in the sera of HIV positive
individuals compared with the groups infected with other viruses and those with no known
viral infection. Although the difference in titre between the control group
(HIV/HCV/HBV negative) and the HCV and HBV positive groups is not statistically
significant, the p-values of 0.063 (HBV) and 0.07 (HCV) suggest there is trend towards
Anellovirus titre that is higher when infection with TTV/TLMV is combined with a second
virus.
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5.2.2 TTV/TLMV titres in sera from transplant recipients
To compare the titre ofTTV/TLMV in sera taken from HIV positive patients with a second
group of patients who were immunocompromised, the TTV/TLMV titre in the serum of 20
anonymised patients who were receiving of immunosuppressive drug treatment were
analysed. Serum samples from patients who had recently undergone either a heart
transplant, a lung transplant or a heart and lung transplant (mean 47.9 days post transplant,
median 45.5 days post transplant), were provided by Dr Paul Hopwood, Department on
Medical Microbiology, University ofEdinburgh Medical School, Teviot Place, Edinburgh.
DNA was extracted from the sera using the Roche High Pure Viral Template kit and the
titre of TTV/TLMV estimated using limiting dilution PCR (Figure 5.2.6).
lOObp
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H13.2 H20.2
100bp
12345 12345 1 2 3 4 5 M
!* H25.2 H30.2 H32.2
100bp
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100bp
Figure 5.2.6 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from serum
taken from transplant recipients. Sample numbers are shown above each row of the
agarose gel. Lanes 1-5: Dilutions of DNA in water added to the primary PCR reaction (Lane
1: amount of DNA equivalent to 4 nl serum then 10 fold dilutions to Lane 5: amount of DNA
equivalent to 4x10"4 jil serum); Lane M: 100bp DNA ladder. Controls, Lanes 1&2: Positive
controls (minipools); Lanes 3&4: Negative controls (water).
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The last PCR positive dilution was used to estimate the number of virus copies present in
one ml of serum, as shown in Table 5.2.3 (mean: 3512.5 copies per ml; median: 2500
copies per ml). The table shows a remarkable consistency in the titre of virus in the serum
of these individuals. With the exception of samples HI 3.2 which contained 250 copies per
ml and H36.2, containing 25000 copies per ml, all of the serum samples contained 2500
copies ofTTV/TLMV per ml.
Following the transplant, patients were subjected to immunosuppressive drug therapy to
artificially suppress the immune system and prevent rejection of the transplanted organ.
Combinations of the corticosteroids prednisolone and methylprednisolone, the cytotoxic
drug azathioprine, and cylosporin A, a calcineurin inhibitor, were used to prevent rejection.
A graph indicating the doses of these drugs in relation to the TTV/TLMV titre is shown in
Figure 5.2.7.
To investigate if any of the drugs influenced the titre of TTV/TLMV in the serum of the
patients, linear regression was carried out. No significant association was found between
the viral load and the drug dose for azathioprine, prednisolone and methylprednisolone
(p>0.2). There was also no significant association with the cumulative drug dose taken up
to the point the serum sample was collected (p>0.5). Although the association between
Anellovirus titre and cyclosporin A dose was not significant (p-value=0.088), there does









Number of copies of
TTV/TLMV per ml of
serum
1 HI.2 36 Heart 2500
2 H2.2 35 Heart 2500
3 H6.2 34 Lung 2500
4 H7.2 29 Lung 2500
5 H13.2 28 Lung 250
6 H20.2 45 Lung 2500
7 H25.2 61 Lung 2500
8 H30.2 56 Lung 2500
9 H32.2 48 Heart 2500
10 H33.2 39 Lung 2500
11 H36.2 56 Heart 25000
12 H39.2 46 Heart and lung 2500
13 H41.2 37 Lung 2500
14 H46.2 107 Heart 2500
15 H51.2 57 Heart and lung 2500
16 H60.2 70 Lung 2500
17 H61.1 21 Heart 2500
18 H87.2 57 Lung 2500
19 H88.2 56 Heart and lung 2500
20 H92.2 41 Heart and lung 2500
Table 5.2.3 - Estimation of the number of copies of TTWTLMV per miililitre of serum
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5.2.2.1 Titre of TTV/TLMV in the serum of transplant patients compared with
TTV/TLMV titre in HIV, HCV or HBV positive or HIV/HCV/HBV negative
sera
The Mann-Whitney U-test was used to compare the titre of TTV/TLMV in the serum of
transplant patients with the titre of virus in serum from HIV, HCV and HBV positive
individuals and HIV, HCV and HBV negative serum (Section 5.2.1). The p-values are
shown in Table 5.2.4. As the table shows, the HCV, HBV and HIV negative serum
samples have significantly less TTV/TLMV and the HIV positive serum samples have a
significantly higher titre ofTTV/TLMV than the transplant sera.
Comparison of the titre ofTTV/TLMV in sera using the Mann-Whitney p-value
U-test
Sera from transplant patients vs. HIV/HCV/HBV negative sera 0.002
Sera from transplant patients vs. HCV positive sera 0.281
Sera from transplant patients vs. HBV positive sera 0.626
Sera from transplant patients vs. HIV positive sera <0.001
Table 5.2.4 • p-values from Mann-Whitney U-test used to compare titres of TTV/TLMV in
serum. The null hypothesis is there is no significant difference of viral titre between the
two groups. Significant p-values where the null hypothesis can be rejected are shown in
red.
5.2.3 Difference in proportion of TTV/TLMV bound to IgG and free
TTV/TLMV in sera infected with HIV, HCV, HBV, non-infected
controls and transplant patients
HIV positive sera appears to contain a much higher titre of TTV/TLMV than sera infected
with other viral agents (HBV and HCV) and sera taken from transplants patients who are
subjected to immunosuppressive drug regimes. Although yet to be proved conclusively, it
is possible that acquired immunodeficiency associated with HIV infection and the
progression towards AIDS in some way reduces the immune response directed towards
TTV/TLMV and TTV/TLMV infected cells and results in unchecked replication of these
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viruses. To investigate the possibility of a decreased antibody response in
immunocompromised patients, the proportion of virus bound to IgG was compared with
the proportion of free virus in the sera of five groups of individuals (HIV positive, HCV
positive, HBV positive, HIV, HCV and HBV negative and transplant recipients) as an
indicator of the antibody response to the Anelloviruses.
IgG present in the ten sera samples from each of the five groups was captured using
protein G magnetic beads. Nucleic acid was extracted from IgG depleted serum and the
protein G bead eluate using the QIAamp Minelute Virus Spin kit and the TTV/TLMV titre
semi-quantitated using limiting dilution PCR. Representative agarose gels are shown in
Figure 5.2.8 (IgG depleted serum) and Figure 5.2.9 (IgG).
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Figure 5.2.8 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from IgG
depleted HBV positive serum. Sample numbers are shown above each row of the agarose
gel. Lanes 1-5: Dilutions of DNA in water added to the primary PCR reaction (Lane 1: 2 |xl
DNA then 10 fold dilutions to Lane 5: 2x10"Vl DNA); Lane M: 100bp DNA ladder. Controls,
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Figure 5.2.9 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from IgG
isolated from HBV positive serum. Sample numbers are shown above each row of the
agarose gel. Lanes 1-5: Dilutions of DNA in water added to the primary PCR reaction (Lane
1: 2 pi DNA then 10 fold dilutions to Lane 5: 2x10"4 pi DNA); Lane M: 100bp DNA ladder.
Controls, Lanes 1&2: Positive controls (minipools); Lanes 3&4: Negative controls (water).
The number of PCR positive dilutions from the IgG depleted serum and the isolated IgG
were compared for each sample as shown in Figure 5.2.10 to Figure 5.2.14. These graphs
show a wide range of variation in the proportion of virus bound to IgG compared with free
virus in all five of the groups. Interestingly, the HIV, HCV and HBV negative group is the
only one of the five groups that included samples which contained TTV/TLMV bound to
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The proportions of bound and unbound virus were calculated by taking the difference in
the number of PCR positive dilutions between the free virus found in the IgG depleted
serum fraction and the virus complexed with IgG from the isolated IgG fraction (free virus
- complexed virus, as shown in Table 5.2.5). The mean value for each group, shown in
the bottom row of the table, indicates that all of the groups have a higher proportion of free
virus then virus complexed with IgG. The exception to this is the HIV, HCV and HBV
negative group which has a mean value of -0.1, showing that in these individuals there is a
higher proportion of virus bound to IgG than free virus.
To investigate if proportions of free TTV/TLMV versus TTV/TLMV bound to IgG were
significantly different between the five groups, the Kruskal-Wallis test, which assumes
there is no significant difference between the groups, was carried out. The p-value for this
test was 0.048, indicating the null hypothesis could be rejected in favour of the alternative
hypothesis that there is significant differences. The Mann-Whitney test was then used on
pairs of groups using the same null hypothesis, as shown in Table 5.2.6. The test shows
there are significantly different proportions of bound and unbound TTV/TLMV between
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Comparison of free TTV/TLMV - TTV/TLMV complexed with IgG in p-value
serum using the Mann-Whitney U-test
HIV positive sera vs. HCV positive sera 0.282
HIV positive sera vs. HBV positive sera 0.460
HIV positive sera vs. HIV, HCV and HBV negative sera 0.002
HIV positive sera vs. sera from transplant recipients 0.090
HCV positive sera vs. HBV positive sera 0.906
HCV positive sera vs. HIV, HCV and HBV negative sera 0.039
HCV positive sera vs. sera from transplant recipients 0.638
HBV positive sera vs. HIV, HCV and HBV negative sera 0.076
HBV positive sera vs. sera from transplant recipients 0.752
HIV, HCV and HBV negative sera vs. sera from transplant recipients 0.099
Table 5.2.6 - p-values from Mann-Whitney U-test used to compare free TTV/TLMV with
TTV/TLMV bound to IgG in serum. The null hypothesis is there is no significant difference
in proportions between the two groups. Significant p-values where the null hypothesis can
be rejected are shown in red.
5.2.4 Titre of TTV/TLMV in sequential serum samples from
transplant recipients
The titre of TTV/TLMV in the serum of 20 patients who had recently received a transplant
was investigated in section 5.2.2, however these samples appeared to lack the variability of
titre seen in the other groups studied, with 90% of transplant recipients having 2500 copies
of virus per ml of serum. It also showed a significant difference between the titre of
TTV/TLMV in transplant patients compared with both HIV positive and HIV, HCV and
HBV negative individuals. To explore the dynamics of TTV/TLMV infection in
individuals post transplant, sequential serum samples from two transplant recipients over
an extended period of time (524 days and 917 days) were provided by Dr. Paul Hopwood
and examined for changes in the virus titre.
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Nucleic acid was extracted from serum samples from lung transplant recipients using the
Roche High Pure Viral Template kit and the TTV/TLMV titre estimated using limiting
dilution PCR (Figure 5.2.15 and Figure 5.2.16). The last positive dilution was used to
estimate the number of copies of TTV/TLMV per ml of serum for both patients (Table
5.2.7 and Table 5.2.8). The tables show that the titre of virus varies over time and
although the initial titre of virus in serum (at day 21 post transplant for patient H10 and day
69 post transplant for patient H21) varies by three logs between the two patients, the titre
increases to peak at 25000000 copies per ml of virus at day 217 (H10) and day 251 (H21).
The change in titre of TTV/TLMV over time is shown with the doses of
immunosuppressive drugs in Figure 5.2.17 and Figure 5.2.18. Although the graphs to not
appear to indicate any relationship between drug dose and virus titre, linear regression was
used to test for any relationship between cyclosporine A, azathioprine and prednisolone,
and TTV/TLMV titre. The p-values for these test were all greater that 0.05, indicating no
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Figure 5.2.15 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from lung
transplant recipient H10. Sample numbers are shown above each row of the agarose gel.
The number after the decimal point is indicative of the sample collection time point. Lanes
1-5: Dilutions of DNA in water added to the primary PCR reaction (Lane 1: amount of DNA
equivalent to 4 pi serum then 10 fold dilutions to Lane 5: amount of DNA equivalent to 4x10"
4 |xI serum); Lane M: 100bp DNA ladder. Controls, Lane 1 and 2: Positive controls
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Figure 5.2.16 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from lung
transplant recipient H21. Sample numbers are shown above each row of the agarose gel.
The number after the decimal point is indicative of sample collection time point. Lanes 1-5:
Dilutions of DNA in water added to the primary PCR reaction (Lane 1: amount of DNA
equivalent to 4 pi serum then 10 fold dilutions to Lane 5: amount of DNA equivalent to 4x10"
4 pi serum); Lane M: 100bp DNA ladder. Controls, Lane 1 and 2: Positive controls
(minipools); Lane 3 and 4: Negative controls (water).
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Number Transplant sample Days post transplant Number of copies of
number (days) TTV/TLMV perml of
serum
1 H10.2 21 250
2 HI 0.3 124 25000
3 HI0.4 155 250000
4 HI 0.5 217 25000000
5 H10.6 251 2500000
6 HI 0.7 309 250000
7 H10.8 334 250000
8 H10.9 411 25000
9 H10.10 524 25000000
Table 5.2.7 - Estimation of the number of copies of TTV/TLMV per ml of serum from lung
transplant recipient H10. 'Number' corresponds to the x-axis of Figure 5.2.17.
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Number Transplant sample Days post transplant Number of copies of
number (days) TTV/TLMV per ml of
serum
1 H21.2 69 250000
2 H21.3 125 250000
3 H21.4 181 2500000
4 H21.5 251 25000000
5 H21.6 378 250000
6 H21.7 432 250000
7 H21.8 483 25000
8 H21.9 551 2500000
9 H21.10 588 2500
10 H21.ll 753 2500
11 H21.12 917 25000
Table 5.2.8 - Estimation of the number of copies of TTV/TLMV per ml of serum from lung
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5.2.4.1 Difference in proportion of TTV/TLMV bound to IgG and free
TTWTLMV in lung transplant recipients
Having already established the titre of TTV/TLMV changes over time in the serum of
transplant recipients, the antibody response to the virus in the same two immunosuppressed
transplant patients was investigated by comparing the amount of virus circulating freely in
serum with the amount of virus complexed with IgG using the protein G capture method
(Figure 5.2.19 to Figure 5.2.22).
The relationship between the titre of TTV/TLMV complexed with IgG and free virus was
explored initially by plotting the number of PCR positive dilutions for both fraction of
each sample as shown in Figure 5.2.23 and Figure 5.2.24. They demonstrate that the
relative proportion of free virus and complexed virus changes over time.
The disparity between the two portions of serum was also evaluated by calculating the
difference between free TTV/TLMV and TTV/TLMV bound to IgG (free virus - bound
virus) and these values were plotted with the titre of TTV/TLMV per ml of serum (Figure
5.2.25 and Figure 5.2.26). These figures show that apart from sample nine from patient
H21 (day 588 post transplant which corresponds to a sharp decrease in TTV/TLMV titre),
there always appears to be more free virus in serum that virus complexed to IgG. The
sequential serum samples taken from patient H10 show the level of free virus increased to
peak at day 251 post transplant whereas the difference in PCR positive dilutions from the
portions of serum from H21 seems to correspond to changes in virus titre. Spearman's test
for significance was carried out to investigate a correlation between the proportion of
bound and unbound virus and the titre of TTV/TLMV (H10 p-value = 0.225, H21
p<0.001) indicating there is a relationship between these two factors in patient H21.
Linear regression was used to test for any association between the dose and type of
immunosuppressive drugs and the proportion of bound and unbound virus. A significant
p-value (p = 0.047) was obtained when the dose of azathioprine was examined in patient
H21. It is possible that in this patient the dose of azathioprine in some way contributed to
the change in proportion of free virus compared with virus complexed with IgG.
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Figure 5.2.19 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from IgG
depleted serum from lung transplant recipient H10. Sample numbers are shown above
each row of the agarose gel. Lanes 1-5: Dilutions of DNA in water added to the primary
PCR reaction (Lane 1: 2 pi DNA then 10 fold dilutions to Lane 5: 2x10"" |xl DNA); Lane M:
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Figure 5.2.20 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from serum
IgG isolated from lung transplant patient H10. Sample numbers are shown above each row
of the agarose get. Lanes 1-5: Dilutions of DNA in water added to the primary PCR reaction
(Lane 1: 2 pi DNA then 10 fold dilutions to Lane 5: 2x10"" pi DNA); Lane M: 100bp DNA
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Figure 5.2.21 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from IgG
depleted serum from lung transplant recipient H21. Sample numbers are shown above
each row of the agarose gel. Lanes 1-5: Dilutions of DNA in water added to the primary
PCR reaction (Lane 1: 2 pi DNA then 10 fold dilutions to Lane 5: 2x10"* pi DNA); Lane M:
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Figure 5.2.22 - UTR PCR for TTV/TLMV on sequential dilutions of DNA extracted from serum
IgG isolated from lung transplant patient H21. Sample numbers are shown above each row
of the agarose gel. Lanes 1-5: Dilutions of DNA in water added to the primary PCR reaction
(Lane 1: 2 pi DNA then 10 fold dilutions to Lane 5: 2x10"" pi DNA); Lane M: 100bp DNA
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5.3 Discussion
Having already shown that TTV/TLMV is present in higher titres in the bone marrow and
spleen of HIV positive individuals who have progressed to AIDS compared with tissues
taken from individuals without HIV infection, the aim of this chapter was to clarify the
dynamics of TTV/TLMV infection in sera taken from immunosuppressed and
immunocompetent patients. Sera from HIV positive patients were analysed for the
presence of TTV/TLMV and the titres compared with those found in patients with hepatitis
C or hepatitis B viruses, neither of which are associated with overt immunosuppression.
Sera from healthy blood donors negative for HIV, HCV and HBV were used as a control
group.
When ten samples from each of the four groups were analysed, 100% of the sera from
individuals infected with a second viral marker (HIV/HBV/HCV) were PCR positive for
TTV/TLMV however only 60% of the healthy group were TTV/TLMV PCR positive.
Anellovirus infection in the remaining 40% of the HIV/HCV/HBV negative group cannot
be ruled out however, it may be the virus is present at levels below the detection limit of
the assay. Epidemiological studies have investigated the titre of TTV within a number of
populations and found that the incidence of TTV was decreased in low risk populations
such as blood donors compared with populations at risk of parenteral exposure [Gallian et
al., 1999; Maggi et al., 1999]. Touinssi suggested that the reported increased prevalence of
TTV was the result of elevated viraemia in high risk populations which increased the rate
of detection ofTTV [Touinssi et al., 2001], We found a statistically significant increase in
TTV/TLMV titre in the sera of HIV positive patients compared with the HCV and HBV
positive groups and the HIV/HBV/HCV negative groups. This finding corroborates the
results of the previous chapter which described increased titres of TTV/TLMV in tissues of
HIV infected patients and an inverse correlation between CD4+ lymphocyte count and
TTV/TLMV titre, again suggesting this is the result of the immunosuppression associated
with HIV as opposed to the concomitant viral infection. Although the differences between
the control group and the HCV and HBV positive group were not significant, the p-values
(0.063 for HBV group and 0.07 for HCV group) suggested a trend towards higher
TTV/TLMV titres in these groups. HCV, HBV and the Anelloviruses share parenteral
transmission routes and there has been evidence that this route of transmission is
associated with elevated TTV titres [Zehender et al., 2001]. It should be noted that the
HIV, HCV and HBV positive samples were collected from blood donors for confirmatory
testing. As such, the individuals were unaware of their infection and were not undergoing
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any treatment that might affect TTV/TLMV titres, for example interferon alpha taken for
HCV infection, which has been shown to decrease the serum titres of TTV in some
patients.
The incidence of TTV was found to be increased in the sera of recipients of renal
transplants, as determined by N22 PCR [Szladek et al., 2003] and increased titre ofTTV in
conjunction with immunosuppressant medication following kidney transplant [Moen et al.,
2003] has also been recorded. In this study we semi-quantitated the TTV/TLMV present
in the sera of recipients of lung, heart or heart and lung transplants. All 20 of the samples
were PCR positive for Anelloviruses, with 90% of samples having a titre of 2500 copies of
TTV/TLMV per ml. Statistical analysis revealed the titre of TTV/TLMV in transplant
samples was significantly higher than titres in sera from HCV or HBV positive individuals
and healthy blood donors however, the transplant samples had a significantly lower titre
than the HIV positive samples. It is hypothesised that the drug induced
immunosuppression needed to prevent the rejection of organs following transplant allows
for an increase in the titre of TTV/TLMV. Although this increased TTV/TLMV titre in
transplant recipients has not been associated with any pathology, an increase in titre or the
reactivation of latent viruses is recognised as having a detrimental effect on the recipients
of solid organ transplants. Of note are the Herpesviruses: Cytomegalovirus (CMV) which
can effect any organ system, enhance immunosuppression and can cause rejection of the
transplanted organ, Herpes simplex virus (HSV) infections post transplant sometimes
result in ulcerative oesophagitis, tracheobronchitis and pneumonia, and Epstein-Barr virus
(EBV) which can initiate post-transplant lymphoproliferative disorder (PTLD), a disease of
uncontrolled proliferation of B lymphocytes which may form tumour masses [Slifkin,
2004],
There has yet to be conclusive evidence of TTV in transplant recipients resulting in
hepatitis or liver injury [Kanda et al., 1999; Michitaka et al., 2000; Shang et al., 2000; Usta
et al., 2002] however, one recipient of a bone marrow transplant developed hepatic injury
corresponding to increased ALT levels which showed correlation to TTV titre. Liver
biopsy reported pathology consistent with viral hepatitis and sequence analysis found a
new genotype of TTV genetically distinct from TTV isolated before transplant. The
authors concluded this novel TTV genotype may be the cause of the viral hepatitis [Kanda
et al., 1999].
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An increase in viral titres in response to immunosuppressive medication is not the only
possible explanation for the high TTV/TLMV viral load seen in transplant recipients. Peri-
transplant blood transfusions or the transplanted organ itself may introduce novel
genotypes into the transplant recipient [Shang et al., 2000].
Immunosuppressive drugs are given to patients post-transplant to prevent the rejection of
the transplanted organ. The transplant recipients used in this study received cyclosporine
A, a calcineurin inhibitor which prevents the activation of interleukin-2 transcriptions and
thus decreases the function of the cytotoxic T cells; azathioprine, a prodrug which converts
in vivo to 6-mercaptopurine. This acts as an antagonist to prevent the synthesis of purines
needed for the proliferation of lymphocytes. Prednisolone and methylprednisolone are
corticosteroids which target several stages of immune stimulation inhibiting antigen
presentation, cytokine production and the proliferation of lymphocytes [Offermann, 2004].
Linear regression found no evidence of association between TTV/TLMV titre and drug
dose for prednisolone, methlyprednisolone and azathioprine however, although there did
appear to be a trend towards increasing virus titre in response to increasing cyclosporine A
dose, the findings were not significant.
The immune responses to TTV and TLMV that allow the development of chronic, and
possibly life-long, viral infections are largely unknown. TTV complexed with IgG has
been isolated from the serum of HIV positive patients and visualised using immunogold
electron microscopy [Itoh et al., 2000], This was one of the first pieces of evidence to
suggest that the immune system was activated in response to infection. Antibody studies
have also been published using TTV particles and portions of the ORF1 protein as antigen
[Ott et al., 2000].
The first antibody secreted by the body in response to viral challenge is IgM. This is
transient and the levels in the blood decline rapidly. A study has found anti-TTV IgM in
two patients who developed post transfusion non A-G hepatitis coupled with acute TTV
infection post transfusion [Tsuda et al., 2001] as well as in healthy adults [Ott et al., 2000]
however, in the latter group, the IgM response was found to persist for years in conjunction
with circulating TTV.
IgG is the most abundant antibody, able to enter tissue as well as being present in the
circulation. It defends against viral infection both by activation of complement and
opsonisation of the virus for phagocytosis. Anti-TTV IgG has been detected for prolonged
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periods of time in a TTV DNA positive individual (detection of antibody was still possible
when the study period ended at 4.4 years), appearing after IgM disappeared from
circulation [Tsuda et al., 2001]. Ott and colleagues reported the isolation of IgG antibodies
in the sera of healthy adults but at a considerably lower frequency than the detection of
TTV DNA (10% IgG positive compared with 86% TTV DNA positive) [Ott et al., 2000].
The increased TTV DNA titre in immunosuppressed individuals reported in this study
suggested a less robust immune response than in immunocompetent adults. To explore
this theory, the titre of free TTV/TLMV was compared with TTV/TLMV complexed with
IgG. This showed that the immunosuppressed individuals (HIV positive and transplant
recipients) always had free virus titres which were greater than or equal to the titre of virus
bound to IgG. This was also seen in all but one of the sequential samples analysed from
two transplant recipients. Ten % of HCV positive, 20% ofHBV positive samples and 40%
of HIV/HCV/HBV negative samples had a higher titre of virus complexed with IgG
compared with free virus. This suggests that in patients with immunosuppression the
increased TTV/TLMV titre could be a result of a decreased IgG response to the viruses.
Evidence that the stimulated PBMCs, but not unstimulated PBMCs were capable of
supporting TTV replication [Maggi et al., 2001b] could imply at least some genotypes of
TTV are able to infect cells of the immune system and that co-infection with other viruses
and the resulting immune stimulation may produce the increased viral titres reported in
this, and other, studies. On the other hand, it has been suggested hypervariable regions of
the TTV genome allow the circulation of quasispecies of the virus which may escape
immune surveillance [Nishizawa et al., 1999] and that number of genogroups present in
serum increased exponentially with the viral load [Maggi, 2005]. Unfortunately,
conclusions cannot yet be drawn about the possibility that increased viral titres increase the
pathogenicity of the virus.
The TTV/TLMV titres of two transplant recipients (H10 and H21) fluctuated over the 1.5
and 2.5 year interval studied. Both patients virus titres increased steadily to peak at time
point four however, this did not correspond to any change in immunosuppressive
medication. Moen and colleagues described increases in the titres of TTV and TLMV 50-
100 days after kidney transplant that corroborates the data obtained in this study.
The data presented in this chapter have given further insight into the dynamics of
TTV/TLMV infection in healthy and immunosuppressed individuals. Sera from HIV
positive patients had a titre of TTV/TLMV significantly higher that all of the other groups
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studied with the majority of the virus circulating without forming complexes with IgG.
Sera from transplant recipients also had significantly elevated Anellovirus titre which, like
the virus seen in the HIV positive group, circulated as free virus. On the other hand, sera
from healthy individuals had low titres of TTV/TLMV present in the serum which was
predominately found circulating in complexed with IgG.
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Chapter 6
Investigation of TTV/TLMV-like Viruses in Non
Human Primates and Farm Animals
6 INVESTIGATION OF TTV/TLMV-LIKE VIRUSES IN
NON-HUMAN PRIMATES AND FARM ANIMALS
6.1 Introduction
Non-human primates, especially chimpanzees, have been used to elucidate the routes of
transmission of all the hepatitis causing viruses. This frequently involved inoculating the
chimpanzee with sera from a human either infected with the hepatitis virus of interest or
suffering from cryptogenic non A-E hepatitis. The ubiquitous nature of TTV and TLMV
has resulted in the inadvertent transmission of these viruses to chimpanzees. It was found
not only that chimpanzees could be infected with human forms of this virus but that the
chronic nature of the infection in chimpanzees was similar to infections observed in
humans [Mushahwar et al., 1999].
Investigations of wild caught chimpanzees have established that they harbour a species-
specific TTV-like virus similar to, but distinct from, human TTV [Barnett et al., 2004;
Verschoor et al., 1999] as well as human TTV, which may be the result of the increasing
interaction wild chimpanzees have with humans as they encroach on their territory [Barnett
et al., 2004], TTV-like viruses have also been isolated from gibbons and rhesus monkeys
[Luo et al., 2000; Noppornpanth et al., 2001].
Using primers from the N22 region of the genome, Leary detected TTV in chickens, pigs,
cows and sheep with high identity to human sequences (79-99% at the nucleotide level)
[Leary et al., 1999]. Since it has already been shown that chimpanzees could be infected
with human TTV, TTV present in domesticated farm animals that was not genetically
distinct from human TTV could be contributing to the ubiquitous nature of the virus within
human populations or could have been transmitted from their human keepers.
This chapter discusses the investigation of sera from a number of non-human primates for
the presence of TTV/TLMV-like viruses. It also attempts to clarify the presence of TTV-
like viruses in domesticated farm animals. Identification of these homologues will not
only give us insight into the origin of these viruses and their evolution but may also
provide answers to outstanding questions as the exact method of replication and the
mechanism of persistence of TTV/TLMV in humans.
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6.2 Results
6.2.1 Prevalence of TTV-like viruses in non-human primates
To investigate the possibility that non-human primates harbour TTV or TTV-like viruses,
serum from a number of non-human primates species were analysed. Nucleic acids were
extracted from the sera of 13 drills (Mandrillus leucophaeus leucophaeus), two mandrills
{Mandrillus sphinx), four cherry-capped mangabeys (Cercocebus torquatus), five
chimpanzees (Pan troglodytes troglodytes and Pan troglodytes vellerosos), 19 gibbons
(Hylobates agilis, Hylobates lar, Hylobates muelleri, Hylobates moloch and Hylobates
gabriellae), 14 Bornean orangutans (Pongo pygmaeus pygmaeus), and one Western
Lowland gorilla (Gorilla gorilla gorilla) and analysed for the presence of TTV and TLMV
using PCR with primers situated in the UTR region of the genome. It was hoped that the
conservation within this region observed when human sequences were analysed would
extend to any TTV homologues infecting apes and African monkey species. A
representative agarose gel is shown in Figure 6.2.1.
4- 100bp
Figure 6.2.1 - PCR products from nucleic acid extracted from non-human primate species
and amplified using the UTR hemi nested primer set CVOS/CVOA and CVOS/CVIA. Lane 1:
negative control (water); Lanes 2-14: secondary PCR product from samples D1-3, D5 & 6
and L1-8 (Drills); Lanes 15-17; secondary PCR product from chimpanzee samples L20, L22
& L24; Lane 18; positive control (minipool); Lane 19: negative control (water).
It was found that not only did these animals harbour a virus in their serum which could be
amplified using primers designed for human TTV, but the prevalence of these viruses were
comparable with the level of infection seen in humans, as shown in Table 6.2.1.
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ChimpanzeeL22 ChimpanzeeL24 Gibbon2 Gibbon3 Gibbon4 Gibbon5 Gibbon6 Gibbon7 Gibbon8 Gibbon9 Gibbon10 Gibbonil Gibbon12
Pantroglodytes Pantroglodytes Hylobateslar Hylobatesgabriellae Hylobatesmuell ri Hylobatesagili Hylobatesgabriellae Hylobatesgabriellae Hylobatesmuell ri Hylobateslar Hylobatesagili Hylobatesagili Hylobatesga riellae
Cameroon+ Cameroon Taiwan3+ Taiwan3+ Taiwan3 Taiwan3+ Taiwan3 Taiwan3+ Taiwan Taiwan3+ Taiwan3 Taiwan3 Taiwan3
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Gibbon13 Gibbon14 Gibbon15 Gibbon16 Gibbon17 Gibbon18 Gibbon19 Gibbon20 Orangutan01 Orangutan02 Orangutan03 Orangutan04 Orangutan05
Hylobatesmoloch Hylobatesmuell ri Hylobatesmuell ri Hylobatesmoloch Hylobatesagili Hylobatesmoloch Hylobateslar Hylobatesmuell ri
Pongopygmaeus Pongopygmaeuss Pongopygmaeuspy Pongopygmaeuss Pongopygmaeuss
Taiwan3+ Taiwan3 Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3 Taiwan3 Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+
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Orangutan06 Orangutan07 Orangutan08 Orangutan09 Orangutan010 Orangutanil Orangutan012 Orangutan013 Orangutan014 GorillaR1
Pongopygmaeus Pongopygmaeus Pongopygmaeus Pongopygmaeus Pongopygmaeus Pongopygmaeus Pongopygmaeuspy Pongopygmaeus Pongopygmaeuss Gorillagori l
Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+ Taiwan3+ Edinburgh4+
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For the non-human primate samples, 100% viraemia was detected in orangutans, cherry-
capped mangabeys, mandrills and the single gorilla tested. Twelve of the 13 drills tested
(92%), 12/19 gibbons (63%) and 4/5 chimpanzees (80%) also had detectable virus in their
serum. Nucleic acid from the serum of all 58 non-human primate samples were also tested
for the presence of a TTV-like virus using the N22 primers which amplify a portion of
ORF1. None of the samples had virus detectable using this primer set.
6.2.2 Investigating primate TTV/TLMV-like viruses using real time
PCR
To assess the heterogeneity of the viruses amplified from the non human primate samples,
a selection of primary product from nucleic acid amplified using the UTR primers (from
section 6.2) were subjected to real time PCR amplification on the Roche Lightcycler as
previously described. A representative melting temperature profile is shown in Figure
6.2.2. It was found that although some of the viruses amplified from the same species had
the same or very similar melting temperatures (L4 and L5, Figure 6.2.2) there were also
viruses within the species group which displayed markedly different Tms, for example L2
and L4/L5 (Figure 6.2.2). Some of the sera also showed two melting peaks, indicating
infection with a heterogeneous mixture of virus (G5, Figure 6.2.2), possibly analogous to
the TTV/TLMV co-infections seen in humans.
6.2.3 Cloning and sequencing of virus from non-human primate
sera
The PCR products from the amplification of virus from non-human primate samples were
inserted into pGEM-T easy vector and transfected into E.coli cells. After plating up the
transformed cells and growing them overnight, cells from a number of colonies containing
viral DNA isolated from the non-human primate serum samples were added to a primary
PCR using the UTR primers. A secondary PCR reaction was carried out on the
Lightcycler to confirm the ligation and transfection reactions had been successful. In order
to investigate further the distribution of melting temperatures, Tms from real time PCR
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From the limited number of clones analysed, it appears that viruses from all the species
investigated are as heterogeneous as TTV and TLMV isolated from human serum samples.
In fact, the differences in Tms seen here could suggest that non-human primates may be
infected with more than one type of Anellovirus that shares the partially conserved
untranslated region. This pattern is most prominent when analysing the chimpanzee clones
which appear to form two discrete groups, one with a high Tm (mean 89.5°C, median
89.7°C) and one with a low Tm (mean 85.7°C, median 85.6°C), which could correspond to
a TTV-like and TLMV-like virus.
To test this theory, sequences were obtained from all of the primate groups and aligned
using Simmonic software. These were then compared with human TTV and TLMV
sequences and published sequences from chimpanzees as well as two sequences from long
tailed macaques (Macaca fasicularis), and sequences from an owl monkey (Aotus
trivirgatus), a cotton-topped tamarin (Sanguinis oedipus) and a tree shrew (Tupaia
belangeri chinesis) (Figure 6.2.4).
Although human TTV and TLMV have regions of conserved sequences within the
untranslated region, aligning the two viruses can be problematic because of the degree of
sequence heterogeneity. This proved an issue during the alignment of the sequences
shown in Figure 6.2.4, with sequences generated from both human and non-human
primates showing such divergence that the alignment became arbitrary. To ensure a degree
of consistency, the insertion of gaps was limited to enable alignment of the downstream
primer to one gap between position 161 and 162.
Analysis of chimpanzee sequences revealed they showed either similarity to human TTV
(PT(v)) or human TLMV (Pt(l)). Sequences comparable to human TTV exhibited a
characteristic such as a conserved 5' region and are generally between three and six
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The PT(v) sequences do, however, appear to share the ATGC motif at positions 120-123
with both human TLMV and chimpanzee TLMV-like viruses. Pt(l) sequences have high
degree of sequence conservation with human TLMV at the 5' end of the untranslated
region but tend to be 1-2 nucleotides shorter than human TLMV and 3-5 nucleotides
shorter than the prototype human TTV.
The sequences showed remarkable length polymorphisms. In this portion of the virus
genome, human TLMV tends to be three nucleotides shorter than human TTV however the
disparity in length between the primate sequences and prototype human TTV sequence
(NC 002076) is far greater. The orangutan sequence Pp-E2/2 was found to be 18
nucleotides longer than the prototype human sequence while H1-E2, a sequence obtained
from a gibbon was six nucleotides shorter. The mean length polymorphisms for all of the
species sequences are summarised in Table 6.2.2. Both the chimpanzee TLMV-like
sequences and the gibbons sequences were shorter than prototype human TTV while the
rest of the non-human primates investigated had viral genomes with an untranslated
regions that were longer than NC 002076.
Due to the length polymorphisms and heterogeneity of the primate samples, phylogenetic
analysis of the region was thought to be inappropriate, as it relied on the assumption that
homologous bases were aligned. In order to illustrate these data, a graphical representation
was achieved by comparing each primate sample with sequences representative of the
untranslated region of both TTV (n=58) and TLMV (n=50) (Figure 6.2.5). Also included
were the human sequences obtained from human serum samples in chapter three (Figure
3.1.8).
The human sequences fell into two reasonably well defined clusters; one showing 20-30%
sequence divergence from TTV but greater than 50% divergence from TLMV, the second
10-35% sequence divergence from TLMV and greater than 50% from TTV. This suggests
that TLMV is in fact more divergent than TTV.
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Pt(v) 11 +2.7 0,+6
Chimpanzee
TLMV-like
Pt(l) 8 -2.6 -5,+7
Gorilla Gg 2 +7.5 +6,+9
Orangutan Pp 4 +6.2 -2,+18
Gibbon HI 3 -4 -6,-3
Macaque Mf 2 +7 +5,+9
Drill Ml 2 +2 0,+4
Mandrill Ms 3 +6.5 0,+7
Cherry- Ct 3 +5.6 +4,+7
capped
mangabey
Table 6.2.2 - Table showing the mean difference in length polymorphisms between primate
species when compared with the prototype human TTV sequence NC_002076.
185
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Interestingly, human sequences TLMV 1/1, 1/2 and 1/3 do not group with the other two
clusters of human samples. Both amplified with a TLMV specific primer, they show
greater than 50% sequence divergence from TTV and 45% from TLMV. Sequence
analysis of TLMV 1/1 and 1/2 (Figure 3.1.8) demonstrated an unusual six nucleotide
deletion at position 162 as well as abnormally low Tm values of 83.7°C (Figure 3.1.9).
The high percentage of sequence divergence could point towards this virus being a
member of a third uncharacterised member of the Anellovirus genus.
As the alignment in Figure 6.2.4 shows, chimpanzee sequences appear to mimic the human
TTV and TLMV relationship, grouping into two separate clusters: TTV-like sequences
(n=ten) which showed 24-48% sequence divergence from TTV compared with greater than
50% divergence from TLMV, and TLMV-like chimpanzee sequences (n=eight) displaying
36-47% divergence from TLMV and greater than 50% from TTV.
Sequences from the other primate species group in the upper left quadrant of Figure 6.2.5,
being approximately 40-70% divergent from human TLMV and 50-70% divergent from
human TTV.
6.2.4 TTV-like viruses infecting farm animals
Leary and colleagues reportedly found TTV in chickens, pigs, cows and sheep using
primers which amplified a portion of the heterogeneous ORF1 [Leary et al., 1999]. The
virus from these animals was found to be "not genetically distinct from those (isolates)
found in humans". To investigate the presence of TTV like viruses in the UK farm animal
population, 20 cows, 20 sheep, 20 goats and 29 chickens were tested for the presence of
TTV-like viruses in their serum using PCR which amplified a portion of the untranslated
region as well as two methods targeting the ORF1 region. Of the 89 farm animal samples
tested, none of them showed signs of infection with any TTV-like viruses.
6.3 Discussion
The conserved UTR region of the TTV and TLMV genome has been invaluable in the
development of detection methods for these viruses. Alignment of limited TTV-like
sequences from chimpanzees and a macaque [Inami et al., 2000; Okamoto et al., 2001b]
suggested this region may also be conserved in any Anellovirus infecting non-human
primates. Sera from a variety of apes and African monkey species were subjected to
analysis by PCR using primers from this conserved region and it was found that high
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frequency of primates (63-100%) were infected with a TTV/TLMV-like virus. Such high
prevalence has been confirmed in other studies which found 83-100% of chimpanzees,
Japanese macaques, red-bellied tamarins, cotton-top tamarins and douroucoulis were
infected with TTV [Okamoto et al., 2000b]. TTV has also been isolated from tupaias,
which share characteristics with both primates and insectivores [Okamoto et al., 2001b].
Melting curve analysis of the PCR products from the primates showed a much larger range
of Tms, especially in the African monkey group, compared with the same analysis of
human TTV and TLMV. A selection of primates used in this study were subjected to
sequence analysis and aligned with published TTV/TLMV sequences from humans as well
as from chimpanzees, long tailed macaques, an owl monkey, a tamarin and a tupaia. None
of the primate sequences from this study corresponded to known human genotypes of
TTV and TLMV. Melting curve analysis of chimpanzee sequences frequently revealed
two melting peaks leading to the hypothesis that chimpanzee sera harboured two
Anelloviruses. The alignment confirmed that this was indeed the case and the UTR
derived chimpanzee sequences could be classed as either TTV-like or TLMV-like. This is
the first evidence of TLMV infection in non-human primates. Unlike the chimpanzee
sequences, sequences derived from the other primate species showed no specific
relationship with human TTV and TLMV. This implies that TTV and TLMV co-evolved
with their hosts, and if both viruses have a common ancestor, the evolutionary split must
have occurred at least seven million years ago before the speciation of humans and
chimpanzees.
In this study, only a small portion of the relatively conserved untranslated region was
sequenced however, full length sequences have also been reported. Like human TTV,
chimpanzee TTV has partially overlapping open reading frames ORF1 and ORF2
however, comparison of the full length chimpanzee sequence with five full length
sequences isolated from humans showed only 48-54% identity at the nucleotide level
[Inami et al., 2000]. Four genogroups of chimpanzee TTV have been reported so far
[Okamoto et al., 2000a], suggesting that chimpanzee viruses may be as heterogeneous as
those found in humans. Chimpanzees infected with multiple genotypes of TTV have been
described [Okamoto et al., 2000a; Romeo et al., 2000; Verschoor et al., 1999] as has a
single case of a chimpanzee simultaneously infected with chimpanzee specific and human
TTV [Okamoto et al., 2000a]. Phylogenetic analysis of examples of the four chimpanzee
genogroups together with human TTV sequences revealed that the chimpanzee sequences
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did not cluster together, but rather were found interspersed with the human genotypes
[Okamoto et al., 2000a] as seen with HIV [Gao, 1999],
Although the full length genomes of TTV isolated from humans and chimpanzees are
genetically divergent, the UTRs have a relatively high degree of sequence similarity [Inami
et al., 2000] with a conserved GC-rich region and TATA box. Even the sequences isolated
from Japanese macaque, tamarin and douroucoulis, all genetically dissimilar to the human
sequences, share UTR nucleotide similarity of 57-72% with human UTR sequences. This
high degree of conservation in such a heterogeneous virus suggests strong evolutionary
pressure.
The high proportion of DNA shared between humans and chimpanzees, which make
chimpanzees an excellent human model, also facilitates the spread of pathogens from one
species to the other. As well as species-specific TTV-like viruses described in this and
other studies [Verschoor et al., 1999], human TTV has also been isolated from non-human
primates caught in the wild [Barnett et al., 2004]. This proves that chimpanzees can be
infected with human TTV and corroborates a study outlining the successful transmission of
human TTV purified from faeces to two chimpanzees [Tawara et al., 2000]. Antibodies to
human TTV genotypes have also been isolated from chimpanzee serum without the
presence of virus, indicating that chimpanzees are capable of resolving human infections
[Okamoto et al., 2000a], Although human TTV is not thought to be pathogenic per se,
studies into the effects on chimpanzees are limited. One such study in which two
chimpanzees were infected with human TTV reported mild biochemical changes including
an increase of ALT in serum and limited hepatocellular ballooning observed during liver
tissue biopsy [Tawara et al., 2000]. The outcome of chimpanzee specific TTV infection in
humans is unknown however, as there has not been any reported instances of this [Barnett
et al., 2004; Okamoto et al., 2000a], HIV is thought to have originated from the Simian
Immunodeficiency virus (SIV) and is the most well known example of a virus which is
non-pathogenic in the host species jumping species and becoming a virulent virus with a
high mortality rate [Gao, 1999].
The hypothesis that TTV and TLMV share a common ancestor and co-evolved with the
host species is at odds with the discovery of TTV sequences similar to human TTV
genotypes in domesticated farm animals [Leary et al., 1999], Using two sets of primers
derived from ORF1 of the human genome and one set from the relatively conserved UTR,
the presence of TTV in sera from cows, sheep, goats and chickens was assessed. Even
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when the conditions outlined in the original study were recreated, none of these animals
were found to be infected with TTV. Given the divergence of the TTV isolated from the
tupaia, and the appearance of mutations within the primer binding sites in TTV isolated
from macaques and tamarins, it would seem safe to assume that any Anellovirus infecting
mammals such as the domesticated farm animals used in this study would not be amplified
using primers derived from human sequences. More recently, a TTV-like virus has been
isolated from pigs, dogs and cats using a non-nested PCR with UTR primers. These
sequences were phylogenetically closer to TTV isolated from the tupaia and lower order
primates, such as the tamarin and douroucouli than human TTV and TLMV [Okamoto et
al., 2002].
In summary, this study has confirmed the near universal infection of apes and African
monkey species with an Anelloviruses. Sequence analysis of viruses isolated from
chimpanzee sera recorded, for the first time, that the viruses tend to be either TTV-like or
TLMV-like and melting curve analysis determined infection with a heterogeneous mixture
of both virus types is not uncommon. A high degree of conservation of the UTR in
sequences from non-human primates was observed, underlining the likely functional
importance of this region of the genome. It has also been clarified that TTV capable of
being amplified by the semi-nested PCR primers used throughout this thesis or primers






Viral infections in humans most commonly result in one of three outcomes: 1) In relatively
few instances, the virus infects the host and quickly causes the death of the infected
individual. An example of this is Ebola virus, of the Filoviridae family, which has a 90%
mortality rate. Although the reservoir for this virus has not yet been identified, there have
been five outbreaks of the most pathogenic of these viruses, Ebola Zaire, in the last 10
years. 2) The most common scenario in human viral infections is the complete elimination
of the virus from the host. Rhinovirus, a genus of the Picornaviridae family, is one of the
viruses that cause the common cold and is the most common virus infection in humans.
The virus replicates primarily in the respiratory tract and the infected cells secrete
interleukins which attract neutrophils to the site of infection, leading to the elimination of
infected cells by phagocytosis. The median length of rhinovirus infection is thought to be
11 days. 3) Viruses can also become latent following primary infection, resulting in the
presence of the viral genome within the host but no overt disease. Following primary
infection, Herpes simplex virus 1 (HSV-1) pervades the nerve ending and travels to the
trigeminal ganglia where in maintains an extrachromosomal latent state for the life of the
host, occasionally becoming reactivated in response to certain trigger factors. Latency in
achieved by evasion of the immune system using a variety of mechanisms, however the
most important of these is the production of the viral protein ICP47 which binds to the
transporters associated with antigen processing and block the MHC class I restricted
antigen processing, decreasing the production of CD8+ cytotoxic T lymphocytes. HSV-1
is also thought to be able to infect natural killer cells, thus inactivating the NK cells
apoptotic activity.
The existence of viruses which can produce chronic, possibly life-long infection in humans
is rare. TTV and TLMV can facilitate active, chronic infections in humans, replicating to
produce 3.8 X 1010 virions per day [Maggi et al., 2001c]. Infection is characterised by
detectable virus both in the bloodstream and in a variety of tissues, which can be the result
of either persistent infection with the same genotype or exposure to novel genotypes
[Irving et al., 1999; Pollicino et al., 2003]. In spite of the DNA nature of the genome, TTV
and TLMV are extremely heterogeneous, with at least 39 genotypes of TTV and 12 TLMV
genotypes identified to date.
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Although the heterogeneous nature of TTV and TLMV has hampered efforts to
characterise these viruses, the discovery of relatively conserved UTR has facilitated the
work presented in this thesis. A sensitive and accurate method of differentiating TTV from
TLMV was developed using PCR primers that amplify all known genotypes of both
viruses. Although only discovered two years after TTV in 1999, relatively little is known
about TLMV. At the current time, only 17 paper have been published on this virus, thus
the data produced by this study will be invaluable in increasing the understanding of the
natural history ofTLMV.
An extremely high frequency of Anellovirus infection has been demonstrated in Scottish
blood donors, which mirrors the findings of other studies [Biagini and de Micco, 2006;
Huang et al., 2001]. The type of Anellovirus was differentiated by analysis of the Tms of
the PCR products, revealing approximately one third of samples harboured single TTV
infection, one third had TLMV DNA in their serum and one third were infected with TTV
and TLMV. The high incidence of dual TTV and TLMV infection has also been described
in French blood donors [Biagini and de Micco, 2006] suggesting that individuals can be
infected with multiple genotypes ofTTV and/or TLMV without any apparent pathology.
SENV D and H, which cluster with TTV genogroup four, are reportedly present at higher
titres in the sera of individuals with liver disease than in healthy populations [Sugiura et
al., 2004] however, as with TTV, causality has yet to be proven. Although the majority of
epidemiological studies have been carried out in Asia [Sugiura et al., 2004], an
investigation of the SENV D and H prevalence in the USA found a much lower prevalence
of both viruses. Interestingly, the frequency of SENV D and H in Scottish blood donors
was the reverse of what has been described in other countries, with a higher proportion of
SENV H than SENV D.
The role of the immune system in TTV/TLMV infection has yet to be elucidated. This
study has not only shown that the titre of Anelloviruses are higher in the serum of those
infected with HIV than patients immunosuppressed following solid organ transplant,
individuals infected with HCV or HBV and healthy blood donors, but also that the
TTV/TLMV present in the sera of these individuals is more likely to be circulating as free
virus than virus complexed with IgG. The titre of TTV and TLMV is also elevated in the
transplant recipient groups compared with the other HCV or HBV co-infected and healthy
cohorts and again is predominately found as free virus. Although TTV can result in both
acute, resolving and chronic infections, chronic infections are more frequent in patients
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with immune deficiencies or underlying conditions [Bjoro et al., 2001], In patients with
chronic infections, the presence of circulating quasispecies of TTV has been described
along with a high frequency of TTV complexed with IgG [Nishizawa et al., 1999]. It is
possible that the sequence divergence described in the hypervariable region of ORF1
resulting in generation of quasispecies facilitates the evasion of TTV from the host
immune system, which could explain the high proportion of free virus in HIV positive and
transplant recipient samples described in this thesis. It was previously proposed that TTV
may establish a commensal relationship with the host [Simmonds et al., 1999] however,
the generation of quasispecies suggest selective pressure on the virus to evade the immune
system which does not correspond with this hypothesis.
As previously mentioned, attempts have been made to correlate TTV/TLMV infection with
disease processes however, a causal role has yet to be established conclusively. Although
the ubiquity of the virus described here and in other publications supports the hypothesis
that Anelloviruses are not pathogenic, comparison with other small DNA viruses suggests
that caution must be exercised. Parvoviridae is a family of linear, non-segmented single
stranded DNA viruses which infect humans and mammalian species. Parvovirus B19, the
only Parvovirus to infect humans, was discovered in 1975 and is relatively common, with
an estimated 90% seropositivity in US citizens over 60 years of age. Infection with
Parvovirus B19 can result in a number ofmanifestations that vary in severity depending on
the immune status of the infected individual. Immunocompetent individuals can remain
asymptomatic or develop erythema infectiosum or slapped cheek syndrome, especially
common in children aged six to ten years. It was only in 1981 that the link was made
between Parvovirus B19 and severe aplastic anemia in those with underlying conditions or
immunosuppression. Human papillomaviruses (HPV) are circular, double stranded DNA
viruses which infect epithelial surfaces. Like TTV and TLMV, they are extremely
heterogeneous with over 100 genotypes identified. Individuals can be infected with
multiple genotypes of these viruses that are not always pathogenic however, certain
genotypes are associated with disease processes, namely genotypes 16 are 18, which are
known to precipitate cervical cancer. These examples suggest that high prevalence in the
general population does not necessarily preclude a pathogenic role for TTV or TLMV. It
is possible that certain genotypes of these viruses, possibly in conjunction with
immunosuppressed host, can cause disease. Although investigations into this will
continue, the nature of the detection methods employed will need to be adapted. The
development of the UTR PCR method has contributed to the epidemiological data on
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Anelloviruses however, the high prevalence in the general population has largely
invalidated any attempt to establish a causal relationship with a disease process. In this
study, investigation into elevated TTV/TLMV titres was used to compare populations but
the establishment of the genotypes infecting control groups such as non-renumerated blood
donor would provide the basis for comparisons with diseased populations.
Elevated titres of TTV/TLMV have determined in the bone marrow and spleen of patients
infected with HIV, and more significantly, those that have progressed to the diagnosis of
AIDS as defined by the Centres for Disease Control and Prevention [CDC, 1993].
Statistical analysis of the Anellovirus titre showed a significant inverse correlation with
CD4+ T cell count although sex and HCV status did not have a significant effect on the
titre of TTV/TLMV within this group. Increased TTV/TLMV titres in the sera of HIV
infected individuals have been reported previously [Shibayama et al., 2001; Touinssi et al.,
2001], as has the presence of TTV in a variety of tissue samples [Okamoto et al., 2001a;
Pollicino et al., 2003]. This is the first study to investigate the titre of TTV/TLMV in
tissues from HIV positive individuals and AIDS patients. Not only do the data provided
here corroborate other evidence of increased TTV/TLMV in people with
immunosuppression, limited analysis found paired serum had significantly lower titres of
virus than in tissue samples suggesting that both bone marrow and spleen may be sites of
virus replication. Both TTV and TLMV are thought to replicate by rolling circle
replication and double stranded replicative intermediates have already been discovered in
bone marrow [Okamoto et al., 2000d], In fact, bone marrow has been proposed as the
reservoir and primary replication site ofTTV following the finding that TTV DNA became
undetectable in the myelosuppressed period following bone marrow transplant [Chan et
al., 2001].
TTV has been found at increased prevalence in the sera of both transplant recipients
[Yokosuka et al., 2000] and in HIV positive patients [Debiaggi et al., 2000] as well as in
patients with non A-E hepatitis [Nishizawa et al., 1997], cancer [Nakagawa et al., 1999]
and diabetes mellitus [Touinssi et al., 2001]. It may be the case, however, that the
increased prevalence is the result of improved detection of the increased titres in those
whose immune system is compromised [Touinssi et al., 2001], This study has validated
that theory, conclusively proving that immunosuppression does result in increased
TTV/TLMV titres. Unfortunately, it is not possible to draw conclusions about the exact
mechanism which results in the elevated Anellovirus titres.
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TTV not only infect humans, but also a range of non-human primates. This study further
characterised non-primate infection by screening a range of ape and African monkey
species for the presence of Anelloviruses and carrying out sequence analysis to compare
them to published sequences. A high proportion of all primates species studied were
infected with a TTV-like virus, corroborating the high prevalence described by Okamoto
and colleagues [Okamoto et al., 2000b]. Alignment of the published sequences as well as
those elucidated here showed that the viruses infecting primates were species specific and
the genetic diversity of the virus from human TTV and TLMV mirrored the divergence of
the host from humans. From this, it was concluded that the viruses evolved along with the
host species. Sequence analysis also revealed chimpanzees can be infected with two
Anelloviruses which can be classed as TTV-like and TLMV-like. This suggests that TTV
and TLMV evolved from a common ancestor and the evolutionary split between TTV and
TLMV occurred before the speciation of humans and chimpanzees.
In conclusion, the body ofwork presented in this thesis has
• shown a high prevalence of TTV/TLMV in Scottish blood donors and for the first
time determined SENV D and H prevalence in the same population.
• established for the first time that the immunosuppression associated with AIDS
results in an increased TTV/TLMV titre in bone marrow and spleen.
• determined Anellovirus titre is higher in the sera of immunosuppressed HIV
positive individuals and transplant recipients than in the HCV or HBV positive sera
or in healthy individuals
• confirmed that non-human primates are infected with species-specific TTV/TLMV-
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Abstract
TT virus (TTV) and TTV-like minivirus (TLMV) are small DNA viruses with single-stranded, closed circular, antisense genomes
infecting man. Despite their extreme sequence heterogeneity (>50%), a highly conserved region in the untranslated region (UTR) allows
both viruses to be amplified by polymerase chain reaction (PCR). TTV/TLMV infection was detected in 88 of 100 human plasma samples;
amplified sequences were differentiated into TTV and TLMV by analysis of melting profiles, showing that both viruses were similarly
prevalent. PCR with UTR primers also detected frequent infection with TTV/TLMV-related viruses in a wide range of apes (chimpanzees,
gorillas, orangutans, gibbons) and African monkey species (mangabeys, drills, mandrills). These findings support the hypothesis for the
co-evolution of TTV-like viruses with their hosts over the period of primate speciation, potentially analogous to the evolution of primate
herpesviruses.
© 2003 Elsevier Science (USA). All rights reserved.
Keywords: TT virus; TTV-like minivirus; Circovirus; Untranslated region; Primate; Ape; Old World monkey
Introduction
TT virus (TTV) is a newly discovered nonenveloped
virus with a small, covalently closed circular genome of
single-stranded DNA. TTV was originally classified as a
member of the family Circoviridae; this included a number
of small DNA viruses with circular, single-stranded ge¬
nomes that infected several domesticated animal and bird
species [chicken anaemia virus (CAV), porcine circovirus
(PCV), psittacine beak and feather disease virus (BFDV)].
Alternative proposals for its classification include the des¬
ignation of TTV as the type member of new virus family,
the Circinoviridae (Mushahwaret al., 1999). More recently,
TTV along with TLMV and CAV have been proposed as
members of a new family, the Paracircoviridae (Takahashi
et al., 2000), as it is now clear that CAV shows greater
similarity to TTV and TLMV than it does to other members
* Corresponding author. Fax: +44-131-650-7965.
E-mail address: Peter.Simmonds@ed.ac.uk (P. Simmonds).
of the original circovirus family. For example, PCV and
BFDV have ambisense genomes, a different virion size and
appearance from CAV and TTV, and major differences in
genome organisation.
TTV shows considerable genetic diversity, with at least
28 genotypes with nucleotide sequences differing from each
other by least 30% (Heller et al., 2001; Okamoto et al.,
2001a; Hijikata et al., 1999). These genotypes can be further
classified into at least four genetic groups that differ from
each other by at least 50% in nucleotide sequence (Hijikata
et al., 1999). However, despite this extensive sequence
diversity, all variants of TTV share a common genome
organisation, with three predicted encoded proteins of sim¬
ilar length and likely function. The great genetic diversity of
TTV complicates the interpretation of previous investiga¬
tions of the prevalence of infection in different human
populations, risk groups, and patient cohorts. A polymerase
chain reaction (PCR) based method originally used to detect
TTV DNA sequences in plasma samples used primers from
a region in ORF1 that shows considerable sequence diver-
0042-6822/03/$ - see front matter © 2003 Elsevier Science (USA). All rights reserved,
doi: 10.1016/S0042-6822(02)00049-1
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sity between TTV genotypes (Okamoto et al., 1998; Sim-
monds et al., 1998, 1999; Itoh et al., 1999). Detected fre¬
quencies of active TTV infection based on this method were
therefore invariably underestimates, as TTV variants show¬
ing substantial sequence divergence from the prototype
strain (TA278) (Nishizawa et al., 1997; Okamoto et al.,
1998) were not efficiently amplified (measurements of lev¬
els of viraemia in plasma samples were similarly flawed).
Combining the results from several subsequent studies that
used primers from the more conserved untranslated region
(UTR), it appears that TTV infection is universal (or nearly
universal) in humans (Okamoto et al., 2001a; Simmonds et
al., 1999; Itoh et al., 1999).
Recently, another small DNA virus distantly related to
TTV was described (Takahashi et al., 2000). Its name as
TTV-like minivirus (TLMV) reflected the fact that its ge¬
nome was smaller than that of TTV (2915 bases compared
with 3852 of the prototype TTV sequence). The difference
in size results from a shorter ORF1 encoding the capsid
protein and shorter untranslated region. TTV and TLMV
show even greater sequence divergence from each other
than between genotypes of TTV; however, the precise de¬
gree of divergence is difficult to determine as neither the
UTR nor the coding sequences from the two viruses can be
easily aligned.
Infection with both TTV and TLMV has been detected in
a range of nonhuman primates (Verschoor et al., 1999; Abe
et al., 2000; Okamoto et al., 2000a,b; Romeo et al., 2000).
However, complicating the interpretation of many of the
primate studies is the occurrence of cross-species transmis¬
sion of TTV genotypes. For example, it is known that
human TTV variants can infect chimpanzees and macaques
(Luo et al., 2000; Tawara et al., 2000). Cross-species trans¬
mission may occur in captivity, or through the administra¬
tion of human plasma-derived blood products containing
infectious TTV and TLMV that frequently occur in exper¬
imental animals. Beyond primates, the host range of TTV
and TLMV is uncertain. One study describes frequent TTV
infection of domestic animals, such as cows, pigs, sheep,
and chickens. This study used a PCR-based method with
primers from the N22 region, implying the presence of
genetic variants closely related to the prototype TTV isolate,
TA278 (Leary et al., 1999). Whether TTV infection in these
species was acquired through contact with humans or vice
versa was not determined. More recently, highly divergent
TTV-like viruses were detected in pigs, cats, and dogs,
distinct from those found using the N22 primers (Okamoto
et al., 2002), suggesting that this virus family may indeed be
widely or ubiquitously distributed in the mammalian order.
In the current study, we have developed a highly sensi¬
tive PCR-based method to detect both TTV and TLMV
sequences in plasma and serum using primers from a highly
conserved region in the UTR. Detection of amplified DNA
sequences in the Roche Lightcycler provided a semiquan¬
titative estimate of the degree of TTV/TLMV viraemia in
plasma, while measurement of melting profiles of ampli-
cons allowed TTV sequences to be reliably distinguished
from TLMV. The PCR was used to determine frequencies
of TTV/TLMV infection in a wide range of wild-caught
apes and African monkeys to establish whether infection
was indigenous to these species. Finally, using large panels
of samples from cows, sheep, goats, and chickens, we de¬
termined whether TTV infection was present in domestic
animals.
Results
Sequence conservation of TTV and TLMV in the UTR
Despite the extensive sequence divergence of TTV and
TLMV in coding regions of the genome, three areas of
remarkable conservation have been identified in the part of
the UTR that contains transcriptional promoters and splice
sites (Kamahora et al., 2000; Okamoto et al., 2000c) (Fig.
1). Sequence conservation is found among all known human
isolates of TTV and TLMV, as well as those recovered to
date from a range of nonhuman primates. One region is
additionally conserved with the very distantly related bird
virus, CAV. Based on this sequence alignment, we devel¬
oped a heminested PCR using primers matching the three
conserved regions in the UTR and used them to screen a
low-risk, adult human population (blood donors; Table 1).
For comparison, each sample was also tested by previously
published PCR methods (Okamoto et al., 1998; Leary et al.,
1999) using primers from a region of ORF1 corresponding
to the originally described N22 clone of TTV (Okamoto et
al., 1998) (Table 1). A total of 88 from 100 samples were
positive using the UTR primers, but only 5 of 100 were
positive using primers from the N22 region (Table 1).
Differentiation of TTV and TLMV sequences
Because of the sequence conservation between TLMV
and TTV in the region targeted by the UTR primers, DNA
amplified by the UTR primers from the human samples may
correspond to either virus or potentially mixtures of both
TTV and TLMV genotypes. To investigate the diversity of
the detected viruses, we analysed amplified DNA in the
Roche Lightcycler. This analysis revealed that melting tem¬
perature (Tm) values, as defined by maxima in rate of change
of fluorescence with temperature [d(f\)ldT\, fell into two
separate distributions, while some samples contained appar¬
ently heterogeneous DNA sequences with maxima in both
distributions (examples of melting curves are shown in Fig.
2A). An analysis of Tm values for the 88 PCR-positive blood
donors indicated that 34 contained sequences in the high Tm
distribution (median value 90.7°C; range 89.0-92.7°C), 18
in the low distribution (median 86.3°C; range 84.5-87.8°C),
and 36 with heterogeneous sequences with both Tms (Fig. 3A).
Sequence composition differences in TTV and TLMV in
the amplified region may influence Tm values. TTV se-
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Fig. 1. Alignment of nucleotide sequences from the TTV/TLMV UTR showing the highly conserved region between genotypes 1,11, and 13 (NC_002076,
ABO 17613, and AB025946), TLMV (NC.002195, AB038629), and homologous sequences of TTV and TLMV from nonhuman primates [chimpanzee
(AB041957, AB041963), macaque (AB041958, AB041959), and the new world primates tamarins (AB041960), and owl monkey (AB041961)], and CAV
(NC_001427). Conserved regions used to specify primers indicated in boxes. Sequences numbered according to the TTV sequence NC_002195. Symbols:
•, sequence identity with prototype TTV sequence; -, gap introduced to preserve alignment of homologous nucleotide sites.
quences have a higher G+C content than TLMV sequences
(mean values of 65.4 and 58.6%, respectively), and TTV
sequences are generally 2-4 bases longer. It is therefore
possible that the upper distribution of Tm values corresponds
to TTV sequences, and the lower distribution of Tm values
corresponds to TLMV as both G+C content and amplicon
length will increase binding strength. To investigate this, we
Table 1
Detection of TTV and related viruses by PCR

















developed primers that were specific for TTV or TLMV
sequences (TTV-OS and TLMV-OS) that bind in the vari¬
able region upstream of the TATA box (Fig. 1). A total of
20 samples were amplified using TTV-OS or TLMV-OS
with CVOA in the first-round PCR, followed by a nested
PCR with CVOS and CVIA. The Tms of the amplified DNA
sequences were compared (Fig. 3B).
From the 20 samples, 7 were PCR-positive using the
TTV-specific primer, 1 with the TLMV-specific primer, and
6 with both primers (total 14). The Tm values of the ampli¬
fied DNA showed a strict dependence on the primers used;
all 13 samples amplified using the TTV-OS primers showed
high Tm values (mean 91°C), while those amplified with
TLMV-OS produced DNA with Tm values exclusively in
the low distribution (mean 86.8°C). To confirm that the
sequences amplified with the virus-specific primers differ¬
entiated between TTV and TLMV, amplified DNA from
four samples positive with TTV-OS and 4 with TLMV-OS
were cloned and sequenced (Fig. 4). In each case, nucleotide
sequences corresponding closely to either TTV or TLMV
were found in DNA amplified with homologous type prim¬
ers.
Finally, the cloned sequences were reamplified with
CVOS and CVIA, and Tms determined (Fig. 2B). For each



















Fig. 2. Melting curve profiles of TTV/TLMV sequences amplified using
the UTR primers and analysed in the Roche Lightcycler, plotted as tem¬
perature (x-axis) vs rate of change in fluorescent intensity (Fl) over
temperature [f(F\)ldT\. (A) Amplified DNA sequences from a random
selection of TTV/TLMV PCR-positive blood donors. Symbols: •, samples
showing high Tm\ O, low Tm\ ♦, evidence for mixed virus population with
high and low T„, TTV/TLMV variants. (B) Amplified DNA sequences
from molecular clones identified as TTV-like (•) or TLMV-like (O) from
sequence comparisons with standard isolates (Fig. 4). The two clones with
Tms of 83.7°C correspond to TLMV1/1 and 1/2 (see text).
being TTV (and originally derived from PCR with the
TTV-specific primer) showed high Tm values, while TLMV
clones showed Tm values corresponding to the low distribution,
as predicted. Interestingly, two sequences (TLMV1/1 and
TLMV 1/2) that have an additional deletion of five nucleo¬
tides in the amplified region (Fig. 4) showed Tm values even
lower than observed for other TLMV sequences (83.7°C;
Fig. 2B); this observation further indicates the dependence
of Tm on sequence length.
Returning to the Tm analysis presented in Fig. 3, it there¬
fore appears that either TTV or TLMV or mixtures of both
may predominate in the plasma of individual blood donors.
Analysis of TTV/TLMV variants infecting nonhuman
primates
To investigate the frequency of infection of viruses re¬
lated to TTV and TLMV in other mammals, we screened
several species of ape [Pan troglodytes troglodytes and Pan
troglodytes vellerosos (chimpanzees), Gorilla gorilla go¬
rilla (western lowland gorilla), Pongo pygmaeus pygmaeus
(Bornean orangutan) and Hylobates agilis, Hylobates lar,
Hylobates muelleri, Hylobates moloch, and Hylobates gab-
riellae (gibbons)] and African monkey species [Mandrillus
leucophaeus leucophaeus (drill), Mandrillus sphinx (man¬
drill), and Cercocebus torquatus (cherry-capped manga-
bey)] by PCR using UTR primers and those based on the
N22 gene (Table 1). To investigate the claim that nonpri-
mates may also be TTV positive (Leary et al., 1999), we
additionally tested samples from domestic animals (cows,
sheep, goats, and chickens) using a PCR protocol and prim¬
ers identical to those described in the original study (N22/2).
High frequencies of viraemia were detected in each of the
nonhuman primate species tested using the UTR primers
(63-100%), while only one chimpanzee from the 57 non-
human primates tested was positive using N22-based prim¬
ers. A total of 89 samples from domestic animals was also
tested with each of the three sets of primers. All samples
were PCR negative, even using primers and PCR conditions
exactly as described previously (Leary et al., 1999).
The distribution of Tm values ofDNA amplified from the
primate samples differed considerably from those of human
samples (Fig. 3C). Amplified sequences from each species
showed considerable heterogeneity, and in some cases, het¬
erogeneous sequences with two Tm maxima were observed
within a sample (as with TTV/TLMV coinfection in hu¬
mans). The distribution of Tm values observed in ape sam¬
ples differed from African monkey species, the former
showing a much greater range in values, which, in the case
of the chimpanzee samples, corresponded approximately to
the range in values observed between human TTV and
TLMV variants. To confirm the sequence heterogeneity of
the amplified sequences, and to investigate the sequence
relatedness of viruses infecting nonhuman primates to hu¬
man TTV and TLMV, amplified DNA from a selection of
chimpanzee, gorilla, orangutan, gibbon, drill, mandrill, and
cherry-capped mangabey samples was cloned and se¬
quenced (Fig. 5). The sequences obtained were compared
with human TTV and TLMV and previously published
sequences from the chimpanzee, two sequences from long-
tailed macaques (Maccaca fasicularis), two sequences from
New World primates [Aotus trivirgatus (owl monkey) and
Sanguinis oedipus (cotton-topped tamarin)], and a sequence
from the tree shrew (Tupaia belangeri chinensis).
Sequence comparison and phylogenetic analysis was
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Fig. 3. Distribution of Tm values (corresponding to d(P\)/tlTmaxima by melting curve analysis; Fig. 2). (A) Samples from the 88 TTV/TLMV-positive blood
donors, categorised in high (H), low (L), and mixed (M) distributions. (B) Distribution of Tm values for samples amplified with TTV-specific or
TLMV-specific primers (TTV-OS and TLMV-OS). (C) Comparison of Tm values of TTV/TLMV-related viruses directly amplified from serum samples of
apes (A) and Old World monkeys (O). Symbols: •, chimpanzee; O, orangutan; □, gibbon; 0, cherry-capped mangabey; +, mandrill; X, drill.
problematic for this region of genome because of the se¬
quence diversity between variants amplified from different
primate species, and between TTV and TLMV, which is so
extreme that attempts to align the sequences are necessarily
arbitrary and therefore somewhat subjective. For consis¬
tency, we have allowed only one gap to be inserted between
position 161 and 162 to allow alignment of the downstream
primer. This data presentation reveals clearly the length
polymorphism of this region, with one particularly long
sequence recovered from an orangutan (Pp-E2/2; 18 bases
longer than the prototype TTV sequence), and short se¬
quences from the gibbon (H1-E2) and the tree shrew (Tbc-
TTV14; 6-8 bases shorter than the prototype). Because of
the alignment problems, we believe that phylogenetic anal¬
ysis is inappropriate for the UTR sequences, as the method
assumes that homologous bases are aligned.
Combined with published sequences, variants infecting
chimpanzees fell into two groups, those resembling TTV
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nc 002076 tgcacttccg aatggctgag ttt tccacgc ccgtccgcag cggtgaagcc acggagggag atctccgcgt cccga gggcg ggtgccgaag gtgag
ab017613 ..aga.c... ga g..cg . .g
ab025946 ..ag. g. . .g agc tc.cga . .g
ttv1/1 .a. . . .a ..aga.ca.. tc.-g . .g
ttvl/2 .ta. . .a g. ..agatc..g aga tcg--a . .g
ttv1/3 .a. . . .a g. ..agatc..g agc ga..ga.... . .g
ttv3/1 .a. . . .a ..aga.c... ...ct . .g
ttv3/2 .a. . . .a ..aga.c... ...ct . .g
ttv3/3 .a. . . .a ..aga.c... ...ct a. .
ttv4/1 .a. . . .a g. ..agatc..g agc gatcga.... a. .
ttv4/2 .a. . . .a g. ..agatc..g agc gatcga a. .
ttv4/3 a. . g. ..agatc..g agc gatcga a. .
ttv5/1 .a. . . .a g. ..agatc..g agc gatcga..cg t a. .
ttv5/2 .a. . . .a g. ..agatc..g agc gatcga..cg t a. .
inc_002195 .a. . atgc... .a.a.g-g.. actg..gcag ttcact.att .ca--g..tg a. .a.
ab038627 .a. . atgc... .a.a.g-a.. acag..tca. ttcagt.act cca—g..tg a. -a.
Itlmvi/i .a. . . .a atgc... ta.a.g-g.. gac ta. .attca...c taa -.ac. a. .
tlmv1/2 .a. . atgc... ta.a.g-g.. gac ta. .attca...c taa -.ac.
tlmv1/3 .a. . . .a a.gc... ta. a. g-g. . aacgcgtcag ttact.act. cgg a. tg . . atc a. .
tlmv1/4 .a. . . .a atgct.. .a.a.g-a.. gctgc.cca. .tcagt.act gca--g..tg a. .a.
tlmv2/1 .a. . atgc... .a.a.g-g.. ac.g..tca. .acagt.act cca--g..tg aa.tt a. .
tlmv2/2 .a. . . .a a.gc... .a.a.g-g.. gc.g..tca. ttcagt.act cca--g..tg a. .a. a. .
tlmv2/3 .a. . atgc... .a.a.g-g.. ac.g..tca. .acagt.act cca--g..tg aa.tt a. .
tlmv3/1 .a. . .ga atgc... .a.a.g-g.. ac.g..gcag tttact.act cca--g..tg a. .a. a. .
tlmv3/2 .a. . . .a atgc... .a.a.g-g.. ac.g..gcag tttact.act cca--g..tg a. .a.
tlmv3/3 att. . .a a .a.a.g-g.. tc.gc.tca. .aaagt.c.. gc.--ga.tg at.tt a. .
tlmv3/4 .a. . . .a atgc... .a.a.g-g.. ac.g..tca. tacagt.act cca--g..tg aa.tt a. .
tlmv4/1 .a. . . .a atgc... .a.a.g-g.. acaac.ccaa gtta.a..ct g.t--g..tg a. .a.
tlmv4/2 .a. . atgc... .a.a.g-g.. acaac.ccaa gtca.a..ct g.t--g..tg a. .a. a. .
tlmv4/3 .a. . atgc... .a.a.g-g.. acaac.ccaa gtca.a..ct g.t—g..tg a. .a. a. .
tlmv4/4 .a. . atgc... .a.a.g-g.. acaac.ccaa gtta.a..ct g.t--g..tg a. .a.
Fig. 4. Comparison of nucleotide sequences of molecular clones obtained from DNA amplified with TTV-specific (TTV1-TTV5; clone number added as
suffix) or TLMV (TLMV1-TLMV4) with previously published sequences of TTV and TLMV (indicated by accession numbers). Sequences numbered
according to the TTV sequence NC_002195. Symbols: •, sequence identity with prototype TTV sequence; -, gap introduced to preserve alignment of
homologous nucleotide sites.















































CACTTCCGAA TGGCTGAGTT TTCCACGCCC GTCCGCAGCG GTGAAGCCAC GGAGGGAGAT CTC
AGA.C GAG. .CG
AG.G. . .G AGCTC .CG
ATGC GAGCAGTGA C.G.AACCGA ACG
.. .ATGC AG..GAG.CG C..CCCG.CG AC. ■
.. .ATGC AC .GAGGAGGCG CTGCC.CCGA .CG
.. . ATGCT AC . GA. . . GTCG CCGCC. . CCG AA.
AC .C.TC..A A..A.C . G. ■
.. .ATGCT AC .GAG..GGC. .CGCC.GCCG AA
AGATC CT-
.. .ATGC AC .GAGGAGGCG CTGCC.CCGA .CG-
ATGC AC .GAGGAGGCG CTGCC.CCGA .CG-
.. .ATGC AC .GAGGAGGCG CTGCC.CCGA .CG-
.. .ATGC AC .GAGGAGGCG CTGCC.CCGA .CG-
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• ATGC...TA . A.G.AGAGA AGAGCA.A.G . TGATCTTCG . .G GA. T. .
.ATGC. . .TA .A.G.AGA. . A.ACCA.AG. A.T.AT.TCG GCT GGA. C. .
.ATGC A .A.G.AGA.. CGAC. . GTTA CTGACAGCOG . .G AG. CT.
.ATGC A .A.GTGGCA. AGACGAA.G. C.C.CAGC.A GAG AGACT TCA. .TGAG. CT.
.ATGC. . .TA .A.G.AGAGA AGATT.G. .A C.C.AATCT. .0.— --TGGA. T. .
.ATGC. . .TA .A.G.AGAGA AGAT. .T.G. A. .CTA.CT. .G. TGT. . CT.
.A.GC...TA .A.G.AGAG. AGAGCAGTTA CTGATCTCCG . .G .T. . A..
.ATGC A .A.G.AGA.T .CAC.CGACA .TGACTGC.A GCT GA. . A..
.A.TC A .A.G.TGCA. .CATC.A.T. .TGA.CTAGC AAG GAGAAGC CTAA.AGAG. CT.
.A.TC A .A.G.TGCA. .CATC.A.TG CT.CT.CA.G GAG AAGC CTAA.AGAG. CT.
G..T.A .A.G.T..A. CGA.C.GAGG T.C. . ACTGC TCT ACGAG. C. .
.ATGC G .A.GAGGAG. CG..C.GAGG CCG.A.C..C TAGCGACCA GCAACCGACC CC G..T CT.
...GC A .A.G.TGCG. AGA.C.AAGA .CGCCAGCGA GGA GATC CC AG.A TT.
...GC A .A.G.TGCG. AGA.C.AAGA .CGCCAG.GA GAT C CC AG.A TT.
.ATTCT.T.A .A.G.T..A. AGAT.CTAGT ATC.CTCTGA .GA GA A..
.ATGC A .A.G.T..A. CGACC.GACT .TG.ACGC.C TGA CGAG. ...





. ATACT.T. . .G GT CG.TG.AGGA .CGACAGT.A .GA-
..T.C.C.GA .A.GCAG... AG..C.AAC. .CGCA.CCTG G.G—
.-T A .A.G.AGC.. CG..GCG.TA CTGCTA..G. AGG-
.A.GC..AGA CCGGAGGA.. .GACG.ATCT .TGA.AC.GA .CG-
C..T.. .G..T.C.GT CC.GC.AG.G CTGACCCAGC GA.-
.A.TCT G..T.G.TC .G..GAGAG. .CCC.CC.CG AA. -
.A.GC..AGA CCGGAGGA.. .GACG.ATCT .TGA.AC.GA .CG—
.A.TCT. . .T ..G..T.G.TC .G.G. .AG.G C.CCC.CCGC GAA—
G..T.G.TC CG.TTCAG.G C.CCA.CCTG AAG—
.A..C...TG .A.GCAGAG. AG.TCTGACA .CGACAGCGA GGA—
.A..GT...G .GGA TCTGCCGAG C. . .GC GCG-
.A.TC G .GTGTAG.A. AC.CGA..GG A.G.A...GC A..-
ATGC A .CGGT...A. CCATCAGAC. ACGCTCT..C GAG-
CCC CAGA.CAG. . CT.
— AGTGACC TCG..CG... .T.
CG AA.T. .G. . . -T.
—AA.TG. . . CT.
CGACC GAGA.CAG. . CT.
GACC GCGA.CAG. . CT.












Fig. 5. Comparison of TTV and TLMV UTR sequences with related viruses recovered from primates. TTV sequences: NC_002076 (genotype 1), AB017613
(11), and AB025946 (13); TLMV sequences: NC002195 and AB038627. Origin of nonhuman primate sequences indicated by initials (common name in
parentheses): Pt: Pan troglodytes troglodytes and Pan troglodytes vellerosos (chimpanzee); Gg: Gorilla gorilla gorilla (western lowland gorilla); Pg: Pongo
pygmaeus pygmaeus (Bornean orangutan); HI: Hylobates lar, Hylobates agilis, Hylobates muelleri, Hylobates moloch, and Hylobates gabriellae (gibbons);
Mf: Maccaca fasicularis (long-tailed macaque); Ms: Mandrillus sphinx (mandrill); Ml: Mandrillus leucophaeus leucophaeus (drill); Ct: Cercocebus torquatus
(cherry-capped mangabey); At: Aotus trivirgatus (owl monkey); So: Sanguinis oedipus (tamarin); and Tbc: Tupaia belangeri chinensis (tree shrew). New
sequences from chimpanzee, gorilla, orangutan, gibbon, drill, mandrill, and cherry-capped mangabey indicated by E prefix; suffixes indicated clone number
if more than one sequence obtained from same sample. Sequences were ordered by their genetic relatedness of host species to humans and numbered
according to the TTV sequence NC_002195. Symbols: •, sequence identity with prototype TTV sequence; —, gap introduced to preserve alignment of
homologous nucleotide sites.
and those resembling TLMV. Characteristic features that
differentiated the sequences included the degree of se¬
quence similarity at the 5' end of the amplified sequence
and overall sequence length; sequences similar to human
TLMV also showed 3-6 base deletion compared with the
prototype TTV isolate sequence. In contrast, TTV-like se¬
quences from chimpanzees were usually longer than TTV.
To demonstrate these sequence relationships graphically,
we compared each primate sequence with representative
sets of TTV UTR sequences (n = 58, with similar repre¬
sentation of each of the four main genetic groups) and
TLMV UTR sequences (n = 50, corresponding to the com¬
plete set of nonidentical sequences available on GenBank).
Based on the minimal alignment used in Fig. 5, sequences
obtained from human subjects (O) fell into two main clus¬
ters, one showing 20-30% sequence divergence from TTV
but >50% divergence from TLMV sequences, and another
more diverse group of TLMV sequences showing 10-35%
sequence divergence from TLMV and >50% from TTV
(Fig. 6). Interestingly, three sequences of human origin
amplified with the TLMV-specific primer showed >50%
divergence from all TTV sequence and >45% from TLMV;
two of these contained an unusual deletion at position 162
(Fig. 4) and very low Tm values (83.7°C; Fig. 2B), and
perhaps correspond to a third (i.e., non-TTV, non-TLMV)
genetic group of viruses.
Variants from chimpanzees (•) also fell into two, less
well-defined clusters, one corresponding to the TTV-related
sequences (n = 10; 24-48%, compared with >50% to
TLMV), and the other most similar to TLMV (n = 8,
36-47%, compared to >55% to TTV). In contrast, se¬
quences from other apes, the Old or New World monkey
species, and the tree shrew showed no evidence for group¬
ing with human-derived TTV or TLMV sequences, being
approximately equally divergent from both (Fig. 6). Even
between the limited numbers of sequences obtained from
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Fig. 6. Sequence divergence of human (this study; Fig. 4) and primate (this
study and previously published; Fig. 5) TTV-related UTR sequences from
representative sequences ofTTV (n = 58) and TLMV (n = 50) (the full list
of reference sequences used is available from the authors on request).
Distances from TTV (jt-axis) and TLMV (y-axis) sequences shown as
uncorrected percentage divergence. Sequence comparisons used the mini¬
mal alignment shown in Fig. 5. Symbols were used to indicate different
species of origin of UTR sequences; O, human; •, chimpanzee; A, other
apes; ♦, Old World monkey species; *, New World primates and tree
shrew.
some species, the genetic diversity within each of the pri¬
mate species matches the diversity of TTV and TLMV
variants found in human samples.
Discussion
Amplification of TTV and TLMV UTR sequences
Despite the great sequence diversity of human TTV and
TLMV genotypes, and homologues in nonhuman primates,
it is fortunate that conserved regions exist in the UTR to
allow a common set of heminested primers to detect a wide
range of TTV/TLMV genetic variants. The conserved re¬
gions are close to regions involved in transcription, such as
the TATA box, and their lack of sequence divergence pre¬
sumably reflects functional constraints, imposed by their
interaction with host replicative machinery (Hijikata et al.,
1999). The sequence conservation in this region allowed the
development of a heminested PCR capable of amplifying
TTV and TLMV viruses in human samples; this method
uses primers that match the known variants of TTV and
TLMV equally well and is therefore predicted to be equally
effective at amplifying each virus from a heterogeneous
mixture in a sample. It was therefore possible to carry out a
meaningful comparison of their relative frequencies and
abundance in human samples.
Among the 88 PCR-positive samples using the UTR
primers, approximately one-third contained exclusively
TTV sequences, one-third contained TLMV, and one-third
contained mixed infection of TTV and TLMV based upon
the Tms of the amplified DNA measured on the Roche
Lightcycler. These results do not rule out the absence of
infection with both viruses in any of the samples, as ampli¬
fied sequences with a low relative abundance may not be
detectable by the melting curve analysis. To determine the
frequency of infection with each, virus-specific primers
would be required. However, our findings indicate that
TLMV infection is equally prevalent to TTV in humans and
that both viruses can coexist and replicate to similar titres in
a substantial proportion of individuals. These findings are
consistent with previous observations of the presence of
multiple TTV genotypes in human plasma and tissues (Ball
et al., 1999; Okamoto et al., 1999; Forns et al., 1999; Niel
et al., 2000). The finding that plasma itself is not represen¬
tative of the range of greater genetic variants that may be
sequestered in tissues such as bone marrow, lymphoid tis¬
sue, and liver (Okamoto et al., 2001a) suggests that infec¬
tion with both TTV and TLMV may be extremely widely
distributed or possibly universal in the human population.
Detection of 1TV/TLMV homologues in nonhuman
primates
The sequence conservation of the UTR primers allowed
an investigation of the distribution of TTV/TLMV-related
viruses in a wider range of nonhuman primates than previ¬
ously attempted. The primer sequences matched previously
published sequences from chimpanzees and the macaque
(an Old World monkey) (Fig. 1) (Inami et al., 2000; Oka¬
moto et al., 2000b). There was also reasonable sequence
conservation with TTV/TLMV sequences recovered from
New World primates and the tree shrew (Okamoto et al.,
2001b), although the sequence differences with the inner
antisense primer would undoubtedly compromise the effi¬
ciency of the UTR PCR for these more divergent viruses.
Despite the sequence diversity of primate viruses and the
potential problem this poses for PCR-based screening, close
to universal infection was found in each ape and Old World
monkey species screened (Table 1). Comparisons of ampli¬
fied sequences from the UTR of each species confirmed it
was improbable the viruses were human in origin; none
corresponded to known human genotypes of TTV or TLMV
(Fig. 5 and data not shown). Furthermore, amplified DNA
from each of the primate species (particularly the African
species) showed a distribution of Tms quite distinct from the
narrow ranges found among the TTV and TLMV sequences
amplified from human subjects (Fig. 3C).
The great sequence diversity of the UTR sequences pre¬
vented any defensible strategy for the alignment of homol¬
ogous bases. On this basis, it was felt unjustified to attempt
to carry out formal phylogenetic analysis. However, inspec¬
tion of the minimal alignment (Fig. 5) and sequence diver-
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gence from representative data sets of human-derived TTV
and TLMV sequences (Fig. 6) indicated that the division of
the chimpanzee UTR sequences into TTV and TLMV
groups was potentially justifiable, principally on the basis of
the sequence at the 5' end of the amplicon (positions 115-
122), although the "ATGC" motif found in human TLMV
sequences at position 120 is also present in the TTV-like
chimpanzee sequences. The assignment of chimpanzee se¬
quences into TTV- and TLMV-related groups is also sup¬
ported by their complete genome sequences; apart from
their greater sequence similarities, Pt-TTV6 has a genome
length of 3690 bases, comparable to that of the prototype
human TTV sequence, NC_002076 (3853 bases), while
Pt-TTV8/II is only 2785 bases, comparable to the TLMV
variant NC_002195 (2860 bases) (Okamoto et al., 1998,
2000b). This finding suggests that the evolutionary split
between TTV and TLMV therefore must have occurred
before the speciation of humans and chimpanzees (7 Myr) if
TTV/TLMV-related viruses coevolved with their hosts (see
below).
In contrast to the chimpanzee-derived UTR sequences,
sequences from the other apes and African monkey spe¬
cies analysed in this study showed no specific relation¬
ship to TTV or TLMV (Fig. 5), being equally dissimilar
to human-derived TTV and TLMV sequences (Fig. 6).
Supporting this conclusion, the complete genome se¬
quences from macaques (Mf-TTV3 and -TTV9, also dis¬
similar to TTV or TLMV in the UTR; Fig. 5) are 3798
and 3763 bases in length, but show no close sequence
relationship to either human or chimpanzee TTV se¬
quences (Okamoto et al., 2000b).
Despite the difficulties associated with the comparison of
highly divergent sequences in the UTR, and elsewhere in
the genome (Okamoto et al., 2000b), none of the data
obtained in the current study is inconsistent with the hy¬
pothesis of coevolution of TTWTLMV-related viruses with
primates over several tens of millions of years. Evidence for
cospeciation includes the increasing divergence of Old and
New World primate variants to human TTWTLMV (Figs. 5
and 6) (Okamoto et al., 2000b), and the outlier phylogenetic
position of the TTV/TLMV-related virus recovered from
tree shrews (Okamoto et al., 2001b), reflecting the depth of
the split of the host species from other species in this
primate order. In many respects, this scheme corresponds
closely to the proposed coevolution of herpesviruses in
primates and other mammals (McGeoch et al., 2000). While
the three groups of herpesviruses (a, /3, and y) are repre¬
sented in each mammalian order investigated and presum¬
ably diverged before or during their original differentiation
90 million years ago, some -/-herpesviruses show evidence
for more recent evolutionary splits and cocarriage during
the period of primate evolution, analogous to the TTV/
TLMV split suggested by the comparison of sequences from
some ape species.
Detection of TTV/TLMV-related viruses in other mammals
The previous finding (Leary et al., 1999) of TTV infec¬
tion in several domestic animals (pigs, cows, sheep, and
chickens) is clearly inconsistent with the hypothesis of
TTV/TLMV coevolution in primates, particularly as the
isolates from farm animals were not apparently genetically
distinct from those found in humans (Leary et al., 1999). To
resolve this discrepancy, we attempted to reproduce the
findings of the study using a nationally collected set of
serum samples from cows, sheep, goats, and chickens.
While this was by no means a comprehensive selection of
farm animals, the high frequencies of TTV detection re¬
ported previously in a probably similarly geographically
restricted sample collection suggested that the materials
available for this study would suffice to reinvestigate the
issue.
To detect TTV infection, we used PCR methods involv¬
ing UTR primers (this study), N22 primers used extensively
in previous surveys of human and primate TTV prevalences
(Okamoto et al., 1998), and a PCR method that precisely
reproduced the experimental conditions of the original study
(Leary et al„ 1999). All 89 samples tested were negative
with each of set of primers and PCR conditions (Table 1).
While we cannot rule out that domestic animals may vary in
TTV prevalence between countries, another interpretation is
that the previously reported findings are incorrect. Return¬
ing to the coevolution hypothesis, the increasing sequence
divergence of TTV/TLMV-related viruses from human
variants observed in primate screening, including the ap¬
pearance of sequence differences in the primer sites (Fig. 1),
suggests that TTV/TLMV-related viruses split from primate
variants even earlier in mammalian evolution (90 Myr) and
may therefore be refractory to amplification with even with
heminested UTR primers. Very recently, evidence for the
existence of the predicted highly divergent viruses in non-
primates has indeed been obtained using nonnested primers
for the UTR corresponding approximately in position to
CVOS and CVOA (Okamoto et al., 2002). Complete ge¬
nome sequences from cat-, dog-, and pig-derived TTV-
related viruses were obtained by reverse PCR from the
amplified UTR region and found to be even more divergent
from the prototype human TTV than those from any of the
primates or the tree shrew. None of the nonprimate viruses
showed any significant sequence similarity to the N22 prim¬
ers.
In summary, the use of direct nucleotide sequencing
combined with melting curve analysis of amplified DNA
sequences documents the extreme sequence diversity of
TTV, TLMV, and related viruses in humans and nonhuman
primates. With the limitations on primer design that results
from this genetic variability, we have also shown that in¬
fection with this virus family is likely to be ubiquitous or
near ubiquitous in primates at least down to the Old World
monkey/ape split. In terms of their ubiquity and persistence,
TTV and TLMV are comparable to the distributions of
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herpesviruses, but differ uniquely in their high-replicative
capacity that leads to life-long persistent viraemia in most
individuals. Their genetic diversity greatly exceeds that of
any other known virus, even that of the papillomaviruses
infecting the skin. Investigating the mechanisms by which
TTV, TLMV, and related viruses can establish multiple,
largely, or entirely nonpathogenic persistent infections in
primates is clearly a fertile area for fundamental virology
and immunology research in the future.
Materials and methods
Samples
A total of 100 human plasma samples from Scottish
blood donors were available for investigation of TTV/
TLMV prevalence in a human population. All samples were
negative for antibodies to human immunodeficiency virus
type 1 and 2 and hepatitis C virus, and negative for hepatitis
B virus surface antigen. Sera from 13 drills, 2 mandrills, 4
cherry-capped mangabeys, 5 chimpanzees, 14 orangutans,
19 gibbons, and 1 gorilla were available for investigation of
TTV/TLMV infection in nonhuman primates. Sanctuaries
in Nigeria, Cameroon, and Taiwan supplied these samples,
with the exception of the gorilla sample supplied by Edin¬
burgh Zoo, and all the primates used had originally been
wild-caught. Each primate species was housed separately
from other primates. Finally, we tested sera from 20 cows,
20 sheep, 20 goats, and 29 chickens collected from a variety
of locations in England and Scotland.
Extraction of nucleic acid
Nucleic acid from 2 ml human plasma was extracted
using a guanidinium thiocyanate/silica-based method (Nu-
clisens, Organon-Teknika, Boxtel, Netherlands) and eluted
in 50 ju.1 Tris-HCl buffer. Nucleic acid from all other sam¬
ples was extracted from 100 jul serum using a standard
phenol-chloroform protocol and precipitated with ethanol.
The resulting pellet was resuspended in 25 /xl nuclease-free
water.
Amplification of TTV and TLMV
Three sets of primers were utilised during this study to
allow a comparison of primer sensitivity and of virus prev¬
alence in different host species. Heminested primers
NG059, NG061, and NG063 (primer set N22), derived from
the original N22 clone, have been used extensively in pre¬
vious investigations of TTV epidemiology (Okamoto et al.,
1998). Fully nested primers (primer set N22/2), originally
published in conjunction with a study of TTV viraemia in
farm animals, were also investigated (Leary et al., 1999).
Conditions for PCR using these primers were as previously
described (Okamoto et al., 1998; Leary et al., 1999). The
third primer set (primer set UTR) is heminested and spans a
conserved region of the UTR. Ambiguities were included in
the primer design to allow TLMV to be coamplified. In the
first round of the PCR 5 /xl of extracted DNA was amplified
using primers CVOA and CVOS (sequences 5'-AGC-
CCGAATTGCCCCTWGACT-3' and 5'-TRCACWKMC-
GAATGGCTGAGTTT-3 ')• Two microliters of this reac¬
tion was carried over to a second round and amplified using
primers CVOS and CVIA (sequence 5'-CTCACCTYCG-
GCWCCCGCCC-3'), resulting in a 95-bp amplicon. Am¬
plification conditions were 94°C/18 s, 55°C/21 s, and
72°C/90 s for 30 cycles, with an additional 6 min extension
at 72°C to finish. PCR products were visualised on a 2%
agarose gel stained with ethidium bromide.
Differentiation of TTV and TLMV using real-time PCR
The first-round PCR using UTR primers was carried out
as above, and 2 /xl of the reaction product was used in a
second round which was performed on a Lightcycler (Roche
Diagnostics GmbH) using primers CVOS and CVIA and
Lightcycler-DNA Master SYBR Green I (Roche Diagnos¬
tics GmbH). Amplification of the template (initial denatur-
ation 95°C/30 s, then 30 cycles of 95°C/0 s, 55°C/5 s, and
72°C/10 s) was followed by melting curve analysis, during
which the samples are heated from 60 to 95°C to allow the
determination of the melting temperature (Tm) of the am¬
plified DNA sequences. The analysis of this melting curve
produced a peak with a virus-specific Tm, which we used to
differentiate and characterise the products.
Molecular cloning and sequencing of TTV and TLMV
DNA
Human samples positive with the UTR primers were
subjected to a second nested PCR in which primer CVOS in
the first round was replaced with a TTV- or TLMV-specific
primer [TLMV specific primer 5'-GGAGGAGHHWMHM-
HACTATATAA-3' (TLMV-OS) and TTV specific primer
5' -AACMKGGTCTACRTCCTSATATAA-3' (TTV-OS)].
The second round of the PCR and conditions are as de¬
scribed for UTR primers, and products were run on the
Lightcycler to ensure the correct virus had been amplified.
Primate samples were amplified with the UTR primers prior
to cloning. PCR products were ligated into pGEM-T Easy
Vector (Promega Corp., Madison, WI) and cloned accord¬
ing to manufacturer's instructions. Nucleic acid was puri¬
fied using QIAprep Spin Miniprep kit (Qiagen).
Nucleotide sequencing and sequence analysis
Miniprepped DNA was sequenced from both ends by
manual cycle sequencing using a thermostable DNA poly¬
merase (Promega) and primers specific to the M13 portion
of the vector. Sequences were analysed using Simmonic
2000 sequence analysis package. Sequences obtained in this
K. Thorn el al. / Virology 306 (2003) 324-333 333
study have been submitted to GenBank and have been the
assigned the Accession Nos. AY 187821-AY187866.
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Abstract
Torque Teno virus (TTV) and Torque Teno minivirus (TTMV) are highly
prevalent in the general population and although no disease has been associated
with these viruses yet, co-infections with other pathological viruses are frequent.
Both viruses are extremely heterogeneous, especially for DNA viruses, and the
role of the immune system in controlling the infections has yet to be established.
In this study the TTV /TTMV viral loads in HIV positive tissues have been
investigated for the first time. The titres of both TTV and TTMV were compared
in the bone marrow and spleen tissues from 3 groups: HIV negative individuals,
HIV positive individuals and HIV positive individuals who had progressed to
AIDS, leading to immunosuppression. Limiting dilution PCR using primers
situated in the UTR region of the genome were used to semi-quantitate the virus,
and TTV and TTMV were differentiated using melting curve analysis of the PCR
product. The AIDS group had significantly higher titres compared with both the
HIV positive and negative groups for both bone marrow (AIDS vs. HIV positive
p=0.006, AIDS vs. HIV negative p<0.001) and spleen (AIDS vs. HIV positive
p=0.022, AIDS vs. HIV negative pcO.OOl). Analysis of TTV /TTMV titre with
CD4 T lymphocyte count showed a significant inverse correlation however
neither HCV co-infection or type of Anellovirus infection (single TTV or TTMV,
or mixed TTV /TTMV) showed any significant correlation with virus titre. The
results show a link between deterioration of the immune system and increased
viral loads in studied tissues.
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Introduction
TTV was originally isolated from the serum of an individual (T.T.) with
post-transfusion non-A-E hepatitis [Nishizawa et al., 1997] in 1997. Further
analysis revealed it to be a small, circular, unenveloped, single stranded DNA
virus of 3.8kb, the first virus of this type known to infect humans. TTMV was
discovered in 1999 when primers designed to amplify TTV were found to be
partially homologous to a region of TTMV [Takahashi et al., 2000]. Although
they share similar genomic organisation, the TTMV genome is approximately
lkb smaller than that of TTV. Recently the decision was made to name TTV as
the type virus of a newly created genus Anellovirus which will also contains
TTMV and the newly described Small Anellovirus (SAV) [Jones, 2005].
Over 90% of adults are infected with TTV and/or TTMV and it is not
uncommon for individuals to be infected with multiple genotypes of one or both
of these viruses [Okamoto et al., 2001; Saback et al., 2002; Thorn et al., 2003]. The
route of transmission that results in such a high prevalence in the general
population is unclear, however TTV DNA has been identified in peripheral
blood, fecaes, saliva and semen, indicating the possibility of parenteral, fecal oral
and sexual transmission [Matsubara et al., 2000; Nishizawa et al., 1997]. TTV has
been detected in a number of different tissues and cell types including liver,
thyroid gland, lymph node, spleen and pancreas [Okamoto et al., 2001], and has
also been shown to be present in high titres in bone marrow cells. The method or
site of replication is not fully understood at this point in time, however there is a
body of evidence to suggest that TTV might replicate in bone marrow. Double
stranded replicative intermediate forms of TTV DNA and 3 mRNA species have
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been isolated from the bone marrow of TTV positive individuals [Okamoto et al.,
2000a; Okamoto et al., 2000b] and TTV levels in the serum of TTV positive
patients became undetectable during the period of myelosuppression following
bone marrow transplant [Kanda et al., 1999] suggesting a role for hematopoietic
cells in maintaining the viraemic status of TTV positive individuals.
No pathological role for TTV/TTMV infection has been established,
however the high prevalence of virus in the general population leads to frequent
co-infections with other viruses. The immune dysfunction associated with
human immunodeficiency virus (HIV) can result in opportunistic infections and
the reactivation of latent viruses, so the natural history of TTV/TTMV in HIV
positive individuals is of particular interest.
The role of TTV/TTMV in HIV infection and the progression towards
AIDS is still uncertain with many studies describing conflicting results on the
significance of co-infection. A Danish HIV cohort had significantly higher
prevalence and titre of TTV compared with blood donors (76% vs 7%)
[Christensen et al., 2000] however the number of blood donors testing positive
for TTV appears to be particularly low. This is probably due to the use of PCR
primers sited in ORF2 of the TTV genome which would restrict the genotypes of
virus amplified. Further analysis of HIV positive cohorts showed a significant
inverse correlation between TTV titre and CD4 T+ cells [Christensen et al., 2000;
Shibayama et al., 2001] and high serum TTV concentration was also cited as an
independent factor associated with decreased patient survival [Christensen et al.,
2000]. These studies appear to indicate a role for the immune system in the
control of TTV/TTMV replication, however a study following changes in TTV
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and TTMV viral load in individual cases failed to find a significant increase in
titre following progression to AIDS or in conjunction with changes in CD4 and
CD8 T lymphocytes counts [Moen et al., 2002J.
The high number of co-infections of HIV and hepatitis C virus (HCV) and
the high prevalence of TTV in HIV positive populations invariably also result in
HIV, HCV and TTV co-infections. Although it is now thought to be unlikely that
TTV is the cause of non A-E hepatitis, there is evidence that infection with TTV
combined with dual HIV and HCV infection increases the alanine amino
transferase (ALT) levels in patients indicating more severe hepatitis than in
patients infected only with HIV and HCV [Shieh et al., 2003]. It has even been
suggested that patients infected with TTV and HIV have lower ALT levels than
those infected with HIV alone [Sherman et al., 2001].
In this study, the titres of TTV and TTMV in bone marrow and spleen
taken from HIV positive and negative individuals and have been investigated
and, in the case of the HIV positive cases, an attempt has been made to correlate
the titre of Anellovirus with the CD4 count. This is thought to be the first




Tissue samples of bone marrow and spleen were obtained at autopsy and
held in the Brain and Tissue bank of Edinburgh and the MRC Tissue Bank for the
Investigation of Sudden Death (Western General Hospital, Edinburgh, UK).
Nineteen tissue samples were from a cohort of HIV infected individuals and of
those in 13 (12 male, 1 female, median age 32 years) the cause of death was AIDS
related while the cause of death in the remaining 6 (3 male, 3 female, median age
29 years) was unrelated to their HIV status. A further 7 (4 male, 3 female,
median age 70 years) HIV negative tissues were also used in this study. Patient
information is summarised in Table I. Where available, CD4 T cell counts were
obtained from medical records. All of the samples were stored at -40°C prior to
DNA extraction. The use of tissue samples was approved for research by the
Lothian Ethics of Research committee.
DNA extraction and TTV amplification
Nucleic acids were extracted from a 25-50mg section of frozen bone marrow
and spleen tissue using a High Pure PCR Template Preparation Kit (Roche
Applied Sciences, Mannheim, Germany), according to the manufacturers
instructions for isolation of nucleic acids from mammalian tissue. NA was eluted
into 200pi of elution buffer. Total DNA concentration was estimated by
spectrophotometry at 260nm.
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The oligonucleotide primers used were situated in the partially conserved
untranslated region of the genome ambiguities were included in the primer
sequences to allow both TTV and TTMV to be amplified simultaneously. In the
primary PCR reaction, a volume of DNA equivalent to O.ljxl was added to a total
volume of 50//1 containing 5/il 10X PCR buffer, 30iuM of dATP, dTTP, dCTP and
dGTP, 1 unit Taq DNA polymerase (Promega UK, Southampton, UK) and
0.25/iM of primers CVOS and CVOA [Thorn et al., 2003]. A secondary reaction
was carried out by transferring 2|ul of the primary reaction to a final reaction
volume of 20jul in which the primers CVOS and CVIA were used. Both the
primary and secondary PCRs were amplified using 30 cycles of 94°C for 18
seconds, 55°C for 21 seconds and 72°C for 90 seconds. PCR products were
visualised using gel electrophoresis on a 2% agarose gel stained with ethidium
bromide. Semi-quantitation of TTV/TTMV was carried out by amplification of
serial 10-fold dilutions of DNA where the last PCR positive dilution was used to
estimate the litre of virus in the tissue. Titres were expressed in terms of number
of copies per million cells, estimated using the assumption that a human diploid
cell contains 6.6pg of DNA.
HCV amplification
Hepatitis C amplification was carried out using nested primers Z4130 and
Z4133 in the primary PCR and Z4132 and Z4132 in the secondary PCR as
described by Cleland and colleagues [Cleland, 1999].
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Real Time PCR
To differentiate between TTV and TTMV, 2(xl of primary PCR product was
subjected to PCR amplification and melting curve analysis on a Roche lightcycler
as previously described [Thorn et al., 2003].
Statistical analysis
Statistical analysis was carried out using SPSS (version 11 for Macintosh,
London, UK). Comparison of unpaired observations was analysed using the
Mann-Whitney U test. The Wilcoxon signed tanks test was used to compare
paired data and the Spearmans rank order correlation to test for associations




Titre of TTV/TTMV in bone marrow and spleen tissues.
Samples from three groups of individuals were investigated in this study:
HIV positive individuals who died of AIDS defining diseases [CDC, 1993], pre-
AIDS individuals whose cause of death was unrelated to their HIV status, and
HIV negative individuals. Bone marrow and spleen tissue was obtained during
autopsy from a total of 13 AIDS, 6 pre-AIDS (HIV positive) and 7 HIV negative
patients (Table I). All of the tissues were positive for TTV/TTMV when
amplified using the UTR primers therefore limiting dilution PCR was used to
semi-quantitate the titre of virus in each of the tissues. The results of this are
summarised in Table II and Table III. Four of 13 (30.7%) pairs of samples from
the AIDS cohort, 2/6 (33.3%) from the pre-AIDS groups and none of the HIV
negative individuals were positive for HCV.
The median virus titre was similar for bone marrow and spleen in each of the
three groups: AIDS group had a median titre of 7xl07 copies per million cells in
both bone marrow and spleen (range; bone marrow: 7xl06 to 7xl08 copies, spleen:
7xl04 to 7xl08 copies), the median titre was 3.6xl05 for HIV positive bone marrow
(range 7x102 to 7xl07) and 7xl04 for HIV positive spleen (range 7x102 to 7xl08).
The lowest titres were seen in the HIV negative group (bone marrow: median
7xl04, range 7X101 to 7xl04, spleen: median 7xl03, range 7xl02 to 7xl04). Titre was
also similar between the two tissues from the same individual, with 71-100% of
all samples having titres of virus in spleen within two logs of the bone marrow
titre (Figure I). Differences between the titre of TTV/TTMV in bone marrow and
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spleen for individuals within the 3 groups were not found to be significant (AIDS
p = 0.24, HIV positive p = 0.68, HIV negative p = 0.59).
Analysis to compare the titre of TTV/TTMV in bone marrow between the
three groups showed significantly higher titre of virus in the AIDS cohort
compared with both the HIV positive group (p = 0.006) and the HIV negative
group (p < 0.001). Significantly higher titres were also seen in the AIDS cohort
when the TTV/TTMV was quantified in spleen (AIDS vs HIV positive: p = 0.022,
AIDS vs HIV negative: p < 0.001). This supports the role of the immune system
in regulating TTV/TTMV titre although the exact mechanism of this remains
unclear. To further investigate this, CD4+ T cell counts were obtained for 9 of the
13 members of the AIDS cohorts and for 5/6 HIV positive individuals. There
was a significant inverse correlation between CD4+ T cell count and TTV/TTMV
titres in both bone marrow (p = 0.007) and spleen (p = 0.008) indicating that
either the depletion of this cell subset or the changes in the immune system
associated with the progression towards AIDS may facilitate either the increased
replication of these viruses or a reduced rate of viral clearance.
Differentiation of TTV and TTMV from bone marrow and
spleen using real time PCR
The UTR primers utilised in the study are able to simultaneously amplify
TTV and TTMV enabling an insight into the prevalence of Anelloviruses in
general within bone marrow and spleen. Given the significantly increased viral
load found in autopsy tissues isolated from HIV positive individuals who had
progressed to AIDS, it was important to differentiated between the two viruses
to assess if the increased viral load was predominately due to TTV or TTMV. A
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previously reported a method of employing melting curve analysis was utilized
to distinguish between TTV and TTMV [Thorn et al., 2003] in the bone marrow
and spleen tissue samples (Figure II and Figure III). Interestingly, the highest
percentage of mixed TTV and TTMV infections occurred in HIV negative bone
marrow and spleen. Mixed infection was not significantly associated with
TTV/TTMV titre, CD4+ T cell count, age, or sex (p > 0.05).
Of the 26 pairs of bone marrow and spleen samples investigated, 19 (73.1%)
had the same type of infection in both tissues (i.e. single TTV infection, single
TTMV infection or mixed TTV and TTMV infection). Four of the seven pairs
which had different infections in the 2 tissues formed part of the AIDS cohort
and 3 were from HIV negative individuals. All showed mixed infection in one of
the tissues and single TTV or TTMV infection in the corresponding second tissue
apart from 1 individual, a 28 year old female who died of AIDS related diseases.
Melting curve analysis showed TTV infection of the bone marrow and TTMV in
the spleen of this individual.
Impact ofHCV status in HIVpositive and negative tissue
samples
Due to the high frequency of HIV/HCV co-infections, it was considered
appropriate to firstly determine the HCV status of the patients whose tissues
were used in this study and secondly to determine if HCV status impacted on the
titre of TTV and TTMV in tissues.
Of the 26 patients tested, 6 were infected with HCV, including 4/13 (30.8%) of
the AIDS cohort, 2/6 (33.3%) of the HIV positive cohort and 0/7 HIV negative
individuals. The difference in TTV /TTMV titres between samples co-infected
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with HCV and HIV compared with those infected with HIV alone was
investigated. The p-value was 0.69 for bone marrow and 0.52 for spleen
indicating that co-infections of HCV and HTV did not significantly alter the titre
of TTV/TTMV in the bone marrow and spleen samples.
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Discussion
The compromised immune system resulting from HIV infection is well
documented, as is the risk of opportunistic infections as immunosuppression
becomes more marked on progression towards AIDS. Co-infections with other
viruses are common in HIV infected patients and evidence is mounting that these
can result in the modification of the HIV disease processes, for example it is
thought the Flavivirus GBV-C has a positive impact on disease progression in
HIV infected patients [Northfield, 2005].
TTV and TTMV are small, circular, DNA viruses which can be transmitted
through parenteral, non-parenteral and faecal oral routes [Puig-Basagoiti et al.,
2000; Tawara et al., 2000]. Since they share some of the same transmission routes
as HIV, TTV and/or TTMV co-infections with HIV are common. TTV was
originally thought to be a candidate novel hepatitis virus and although its role in
liver disease remains controversial, until its pathogenic potential is fully
characterised it will remain relevant to investigate the implications in those with
immune dysfunctions.
In this study, semi-quantitation of the Anellovirus titre in bone marrow
and spleen tissues from three cohorts: HIV positive individuals who died of
AIDS related infections, HIV positive patients who died pre-AIDS and HIV
negative individuals was carried out. Significantly increased viral load in tissues
removed from those with an AIDS defining illness compared with both the HIV
positive and negative groups were found, suggesting that the immune system
does have some role of regulating TTV and TTMV viraemia. A significant
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association between CD4+ T cell count TTV/TTMV litre was also established,
corroborating studies showing an inverse relationship between TTV viral load
and level of immunosuppression [Shibayama et al., 2001; Touinssi et al., 2001]. It
has been suggested that 90% of TTV particles are cleared from plasma every day
[Maggi et al., 2001] so the increased titre reported here could be indicative of a
reduction in viral clearance however, to conclude that CD4+ T cells are in some
way central to the clearance of TTV is contrary to studies suggesting that the
immune reconstitution associated with high-activity antiretroviral therapy
(HAART) did not lead to a decrease in TTV viraemia [Takamatsu et al., 2001].
The role of the immune system in the natural history of these viruses is further
implicated by the evidence that TTV DNA became undetectable in patients
during the myelosuppressed period following bone marrow transplant [Kanda et
al., 1999], possibly due to the depletion of hemic cells which act as a reservoir for
TTV. There was no correlation between the TTV/TTMV viral load in bone
marrow and spleen and HCV status, age or sex (p > 0.05).
It is hypothesised that TTV maybe able to replicate in the haematological
compartment and double stranded replicative intermediates have been found in
the bone marrow as well as in liver in humans [Okamoto et al., 2000b; Okamoto
et al., 2000c] and in the liver, bone marrow and small intestine of experimentally
infected rhesus monkeys [Xiao et al., 2002]. Peripheral blood mononuclear cells
(PBMCs) were thought to act as a reservoir for TTV but double stranded
intermediates have not been isolated from these cells suggesting that this is not a
site of replication [Okamoto et al., 2000b]. However, TTV replication has been
achieved in vitro by stimulation of PBMCs with phytohemagglutinin,
lipopolysaccharide, and interleukin-2 [Desai, 2005; Mariscal et al., 2002]. Similar
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titres of TTV/TTMV in bone marrow and spleen suggests either the spleen is also
a site of replication or the infiltration of spleen by cell types supporting
replication.
The use of PCR primers, which can simultaneously amplify both TTV and
TTMV, and the real time PCR method of differentiating between them provides
much needed data on the relationship between these viruses. These data have
shown that like TTV, TTMV can infect and possibly replicate in bone marrow
and spleen tissue both independently and in the presence of TTV. Surprisingly,
the highest percentage of dual TTV and TTMV infection occurred in the bone
marrow of the HIV negative cohort which had the lowest virus titre. There was
no significant association between the presence of dual TTV and TTMV infection
and Anellovirus titre in either the bone marrow or spleen tissues.
It has not yet been ascertained if the increased titre of virus in
immunosuppressed individuals observed here and in other publications is the
result of an increase in viral replication or a decrease of immune mediated viral
clearance. A high percentage (71%) of mixed infections with up to 5 isolates of
TTV has been noted in HIV infected patients compared with blood donors (21%)
and HBV carriers (29%) [Devalle and Niel, 2004]. It is possible that people with
compromised immune systems are unable to mount an immune response on
exposure to new genotypes of TTV. This would support the finding that
stimulation of the immune system with interferon can result in clearance or
reduction of TTV viraemia [Akahane et al., 1999; Hagiwara et al., 1999; Maggi et
al., 2001]. Published work on HIV-TTV/TTMV co-infections analysed viral loads
in serum. Here the analysis has been extended to tissues previously shown to be
susceptible to TTV/TTMV.
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In conclusion, the data presented here have demonstrated that both TTV
and TTMV are present in bone marrow and spleen and the titres of these viruses
increases in response to the immunosuppression and decreased CD4 T cell count
associated with the progression to AIDS, implying the replication of these viruses
is regulated by the immune system. The mechanisms that result in this increased
viraemia warrant further investigation however it seems unlikely that the
depletion of lymphocytes alone can account for this phenomenon.
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Characteristic AIDS Pre-AIDS HIV negative
Number 13 6 7
Male gender: n (%) 12 (92.3) 3(50) 4 (57.1)
Age: median (range) 33 (20-60) 29 (25-31) 70 (49-84)
HCV RNA +ve: n (%) 4 (30.7) 2 (33.3) 0
CD4+ T cells/mm3:median (range) 3 (0-170) 230 (200-247) NK*
Table I - Characteristics of 3 sample groups used to investigate the prevalence
and titre of 11V and TTMV defined by cause of death. * Data not available.
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Number of copies
of TTV /TTMV per
million cells in
bone marrow
AIDS HIV positive, pre-
AIDS
HIV negative
>lxl08 3 (23.1%) 0 0
>lxl07 6 (46.1%) 1 (16.6%) 0
>lxl06 4 (30.8%) 1 (16.6%) 0
>lxl05 0 1 (16.6%) 0
>lxl04 0 1 (16.6%) 4 (57.1%)
>lxl03 0 1 (16.6%) 2 (28.6%)
>lxl02 0 1 (16.6%) 0
>lxl01 0 0 1 (14.3%)
Table II - Number of copies of TTV/TTMV per million bone marrow cells as
estimated by limiting dilution PCR using primers situated in the UTR region
of the TTV and TTMV genome.
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Number of copies
of TTV /TTMV per
million cells in
spleen
AIDS HIV positive, pre-
AIDS
HIV negative
>lxl08 1 (7.7%) 0 0
>lxl07 7 (53,8%) 1 (16.6%) 0
>lxl06 1 (7.7%) 1 (16.6%) 0
>lxl05 3 (23.1%) 0 0
>lxl04 1 (7.7%) 2 (33.3%) 3 (42.8%)
>lxl03 0 1 (16.6%) 3 (42.8%)
>lxl02 0 1 (16.6%) 1 (14.3%)
>lxl01 0 0 0
Table III - Number of copies of TTV/TTMV per million spleen cells as
estimated by limiting dilution PCR using primers situated in the UTR region
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